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                                                   ABSTRACT 
                     PEPTIDE NANOFIBERS FOR  
             ENGINEERING TISSUES AND IMMUNE SYSTEM 
               Rashad Mammadov 
      PhD in Materials Science and Nanotechnology 
     Supervisor:    Assoc. Prof. Dr. Ayşe Begüm Tekinay  
     Co-supervisor: Assoc. Prof. Dr. Mustafa Özgür Güler 
                                          February, 2014 
Interdisciplinary work at the interface of biology and materials science is important 
for finding cures to complex diseases.  Achievements in materials science allow us to 
control materials at nanoscale and design them according to specific therapeutic 
purposes. This includes incorporating biophysical and biochemical signals into 
materials to make them biologically functional. These signals are sensed by cells in 
normal or pathological cases and influence their decision-making process, which 
eventually alters cellular behavior. However, cellular environment is so complex in 
terms of these signals that recapitulating it with synthetic materials is unattainable 
considering our limited resources. Therefore, we need to distinguish those signals 
that are structurally simple, but at the same time biologically critical, that would 
drive cellular behavior to desired outcome.  
In this thesis, I will describe peptide nanofiber systems for tissue engineering and 
vaccinology applications. First system is inspired from heparan sulfate (HS) – a 
natural polymer in extracellular matrix – that bind to growth factors and regulate 
their functioning, therefore central for induction of various physiological processes. 
Peptide nanofibers with right composition of bioactive chemical functional groups 
from HS showed specific interaction with growth factors and induced endothelial 
cells to form blood vessels similar to natural matrices carrying HS. Considering 
mentioned features, these peptide nanofibers could be useful for effective 
regeneration of tissues. Secondly, the peptide nanofiber system carrying pathogenic 
DNA motives, which is an infection signal, was developed. While non-immunogenic 
by itself, these nanofibers shifted immune response against pathogenic DNA towards 
a context that is useful for fighting intracellular pathogens and cancer. 
Overall, this thesis demonstrates that structurally simple but appropriate biophysical 
and biochemical signals could be synergistic for inducing desired biological 
processes at the nanoscale. 
Keywords: peptide amphiphiles, nanofibers, biomaterials, tissue engineering, drug 
delivery, immunomodulation.  
 
ii 
 
ÖZET 
DOKU VE İMMÜN SİSTEMDE MÜHENDİSLİK İÇİN PEPTİT 
NANOFİBERLER 
 
Rashad Mammadov 
Malzeme Bilimi ve Nanoteknoloji, Doktora 
 Tez danışmanı: Assoc. Prof. Dr. Ayşe Begüm Tekinay  
Eş Danışman: Assoc. Prof. Dr. Mustafa Özgür Güler 
Şubat, 2014 
Biyoloji ve malzeme biliminin disiplinlerarası çalışması kompleks hastalıklara çare 
bulunması için önemlidir. Malzeme biliminin geldiği nokta bize malzemeleri 
nanoölçekte kontrol etmemizi ve onları spesifik tıbbi amaçlara yönelik tasarlamamızı 
mümkün kılıyor. Bu biofiziksel ve biyokimyasal sinyalleri malzemelere onları 
biyolojik olarak fonksiyonel yapmak için ekleyebilmemizi içeriyor. Bu sinyaller 
normal veya hastalık durumunda hücreler tarafından algılanarak  onların karar verme 
süreçlerini etkiliyor ve sonunda hücre davranışında değişikliğe yol açıyorlar. Ancak 
hücre ortamı bu sinyaller açısından o kadar karmaşıktır ki sentetik malzemelerle 
bunları taklit etmemiz – kaynaklarımızın sınırlılığını göze alınca – ulaşılabilir 
değildir. Bu yüzden yapısal olarak sade fakat aynı zamanda biyolojik olarak kritik ve 
hücre davranışını arzu edilen yöne doğru çekecek sinyalleri ayırt etmemiz gerekiyor.  
Bu tezde doku mühendisliği ve bağışıklık uygulamaları için peptit nanofiber 
sistemler açıklanmıştır. İlk sistem hücrelerarası matrisde büyüme faktörlerine 
bağlanan ve onların fonksiyonlarını düzenleyen, bu yüzden fizyolojik süreçlerin 
çalıştırılması için merkezi olan polimerden – heparan sülfattan (HS) esinlenilmiştir. 
HS’tan doğru kimyasal fonksiyonel grupları taşıyan peptit nanofiberler büyüme 
faktörlerine karşı spesifik etkileşim göstermiş ve HS içeren doğal matrisler gibi 
endotel hücreleri damar oluştumaya yönlendirmiştir. Bu özellikleri göz önünde 
bulundurduğumuzda bu peptit nanofiberler dokuların efektif rejenerasyonu için 
faydalı olabilir. İkinci olarak bir enfeksiyon sinyali olan patojenik DNA’dan motifler 
taşıyan peptit nanofiberler sistemler geliştirilmiştir. Kendi başına immünojenik 
olmamasına rağmen, bu nanofiberler patojenik DNA’ya karşı immün tepkiyi hücreiçi 
patojenler ve kansere karşı savaşmasına yararlı olabilecek bir kontekste 
yönlendirmiştir.  
Bütünlükte, bu tez yapısal olarak sade fakat uygun biyofiziksel ve biyokimyasal 
sinyallerin arzuedilen biyolojik süreçleri çalıştırabilmemiz için sinerji 
oluşturabileceğini gösteriyor. 
Anahtar kelimeler: peptit amfifil, nanofiber, biyomalzeme, doku mühendisliği, ilaç 
taşıma, immünomodülasyon. 
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1. INTRODUCTION 
Biomaterials could provide solutions to various health problems. Today, as a result 
of economic and technological development, people live longer; communication and 
transportation are in unprecedented levels. However, increased life expectancy 
brought elevated incidence rate of chronic and degenerative diseases such as organ 
failures, cancer, neurodegenerative diseases, and chronic wounds, which cause 
extensive tissue damage. Also, enhanced communication and transportation cause 
pathogens to breach barriers against their intercontinental spread, increasing risk of 
pandemics. To find cures to these diseases, we need a paradigm shift in our 
approach. Interdisciplinary work of biology and materials science is promising in this 
regard. Recent achievements in materials science allow us to design materials with 
the purpose of curing pathophysiologies. Materials relevant to biology can be 
controlled, functionalized and characterized at nanoscale. Nanofibrous hydrogels for 
supporting cell adhesion and survival in damaged areas can be obtained with fiber 
sizes of a few nanometers. Drug delivery vehicles from polymeric nanoparticles and 
liposomes to gold nanoparticles can be obtained with different sizes and 
functionalized depending on specific purposes. In this thesis, we used self-
assembling peptide amphiphile systems to design novel materials for tissue 
engineering and modulating immune response.  
 
1.1. Self-assembling peptide amphiphile molecules 
Peptide amphiphile molecules are composed of a hydrophilic peptide part and a 
hydrophobic alkyl tail covalently bound to each other (Figure 1.1a).
1
 Charged 
aminoacids are included in peptide part, which besides increasing solubility of 
molecule, allows controlling the self-assembly process. Upon neutralization of these 
charges with oppositely charged ions, pH change, macromolecules or another peptide 
amphiphile, they self-assemble into higher order nanostructures such as nanofibers 
and nanospheres through collapse of hydrophobic part inward and peptide part 
outward (Figure 1.1b).
2
 Nanofibers produced by this way are typically 5-15 nm in 
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diameter, which is fairly similar in size to fibers comprising natural extracellular 
matrices (ECM), therefore important to mimick ECM for regenerative medicine 
(Figure 1.1d.).  
 
 
 
Figure 1.1. A peptide amphiphile structure. a. Chemical structure of a representative 
PA with four rationally designed modules. b. Molecular graphics illustration of a PA 
molecule with a bioactive epitope and its self-assembly into nanofibers. Note that 
bioactive epitopes are exposed to surrounding media in aqueous solution. c. Scanning 
electron micrograph of the PA nanofiber network formed by adding cell media 
(DMEM) to the PA aqueous solution. d. Transmission electron micrograph of the PA 
nanofibers. (Reproduced with permission from ref. 3, copyright © 2010 John Wiley 
& Sons, Inc.).
3
  
 
Peptide nanostructures are versatile materials that are amiable to engineering for 
presenting biofunctional ligands (Figure 1.1a). Nanoscale structure of fibers provide 
high surface area to volume ratio that allows them carry epitopes (biofunctional 
ligands) with high density due and make them more suitable for guiding cellular 
physiology. Entanglements of these nanofibers emerge as macroscopic self-
supporting gels at adequate concentrations (Figure 1.1c, 1.2). Gel formation can be 
controlled via neutralization of charges via pH change or mixing with oppositely 
charged molecules. This makes PA gels suitable for encapsulation of cells, growth 
factors or small molecules in 3D environment for in vitro and in vivo applications. 
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Since gel formation can be controlled externally, they can be applied also as an 
injectable matrix to replace native extracellular matrix in damaged tissues via less 
invasive methods. Besides serving as scaffolds, these nanofibers provide an 
environment to cells invading into matrix where they can be manipulated with 
peptide signals exposed to aqueous solution from nanofibers, such as shown in 
Figure 1.1b.  
 
 
Figure 1.2. Time-dependent PA gel formation and reversion of process via changing 
pH.  In upper part of figure, PA molecule is dissolved in water at a concentration of 
0.5% by weight at pH 8 and is exposed to HCl vapor. As the acid diffused into the 
solution a gel phase is formed, which self-supports upon inversion (far right). In 
lower part of figure, the same gel is treated with NH4OH vapor, which increases the 
pH and disassembles the gel, returning it to a fully dissolved solution (Reproduced 
with permission from ref. 2, copyright © 2002 National Academy of Sciences, 
U.S.A.).
2
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Peptide part can be engineered to carry epitopes from active domains of proteins 
such as growth factors and ECM proteins or to bind high molecular weight molecules 
such as heparin to generate functional nanofibers. All these properties make them 
very powerful tools for drug delivery and regenerative medicine. Peptide 
amphiphiles with heparin binding epitopes has been previously shown to exhibit 
strong binding to heparin.
4-5
 Heparin binding conferred these nanofibers a strong 
affinity to angiogenic growth factors. Probably due to the mentioned feature, these 
nanofiber gels induced in vitro and in vivo vascularization better than control PA gels 
and standard scaffolds such as collagen (Figure 1.3).
4-5
  
PA nanofibers with laminin-derived epitope (IKVAV) induced neuronal 
differentiation of NSCs better than laminin, probably due to increased density of 
bioactive epitope on nanofibers.
6
 PAs carrying epitopes for TGF-β (transforming 
growth factor) binding derived from phage display library induced in vivo cartilage 
regeneration.
7
 In addition, several studies for tissue regeneration and drug delivery 
by using PA molecules were published in recent years making PA nanostructures a 
promising platform for regenerative medicine applications.  
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Figure 1.3. Heparin-binding peptide amphiphile. a. Illustration of nanofibers formed 
by mixing heparin and PA. Heparin is presented by nanofibers into aqueous solution 
b. TEM image showing bundle of nanofibers bound to heparin-gold nanoparticles 
(black dots) (scale bar = 40 nm) c. SEM image of nanofiber network formed by 
heparin and PA (scale bar = 2 µm). d-k. In vivo angiogenesis assay. Rat cornea 
photographs 10 days after the placement of various materials at the site indicated by 
the black arrow. d. Heparin/PA nanofiber networks with growth factors induced 
extensive neovascularization. Collagen with heparin and growth factors (e) and 
collagen with growth factors (f) show some neovascularization. Heparin with growth 
factors (g), collagen with heparin (h), PA with growth factors (I), Heparin/PA 
without growth factors (j) and growth factors alone (k) showed little to no 
neovascularization. The bar graph (l) contains values for the average and maximum 
length of new blood vessels and the area of corneal neovascularization. A 100% 
value in the area measurement indicates that the cornea is completely covered, and a 
100% value in the length parameters indicates that the new vessels are as long as the 
diameter of the cornea (bars are 95% confidence levels, * p < 0.05 when Heparin/PA 
gel was compared to collagen gel with growth factors, ** p < 0.005 when 
Heparin/PA gel with growth factors was compared to all of the other controls). 
(Reproduced with permission from ref. 5, copyright © 2006 ACS).5 
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1.2. Materials for tissue engineering 
Organ failures and tissue damages require organ and tissue replacement, however 
organ donors are in scarcity. Another way is to unleash regenerative potential of our 
body, which naturally occurs during development of fetus. This requires the 
understanding of type of signals that are sensed by cells in their extracellular matrix 
and coax them into regenerative pathway. While biology provides us with this type 
of knowledge, regenerative medicine aims to find ways for presenting these cues to 
cells in an appropriate way. Tissue engineers exploit biomaterials decorated with 
these signals to direct cells to proliferate, differentiate or organize into desired tissue 
structures such as inducing endothelial cells to form blood vessels. Extracellular 
matrix (ECM) of cells has long been deemed as support material for cells, so main 
features sought in biomaterial scaffolds were mechanical properties.
8
  Physical 
properties such as porosity and stiffness have been emphasized extensively in 
material design for tissue engineering in the infancy of field. Moreover, these 
materials were expected to be `inert` - having minimal toxicity and immunogenicity.
9
 
However, lacking necessary biochemical cues for instructing cells, effect of these 
materials in tissue engineering were limited. Aim of material design for tissue 
engineering in the current paradigm is to recapitulate biophysical and biochemical 
features of extracellular matrix, where cells live in their natural environment, to 
achieve instructing cells for specific destiny.
10
 However, financial considerations 
limit to project all complexity in ECM to designed biomaterial.
11
 Natural 
macromolecules in ECM are used extensively as biomaterials for tissue engineering 
since biological cues are inherent in them.
10
 However, these materials have also 
inherent problems regarding pathogen transmission, immunogenicity and 
purification. Thus, there is a need to design materials with similar functional 
sophistication as ECM but with simpler structural complexity. Growing 
understanding of principles of how cells recognize biophysical and biochemical 
signals in their environment, integrate them at the level of gene expression and make 
appropriate decisions (Figure 1.4) will pave the way to design synthetic – thus more 
defined - materials for tissue engineering.  
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Figure 1.4. Coordination of complex physiological processes via signals sensed by 
cells. Cells recognize various physical and chemical signals in their environment 
through receptors on their membrane. This recognition is converted into signaling 
pathways, which eventually ends up with expression of different genes. Concerted 
actions of these genes influence cellular fate and induce various processes such as 
replication, migration or apoptosis. These cellular performances determine 
physiological processes at tissue level (Reproduced wıth permission from ref. 10, 
copyright © 2005 Macmillan Publishers Ltd.).10    
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What are those principles? Which distinguishable aspects of extracellular matrix are 
sensed by cells and what type of behavioral alterations in cells are observed as we 
change them? Immense amount of studies were published explaining how cells 
respond to biophysical signals such as stiffness, topography and size of individual 
fibers in ECM-like network. Stiffness of environment have shown to be a 
determining factor for mesenchymal stem cell (MSC) differentiation: with the 
increasing order of stiffness, MSCs were committed to neurogenic, myogenic and 
osteogenic pathways.
12
  Size of fibers forming scaffolds is another cue affecting 
cellular behavior. Natural ECM is formed by network collagen fibrils of size at 
nanoscale (50-500 nm).
13-14
 Smaller fiber size has larger surface area which might act 
synergistically with ligands carried on fibers. Endothelial cells showed more 
elongated phenotype, migration and capillary-like structures on micro/nano-fiber 
scaffold than one without nanofiber network.
15
 Nanofibers allowed stretching of 
endothelial cells between microfibers, which is known to be critical for their 
responsiveness to growth factors.  Neural stem cells differentiated into different 
lineages according to size of fibers of scaffold they were cultured on.
16
 Considering 
available knowledge, scaffold stiffness, fiber size, porosity and topography can be 
adjusted according to purpose. 
Recapitulating biochemical signals of natural ECM is incomparably difficult and 
expensive, when one considers complexity of network of these signals in ECM. 
Activation and performance of physiological mechanisms such as angiogenesis or 
neural regeneration depend on concerted act of numerous biological signals. Among 
these signals there are growth factors, cytokines, signaling epitopes on various 
structural proteins such as laminin and fibronectin, and glycosaminoglycans which 
bind and regulate activity of growth factors. Besides mere existence, their spatial and 
temporal presentation is also critical for effective regeneration. Since introducing all 
these ingredients into biomaterial scaffold and regulating their release from scaffolds 
spatiotemporally is an unattainable task, tissue engineers aim to identify critical 
elements in this network of biochemical signals, perturbations of which will induce 
regenerative pathway or desired bioactivity. In this context, conjugating integrin-
binding epitopes of structural proteins, such RGD or IKVAV peptides, promote cell 
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adhesion to matrix.
17-20
 Another strategy is delivering critical growth factors in 
biomaterial scaffolds. Dose of growth factors sensed by cells is a critical issue, since 
higher doses of growth factors might cause unwanted effects.
21
 Physical 
encapsulation of growth factors may not be enough for slowing their release 
adequately, so they are conjugated to scaffolds via either non-covalent or covalent 
bonds. For this purpose, heparin (a highly sulfated glycoasminoglycan) has been 
conjugated to scaffolds, such as alginate and collagen, for binding to growth factors 
non-covalently and enhance their bioactivity.
22-23
 This binding slowed growth factor 
release from scaffold and improved potency of scaffold to induce angiogenesis.  
Other polymers carrying sulfate groups as heparin or affinity binding peptides also 
exhibited increased growth factor binding and performance regarding bioactivity.
24-27
 
Chemical functional groups as biochemical signals are probably an irreducible form 
of complexity in extracellular matrix. Amazingly, it seems that they were enough to 
induce mesenchymal stem cell differentiation and by changing functional groups 
researchers were able to control cell fate.
28
 These functional groups are inspired from 
chemical structure of extracellular matrix of various tissues. Although exact 
mechanism was not clear, each functional group induced stem cell differentiation 
into the same tissue it was inspired from. For example, phosphates (from 
hydroxyapatites in bone matrix) induced differentiation into osteocytes.  
Both biochemical signals and biophysical signals work in the context of each other in 
nature. Number of ligands bound by integrins was observed to be a function of 
matrix stiffness in 3d scaffolds.
29
 Optimal integrin binding by RGD ligands was 
responsible actually for induction of osteogenesis in mesenchymal stem cells at 
optimal stiffness.  This shows that rather than focusing on biochemical signals or 
biophysical ones, using the right combination of simple signals from both might 
work synergistically and have tremendous effects on cellular behavior.   
In Chapter 3 and 4 of this thesis, scaffold materials formed from networks of 
entangled nanofibers are described. We rendered building blocks of these nanofibers 
to carry chemical functional groups, which also exist on sulfated glycosaminoglycans 
(GAG) (please look to 1.2.1.). These building blocks are peptide amphiphile 
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molecules which form nanofibers when mixed with oppositely charged molecules via 
self-assembly. Nanofibers formed this way present chemical functional groups into 
environment just as GAG polymers. In chapter 3, I demonstrate that right 
composition of functional groups - sulfonate, hydroxyl and carboxylate together - 
render nanofibers avid to vascular endothelial growth factor (VEGF) and effective at 
inducing angiogenesis – new blood vessel formation. There, I also show that when 
this combination of functional groups lack one or two of these groups, functionality 
is severely impaired.  In chapter 4, study on interaction of these nanofibers with 
growth factors is described. Functional groups on nanofibers made them affine to 
many growth factors such as VEGF, HGF and FGF-2, when compared to control 
nanofibers, which don’t have the same composition of chemical groups. Also, 
interestingly, they showed affinity to the same domain of growth factors where 
heparin binds, which is important for bioactivity of growth factors. 
 
1.2.1. Heparin and heparan sulfate glycosaminoglycans. 
Glycosaminoglycans (GAGs) are polymers of disaccharides, carrying chemical 
functional groups on them (Figure 1.5). Biological roles of GAGs are not completely 
identified, however, it is obvious that most of them is related with their remarkable 
capability to bind to many proteins.
30
 Heparin and heparan sulfates are members of 
GAGs, which has been studied extensively for their property of binding various 
proteins and modulate their activity. Heparin is found in mast cell and basophilic 
granules and serve as anti-coagulant.
30
 It has the highest negative charge density of 
any known biological macromolecule, thanks to the sulfate and carboxylic acid 
groups found in its structure.
31
 Average number of sulfates per disaccharide is 2.7 
(Figure 1.5).
30
 Heparan sulfates have similar structure but less negative charge 
density (average sulfate groups per disaccharide is less than 1).
30
 However, 
disaccharide units are more variable in heparan sulfates, making them more 
heteregenous than heparin in terms of domains.
31
 Different domains in heparan 
sulfates show different levels of sulfation probably allowing them to perform more 
complex functions (Figure 1.5). Highly sulfated domains are assumed to take role in 
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protein binding. Heparan sulfates are found in extracellular matrix and membrane of 
cells. They bind to growth factors there and protect them from enzymatic 
degradation, provide a reservoir of growth factors to cells and assist growth factors in 
their interaction with cognate receptors. Heparin is extensively used in tissue 
engineering because of high degree of sulfation of its monomers, which increase 
ability of scaffolds with heparin to bind to growth factors.  
 
 
   
Figure 1.5. Chemical structure of heparin and heparan sulfates showing major and 
minor disaccharide repeating units. (X=H or SO3
-
, Y=Ac, SO3
-
, or H) (Reproduced with 
permission from ref. 31, copyright © 2002 John Wiley & Sons, Inc.)31. 
 
1.3. Materials for engineering immune response 
Last part of this thesis is about materials for directing immune activity and 
developing vaccines against infectious diseases. Conventional vaccinology relies on 
introducing inactivated or live-attenuated form of pathogens into patients in an 
attempt to educate immune system about how to fight with the active pathogen. 
Basics of this strategy are fairly unchanged since invention of vaccination (“vacca” 
13 
 
in Latin means cow) by remarkable observation of Edward Jenner that infection with 
cowpox provides immunity against smallpox, in 1796. Although this strategy 
generates successful immune response against pathogens, it has several 
disadvantages. First of all, in cases of pandemic, mass production could be hampered 
by low growth of pathogens or scarcity of resources. Second but not least, using 
pathogen itself is not a defined formulation, so brings unwanted side effects and risk 
of becoming virulent of pathogen. For this reason, we need rational design of 
vaccines, which will drive immune response towards desired context (considering 
type of cytokines and costimulatory molecules expressed, type of cells activated) and 
induce long-lasting immune response, without compromising safety.
32
 However, this 
is challenging because our knowledge of these two subjects is not sufficient.
33
 
 
1.3.1. Pathogen-specific immune context  
One question is which type of immune response is required to protect an individual 
from each pathogen. Immune system has evolved to protect organism against diverse 
pathogens, while being tolerant to self. Having a similar level of sophistication 
allows immune system to solve this problem (Figure 1.6). Pathogens that are able to 
pass first-line barriers such as skin (e.g. in cases of tissue damage) encounter with 
innate immune system. Innate immune system cells inspect pathogen entry sites of 
body such as skin or mucosal surfaces and destroy pathogens through phagocytosis 
or secreting antimicrobial substances upon recognition.  
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Figure 1.6. Complexity of immune system, which is evolved to distinguish pathogen 
from self and to provide immune context relevant to nature of pathogens. Dendritic 
cells (DC) distinguishes between foreign and self antigens according to 
microenvironmental signals. Along with other innate immune cells, their response to 
these signals determines the outcome of antigen recognition by T and B cells. a. 
Dendritic cells recognize immunogenic signals from infected or immunized, dying 
cells through danger receptors on them (TLRs, CLRs, NLRs, RLRs, SRs) and 
tolerogenic signals from dying self-cells or cellular debris generated by homeostatic 
turnover; these produce a continuous spectrum of output responses ranging from 
strong induction of effector-phase immunity to strong induction of tolerance, with 
the exact outcome determined by the integration of inputs by the dendritic cell. In 
response to these ‘danger’ or tolerizing signals, dendritic cells (and other innate cells) 
create the immunological context for antigen recognition by secreting cytokines, 
expressing diverse adhesive, co-stimulatory or regulatory receptors that provide cues 
to responding lymphocytes. b. According to mentioned cues, B cells can undergo 
somatic hypermutation, become short-lived plasmablasts, or differentiate into long-
lived memory B cells or plasma cells while T cells can differentiate into effector 
cells or memory cells with distinct homing and functional capacities; effector cells 
can have diverse functions (Th1, Th2, Th17 and so on) depending on the context set 
by dendritic cells. Regulatory feedback loops are engaged even in highly 
inflammatory contexts, as part of the natural control system regulating immunity, and 
primed effector cells can be driven to anergic/exhausted states similar to tolerance at 
later stages of an immune response. c. Peripheral tolerance is maintained by a distinct 
set of signals: In tolerogenic contexts, T cells are driven into several different states 
of non-responsiveness that prevent effector responses against self or harmless 
environmental antigens. (Reproduced with permission from ref. 33, copyright © 
2013 Macmillan Publishers Ltd.).
33
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Pathogen recognition by innate immune cells is maintained by germ-line encoded 
receptors, which do not change during the lifetime of organism, differing from 
adaptive immune cells. These receptors, collectively known as pattern recognition 
receptors (PRR), recognize certain common patterns from pathogens, such as 
peptidoglycan molecules in bacterial cell wall or unmethylated CpG (or CG, 
denoting cytosine and guanine) motives from viral/bacterial DNA.
34-35
 PRRs include 
several family of secreted (mannose-binding lectin), transmembrane or cytosolic 
receptors.
36
 Most studied and known receptor family among PRRs are Toll-like 
receptors (TLR). Toll-like receptors can be at cell-membrane (those recognizing 
surface features such as peptidoglycan or LPS layer of bacterial cell wall and 
membrane) or endosomal membrane (those recognizing microbial nucleic acids).   
Binding of pathogenic patterns to PRRs shape adaptive immune responses.
36
 This 
happens through activation of various signaling pathways which end up with 
expression of cytokines and surface receptors called as co-stimulatory molecules. 
Cytokines are protein molecules binding to their receptors on target cells and induce 
signalling pathway. Co-stimulatory molecules are expressed by antigen-presenting 
cells and required for activation of adaptive immune cells specific for antigen.  
Although these signals are necessary, neither of them is sufficient to induce adaptive 
immune response. However, TLR-induction is known to be sufficient to provide all 
factors for initiation of robust adaptive immune response.
36
  Thus, besides forming 
another line of defense to clear infection, innate immune cells also controls the 
activation, types and duration of the adaptive immune response.
36
 
Adaptive immune system fights with infections with two main types of immune cells 
– B cells and T cells.  Both of cell populations have vast repertoire of antigen 
receptors for almost every possible antigen in the environment. These receptors are 
generated through random arrangement of genes, which gives rise to receptor for 
specific antigen on every cell. Adaptive immune response also provides memory 
formation about pathogens after clearing infection, through memory cells. These 
cells re-induce adaptive immune response after encountering antigens later. Antigen-
presenting cells (APC), which are mainly dendritic cells, form link between innate 
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and adaptive immune system. They process and present antigens, which they 
recognized as foreign, on their surface to T-cells. Cytokines and co-stimulatory 
molecules expressed by APCs accompany to presentation of antigen at 
immunological synapse (Figure 1.7.).
37
 T-cells integrate these signals and decide on 
nature of ensuing immune response.
33
 
B-cells are activated by T-cells and accompanying cytokine signals. They secrete 
antibodies – receptors on their surface formed by combinatorial mechanism, as an 
effector function. These antibodies detect antigens in body fluid, so this type of 
response is called humoral response (Figure 1.6). Antibody binding renders toxins 
ineffective, and pathogens vulnerable to phagocytosis by macrophages. This is why 
this type of immune response is especially effective on extracellular pathogens. 
However, some pathogens such as viruses or mycobacterium reside in cells. Cell-
mediated immune response is required to clear this type of infections. Effector 
function of cell-mediated immune response is activated by CD8+ cytotoxic T-cells, 
which induce death mechanism in cells expressing particular antigen. T-cell 
receptors, contrasting to B-cell ones, are not secreted, but interact with MHC 
molecules presented by antigen-presenting cells – mainly dendritic cells.  
To summarize, adaptive immune response is antigen-specific immune response 
against pathogens, providing effective clearance from and memory formation about 
pathogens. Nature of adaptive immune response to antigen is determined by 
cytokines, co-stimulatory molecules and possibly other factors expressed by antigen-
presenting cells (Figure 1.7).
33
 These molecules are expressed according interaction 
of pathogen with innate immune cells through binding of pathogen-associated 
molecular patterns – LPS layer, CpG DNA - to pathogen recognition receptors such 
as TLRs.
32-33
 Understanding these mechanisms might allow us to trigger them upon 
purpose with synthetic and defined formulations, rather than pathogen itself. 
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Figure 1.7. Illustration of key receptor-ligand interactions at the immunological 
synapse formed between an antigen presenting cell and a T-cell during T-cell 
activation. Profile of cytokines and co-stimulatory molecules binding to their target 
receptors educate adaptive immune system about nature of infection, which allows 
adaptive immune cells to elicit an appropriate immune response. (Reproduced with 
permission from ref. 37, copyright © 2012 John Wiley & Sons, Inc.)37 
 
1.3.2. How to drive immune response to desired context? 
Another barrier to rationalize vaccine design is our insufficient understanding of how 
we can drive immune response to desired context such as balance between 
effector/memory cells, or cell-mediated or humoral immunity.
33
 Antigens themselves 
do not generate immune response, so molecules called adjuvants are added into 
vaccine formulations, which trigger immune system against antigen. Success of these 
adjuvants are based largely on antibodies made by B-cells.
38
 This type of immune 
response is not competent against intracellular pathogens (e.g. tuberculosis), which 
can be cleared by the action of T-cells and macrophages (cell-mediated immunity). 
We need tools that would allow us to tune activity, magnitude and duration of 
various modules of immune system, such as cytotoxic T-cell activity or antibody 
secretion by B-cells. These tools could be found among signatures of pathogens that 
are recognized by immune system. Mentioned signatures can be classified as 
18 
 
chemical ones, which are known in literature as pathogen-associated molecular 
patterns (PAMP), and physical ones such as size and shape of pathogen.  
PAMPs that bind PRRs (Pathogen Recognition Receptors) are promising as vaccine 
adjuvants, since they induce innate immune cells, which eventually shape adaptive 
immune response. Existence of TLR ligands in phagocytosed antigenic cargo is 
necessary for presentation of antigens with MHCII on the surface of dendritic cells.
39
 
Besides inducing antigen-presentation, profile of cytokines and co-stimulatory 
molecules induced by different PAMPs shape immune response according to 
pathogen to be destroyed. 
In this context, CpG ODNs have been shown to act as safe adjuvants and drive 
immune response to cell-mediated immunity (Table 1.1). These are 
oligodeoxynucleotides with cytosine-guanine motives, where cytosine is 
unmethylated.
40
 These motives are less frequent in vertebrate DNA than bacterial 
DNA, also higly methylated.
40
 Mammalian immune system recognizes bacterial/viral 
DNA or CpG ODNs in endosomes of certain immune cells like B-cells and 
plasmacytoid dendritic cells via TLR9 receptor.
41
 Binding of CpG ODN to TLR9 
induce signaling pathways which end up with synthesis of pro-inflammatory 
cytokines, interferons and co-stimulatory molecules and maturation of dendritic cells. 
Interactions of the immune system with pathogens are shaped not only by danger 
signals, but also by the physical nature of microbes, which are biological 
microparticles and nanoparticles.
33
  Soluble exogenous antigens are not displayed by 
cross-presentation (MHCI), while pathogenic or particlulate antigens can be 
displayed.
37
  Designing materials presenting these signatures to immune system on 
the same physical entity as pathogens, would allow us to exploit synergism between 
chemical and physical signals.  Understanding effect of each signal on immune 
system will allow us to shape immune response by rationally changing concentration 
of each signal. While biochemical signals on pathogens are studied deeply, there is a 
lack of knowledge on how these perform in the context of physical signals such as 
size and shape. In Chapter 4, we studied how pathogenic CpG DNA signal acts in the 
context of shape of carrier. Our findings show that shape alters immune response to 
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CpG DNA, where nanofiber delivery is more relevant to induce cell-mediated 
immunity. 
 
Table 1.1. Effect of “K/B” and “D/A” ODN on the Immunogenicity of Engerix B. 
Normal recipients 
Immunization 
1
o
 2
o
 3
o
 
Vaccine alone <30 (60) 4300 (100) 9200 (100) 
Vaccine + D/A ODN 940 (100) 8400 (100) 21,700 (100) 
Vaccine + K/B ODN 120 (80) 10,600 (100) 20,500 (100) 
SIV-infected recipients 
(viral load < 10
7
) 
Immunization 
1
o
 2
o
 3
o
 
Vaccine alone < 10 (0) <10 (20) <10 (20) 
Vaccine + D/A ODN < 10 (0) 320 (100) 430 (100) 
Vaccine + K/B ODN 220 (80) 400 (100) 740 (100) 
 
Rhesus macaques (5–6/group) were immunized with 500 μl of Engerix B vaccine 
plus 300 μg of “K/B” or “D/A” ODN in alum. Serum anti-HepB Ab titers were 
monitored by ELISA. Average titers, and percent of animals with protective titers (in 
parenthesis) are shown. Note that the average response after both primary and 
secondary immunization was significantly higher in groups immunized with CpG 
ODN plus Engerix B vs. vaccine alone (Reproduced with permission from ref.42, 
copyright © 2009 Elsevier).42 
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CHAPTER 2 
 
2. DESIGN OF HEPARIN-MIMETIC PEPTIDE NANOFIBERS 
FOR INDUCTION OF ANGIOGENESIS. 
 
This work is partially described in the following publication: 
Mammadov R., Mammadov B., Toksoz S., Aydin B., Yagci R., Tekinay A.B. and 
Guler M.O. Biomacromolecules, 2011, (10), pp 3508–3519.43 
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2.1. Objective 
Regeneration of tissues after damage requires formation of blood vessels for survival 
and performance of cells migrating into damaged area. Designing materials 
decorated with biological signals for induction of angiogenesis would be useful for 
tissue engineering purposes.  However, recapitulating all the signals regulating blood 
vessel formation is not feasible. Simpler and still effective approaches in mimicking 
microenvironment of angiogenesis (new blood vessel formation) are required. 
Sulfated glycosaminoglycans (GAG), which are an essential part of basement 
membrane, a specialized extracellular matrix of endothelial cells, bind to growth 
factors critical for angiogenesis and regulate their activity. Chemical functional 
groups and their distribution on GAGs, especially on heparan sulfates, are known to 
be critical for growth factor binding and induction of angiogenesis. In this study, our 
objective was to design scaffold material with similar fiber size to natural ECM and 
GAG-mimicking chemical functional groups on fibers. We aimed to identify 
appropriate composition of simple functional groups on nanoscale fibers that would 
be sufficient to induce angiogenesis. 
 
2.2. Introduction 
Regenerative medicine studies offer promising therapeutic approaches for the repair 
of damaged tissues. Induction of angiogenesis is an important mechanism for tissue 
repair.
10
 The capillaries can only deliver oxygen and nutrients to the cells that are 
located at a distance of up to 200 μm, and thus angiogenesis is required for cells 
further away during new tissue formation.
44
 Angiogenesis is triggered by the 
integration of various neovascularization signals by endothelial cells, which in turn 
differentiate to form new capillaries. Structural proteins of the extracellular matrix 
(ECM) (laminin, collagen, etc.), growth factors (VEGF, FGF-2, etc.), and 
glycosaminoglycans (heparan sulfate, etc.) make up a framework of 
neovascularization signals for endothelial cells.
45
 Understanding the interactions 
between these biomolecules and endothelial cells and their roles in the regulation of 
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angiogenic processes paves the way to design effective synthetic biomaterials for 
induction of new blood vessel formation. Conventional tissue engineering strategies 
utilized some of the biological molecules mentioned above to provide bioactivity for 
promoting angiogenesis
46
 because synthetic biomolecules that have been produced so 
far lacked the ability to mimic the functions of all of these biological components. 
The main motivation for developing new synthetic ECM mimicking biomaterials is 
to minimize utilization of the above-mentioned natural biomacromolecules 
exogenously with the aim of reducing cost, preventing batch-to-batch variation, and 
avoiding biological contamination. Therefore, designing smart biomaterials that can 
harness endogenous factors for desired bioactivity is essential.  
Among the basic components of the signaling framework for endothelial cells, 
heparan-sulfate proteoglycans (HSPGs) bind to angiogenesis promoting growth 
factors and their receptors through heparan sulfate chains and induce growth factor 
signaling (Figure 2.1.).
47-50
 Mice lacking heparan sulfate chain on HSPG molecule 
reveal defective angiogenesis and wound healing.
51
 Binding of growth factors to 
HSPGs, which strictly depends on the distribution of functional groups, such as 
sulfate, hydroxyl and carboxyl groups, on heparan sulfate chains, protects growth 
factors from degradation, increases local concentration of growth factors, and 
enhances growth factor-receptor interactions, which are important for long-term 
stimulation of signaling pathways in endothelial cells.
8, 50, 52-53
 Using 
glycosaminoglycans (e.g., heparin) within tissue engineering scaffolds has been 
shown to enhance angiogenesis significantly while reducing the need for exogenous 
growth factors at in vivo studies.
5
 A peptide amphiphile (PA) scaffold for 
angiogenesis was previously developed by mixing heparin-binding PA molecule and 
heparin.
5
 Heparin-binding PA molecule allowed growth factor binding and helped 
formation of various functional tissues.
5, 54-55
 However, being an animal-derived 
product, utilization of heparin in tissue engineering systems might have potential side 
effects (e.g., immune reactions).
56
 Designing heparin mimetic biomaterials will have 
high impacts in cellular therapy and regenerative medicine because they will enable 
us to avoid the use of heparin while minimizing the use of exogenous growth factors. 
Recent research efforts have focused on developing new scaffold materials with 
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proper functional groups that are sufficient to induce the desired physiological 
response in vitro without any need for growth factors or any other supplements.
28
  
 
 
Figure 2.1. Co-receptor function of HSPG in VEGF signalling. a. VEGF receptor – 
VEGFR2 is unable for signal transduction when cells lack HSPG. b. HSPG (GAG 
side chains are shown in blue and protein part in green) expressed on endothelial 
cells are engaged in the VEGF/VEGFR signaling complex and may affect signaling 
quantitatively (by stabilizing the complex) and qualitatively (by allowing 
transduction of signaling pathway not induced in the absence of coreceptors. c. 
Presentation of HSPGs in trans (i.e. by another cell)  leads to further stabilization of 
the VEGF/VEGFR signaling complex, and prolonged signal transduction (red 
activity arrows) (Reproduced with permission from ref. 57, copyright © 2008 Springer 
Science+Business Media, LLC).
57
 
 
The addition of functional groups inspired by heparin on peptide sequences and 
polymers has also been previously shown to enhance growth factor binding 
capacity.
24, 26, 58-60
 For example, sulfated alginate polymers gained growth factor 
binding capability and induced in vivo angiogenesis significantly better than 
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nonsulfated alginate in the presence of growth factors.
24-25
 Considering these 
findings, we hypothesized that chemical functional groups from heparan sulfates on 
peptide nanofibers, will recapitulate their function. As a result, heparin-mimetic PA 
nanofiber gel would bring together two distinct signal in ECM – biophysical signal 
of nanofiber network mimicking nanofibrous matrix of ECM and biochemical signal 
of chemical functional groups on heparan sulfates. Heparin-mimetic PA molecule 
functionalized with bioactive groups was designed and synthesized for mimicking 
functionality of heparan sulfates in ECM. The heparin-mimetic PA molecules self-
assemble to form nanofibers with ability to bind to growth factors and to promote 
angiogenesis without the need for addition of exogenous heparin or growth factors. 
This chapter demonstrates that nanostructures with bioactive chemical groups 
inspired from biological macromolecules can be used to activate biological 
machinery for regenerative medicine applications.
11, 28
 
 
 2.3. Results and Discussion 
To mimic natural extracellular environment that induces angiogenesis, we designed 
PA molecules which carry chemical features of heparan sulfate molecules in ECM to 
enable enhanced functioning of the growth factors that are crucial for angiogenesis. 
Heparan sulfates are sugar polymers with chemical functional groups on these sugar 
units. Key functional groups in heparan sulfate polymer chain are highlighted in 
Figure 2.2 for heparin – clinically used glycosaminoglycan molecule with similar 
structure to heparan sulfate. These functional groups are carboxylic acid (-COOH), 
hydroxyl (-OH), sulfate (-SO4), sulfonate and sulfamate or N-linked sulfonate (-N-
SO3). To assess the importance of these functional groups during angiogenesis 
process, several PA molecules were designed that carry from three to zero of these 
functional groups (Figure 2.2). Heparin-mimetic PA (HM-PA after here) molecule is 
decorated with carboxylic acid, hydroxyl, and sulfonate groups. Carboxylic acid and 
hydroxyl groups are added through coupling aspartic acid/glutamic acid and serine 
amino acids (side chains of these amino acids), respectively. Sulfonate group is 
added through coupling sulfobenzoic acid to side chain of lysine amino acid.  
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Figure 2.2. Chemical structures of heparin and designed peptide amphiphiles. 
Functional groups inspired from heparin are colored. Heparin-mimetic PA molecule 
SO3-PA, D-PA and H-PA carries 3, 2, 1 and 0 functional groups from heparin, 
respectively. K-PA is used to induce nanofiber formation with (-) charged PAs.  
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The other molecules have less functional groups than HM-PA: SO3-PA, has 
sulfonate and carboxylic acid groups, D-PA only carboxylic acid groups and H-PA 
no functional groups from heparin. H-PA was designed to neutralize and self-
assemble into nanofibers at physiological pH to control the effect of a nonbioactive 
PA gel during angiogenesis. Heparin was mixed with K-PA (K-PA/Heparin) to 
observe the effect of heparin on bioactivity of the PA gel. 
All synthesized PA molecules were purified with High-Performance Liquid 
Chromatography (HPLC) and analyzed with liquid chromatography-mass 
spectrometry (LC-MS). In LC analysis, molecules were passed from hydrophobic 
stationary phase (c18 alkyl tails covalently bound to silica particles), which interacts 
with alkyl tails of PA molecules.  By running gradient from an aqueous phase (water) 
to organic phase (acetonitrile), PA molecules were eluded according to 
hydrophilicity and detected with UV detector (at 220 nm wavelength). Indeed, 
elution time points given in LC chromatograms (Figures 2.3b – 2.7b) were consistent 
with hydrophilicity of molecules. More hydrophilic ones are eluded at earlier time 
point, such as HM-PA with the highest number of charged groups eluded at the 
earliest time point, while K-PA with the lowest number of charged group eluded at 
the latest time point. Mass spectra of peaks obtained in LC chromatograms indicated 
that all synthesized PA molecules have similar masses to the expected ones (Figures 
2.3c – 2.7c). These purified molecules were used in further studies.    
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Figure 2.3. LC-MS analysis of synthesized Heparin-mimetic PA (HM-PA) 
molecule. a. Chemical structure of HM-PA molecule. b. LC chromatogram of 
purified HM-PA molecules at 220 nm indicates high purity of molecule. c. Mass 
spectrometric analysis of peak in HM-PA LC chromatogram. [M-H]
-
(calculated)=1225.4, [M-H]
-
( (observed)=1224.8.   
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Figure 2.4. LC-MS analysis of synthesized SO3-PA molecule. a. Chemical structure 
of SO3-PA molecule. b. LC chromatogram of purified SO3-PA molecules at 220 nm 
indicates high purity of molecule. c. Mass spectrometric analysis of peak in SO3-PA 
LC chromatogram. [M-H]
-
(calculated)=966.2, [M-H]
-
( (observed)=965.7.   
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Figure 2.5. LC-MS analysis of synthesized D-PA molecule. a. Chemical structure of 
D-PA molecule. b. LC chromatogram of purified D-PA molecules at 220 nm 
indicates high purity of molecule. c. Mass spectrometric analysis of peak in D-PA 
LC chromatogram. [M-H]
-
(calculated)=640.8, [M-H]
-
(observed)=640.6.   
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Figure 2.6. LC-MS analysis of synthesized K-PA molecule. a. Chemical structure of 
K-PA molecule. b. LC chromatogram of purified K-PA molecules at 220 nm 
indicates high purity of molecule. c. Mass spectrometric analysis of peak in K-PA 
LC chromatogram. [M+H]
+
(calculated)=654.9, [M+H]
+
(observed)=654.5.   
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Figure 2.7. LC-MS analysis of synthesized H-PA molecule. a. Chemical structure of 
H-PA molecule. b. LC chromatogram of purified H-PA molecules at 220 nm 
indicates high purity of molecule. c. Mass spectrometric analysis of peak in H-PA 
LC chromatogram. [M+H]
+
(calculated)= 663.9, [M+H]
+
(observed)=663.5.   
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2.3.1. Structural characterization of peptide nanostructures 
The abilities of these molecules to form a fibrous network, that can mimic the 
morphology of natural ECM,
61-62
 were analyzed by Scanning Electron Microscope 
(SEM) imaging. Five different PA gels were prepared with final pH of 7.4 in order to 
render them suitable for physiological conditions. HM-PA, SO3-PA and D-PA gels 
were formed by mixing negatively charged HM-PA, SO3-PA and D-PA with 
positively charged K-PA at pH=7, respectively. Negatively charged heparin was 
mixed with positively charged K-PA to get K-PA/heparin gel. H-PA can be 
neutralized at pH=7 due to only histidine amino acid as a charged residue (pKa of 
histidine side chain is 6.0), which allows self-assembly to occur without help of 
another molecule at pH=7. PA gels were dehydrated by using critical point dryer to 
preserve 3D structure. Dehydrated 3D networks were coated with Au-Pd and 
analyzed by SEM imaging. All PA molecules that were analyzed exhibited similar 
nanofibrous network that is suitable for providing the necessary mechanical support 
for cells (Figure 2.8a-2.8e), similar to natural collagen matrix (Figure 2.8f). 
Nanofibrous matrix also allows communication between cells through pores via 
sprouting of cells or diffusion of soluble molecules. Thus, cells can form integrated 
tissue-like structures in these PA matrices, similar to natural ECM.  
We further diluted these PA gels to visualize individual units forming nanofibrous 
networks by using and Transmission Electron Microscopy (TEM) and Atomic Force 
Microscopy (AFM). These images revealed that investigated PA formulations form 
high-aspect ratio nanofibers (Figures 2.9 to 2.13). Nanofiber diameter is critical, 
since it determines density of functional groups presented to cells or growth factors, 
therefore might be critical for bioactivity.  For this reason, we compared nanofiber 
diameters between different PA combinations that were measured based on TEM 
images (Table 2.1). These measurements revealed that nanofiber diameters for HM-
PA/K-PA, SO3-PA/K-PA, D-PA/K-PA, K--PA/heparin, and H-PA samples do not 
differ significantly. This indicates that density of functional groups presented by 
different type of nanofibers is similar. 
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Figure 2.8. Scanning Electron Microscopy (SEM) imaging of dehydrated PA gels 
and collagen matrix. HM-PA/K-PA (a), D-PA/K-PA (b), SO3-PA/K-PA (c), K-
PA/Heparin (d), and H-PA (e) gels show nanofibrous networks similar to collagen 
matrix (f; reproduced with permission from ref. 62, copyright © 2006 The Company of 
Biologist Limited)
62
.   
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Figure 2.9. Transmission Electron Microscopy (TEM) and Atomic Force 
Microscopy (AFM) imaging of surfaces coated with HM-PA/K-PA formulation. a. 
TEM image reveals formation of nanofibers with 5-10 nm diameter. b. AFM image 
shows bundles of nanofibers along with single nanofibers. 
 
 
 
 
 
Figure 2.10. Transmission Electron Microscopy (TEM) and Atomic Force 
Microscopy (AFM) imaging of surfaces coated with SO3-PA/K-PA formulation. a. 
TEM image revealed formation of nanofibers with 5-10 nm diameter and their 
bundling. b. AFM image shows mainly bundles of nanofibers. 
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Figure 2.11. Transmission Electron Microscopy (TEM) and Atomic Force 
Microscopy (AFM) imaging of surfaces coated with D-PA/K-PA formulation. a. 
TEM image revealed formation of nanofibers with 5-10 nm diameter. b. AFM image 
shows mainly bundles of nanofibers. 
 
 
 
 
 
Figure 2.12. Transmission Electron Microscopy (TEM) and Atomic Force 
Microscopy (AFM) imaging of surfaces coated with K-PA/Heparin formulation. a. 
TEM image revealed formation of nanofibers with 5-10 nm diameter. b. AFM image 
shows mainly bundles of nanofibers. 
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Figure 2.13. Transmission Electron Microscopy (TEM) and Atomic Force 
Microscopy (AFM) imaging of surfaces coated with H-PA pH=7 formulation. a. 
TEM image revealed formation of nanofibers with 5-10 nm diameter. b. AFM image 
shows mainly bundles of several nanofibers. 
 
     Table 2.1. Nanofiber size measurements of PA gels. 
 
 
 
 
 
 
Nanofiber diameters are measured by using TEM images for each formulation. 
Averages of nanofiber sizes between different formulations were proved to be 
similar.   
 
Driving force for nanofiber formation was proposed to be hydrogen bonding between 
peptide molecules with β-sheet secondary structure that cause their densely packing 
within nanofibers.
63-64
 In order to assess secondary structure character of PA 
PA nanofiber type Size (nm) 
HM-PA/K-PA 7.5 ± 1.6 
SO3-PA/Lys-PA  7.0 ± 1.5 
D-PA/K-PA 7.1 ± 0.7 
K-PA/Heparin 7.1 + 1.1 
H-PA pH=7 6.3 ± 0.7 
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combinations, we obtained their circular dichroic (CD) spectra. Strong negative peak 
at 218-19 nm and positive peak around 195-200 nm for HM-PA/K-PA, SO3-PA/K-
PA and D-PA/K-PA indicates formation of β-sheet secondary structure (Figure 2.14). 
These results further confirm that β-sheet character of peptide amphiphiles might 
stabilize formation of cylindrical nanostructures.  
  
Figure 2.14. Circular dichroism analysis of heparin-mimetic and control PA 
molecules. Circular dichroic spectra of Heparin-mimetic PA, SO3-PA or D-PA 
molecules mixed with K-PA show characteristic signals for β-sheet structure. 
 
Mechanical properties of the extracellular environment are crucial for determining 
cell fate and behavior,
12, 65
 and thus we compared viscoelastic properties of PA gels. 
For this we used oscillatory rheology to characterize viscoelastic properties of 
different PA gels (Figure 2.15). In oscillatory rheology stress response of gels to 
applied strain is measured by storage modulus (G`) and loss modulus (G``). Storage 
modulus measure stored energy after strain applied and represent contributions from 
elastic component of material. Loss modulus measure dissipated energy and 
represent contributions from viscous component of material. If G` is higher than G``, 
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material has more elastic, solid/gel-like behavior; while if G` is lower than G``, 
material has more viscous-like character.  Each of the gels (HM-PA/K-PA, SO3-
PA/K-PA, D-PA/K-PA and K-PA/Heparin gel) had storage moduli (G`) higher than 
loss moduli (G``), indicating gel formation (Figure 2.15). Storage moduli (G`), 
indicating stiffness of the gels, were in the same order of magnitude for all gels 
designed for this study. Furthermore, loss tangents (tan δ = G``/G`) of all materials 
were compared, which provides information about elastic character of the gels and 
their gelation properties.
66-67
 These values were found to be comparable for all of the 
PA gels tested here (Table 2.2), indicating that all materials used here has similar 
gelation and elastic properties. Overall, rheology measurements suggest that 
differences in mechanical properties of gels are not significant enough to modulate 
bioactivity. 
 
Figure 2.15. Oscillatory rheology measurements of different PA gels. Storage (G`) 
moduli of equimolar PA formulations were higher than loss moduli (G``) for all 
tested formulations, indicating gel formation. Storage moduli of HM-PA, SO3-PA 
and K-PA/Heparin are similar, while difference of D-PA from others is lower than 
order of magnitude (n=3; Error bars are standard error mean). 
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        Table 2.2. Loss tangents of PA gels (G''/ G'). 
 
 
 
 
 
 
Loss tangents give information about elastic character of gels. Similar values for all 
tested gels are a sign for similarity between elastic character of PA gels. 
 
2.3.2. Evaluation of in vitro angiogenic potential of peptide nanofibers  
Endothelial cells are known to form capillary-like tubes on different materials 
derived from natural ECM, when angiogenic signals are available.
68-71
 We performed 
similar in vitro angiogenesis assay in order to understand whether functional groups 
from heparin on nanofibers confer advantage for inducing angiogenesis. For this 
purpose, human umbilical cord vein cells (HUVEC) were cultured on surfaces coated 
with PA gel and cellular morphologies were followed with light microscope. 
Similarly, we cultured HUVECs on Matrigel
TM -
 basement membrane gel, which 
consists of natural ECM proteins as well as various growth factors, as a positive 
control. We observed that cells coalesce to form capillary-like structures, which 
emerged as polygonal network, on Matrigel
TM
, as it is reported in the literature 
(Figure 2.16a, b).
68
 Interestingly, cells cultured on Heparin-mimetic PA (HM-PA) 
matrix also formed capillary-like structures and polygonal network (Figure 2.16c, d 
and e), although this matrix is synthetic and does not contain any growth factors or 
GAG molecules. The most potent of other matrices, D-PA, induced only formation 
of a few tubes and lower cell migration than HM-PA matrix (Figure 2.16f). Including 
all the necessary functional groups from heparin might be the explanation for 
potency of HM-PA nanofiber gel system to induce angiogenic phenotype on 
endothelial cells.  
PA gel G''/ G' 
HM- PA/K-PA 0.194 
SO3-PA/K-PA 0.177 
D-PA/K-PA 0.214 
K-PA/Heparin 0.180 
40 
 
 
 
Figure 2.16. In vitro angiogenesis assay - Matrigel, HM-PA and D-PA. HUVECs 
were cultured on Matrigel (a, b), HM-PA nanofiber matrix (c, d and e) and D-PA 
nanofiber matrix (f); then followed for 48 h to evaluate migration and tube 
formation. Cells formed capillary-like tubes on Matrigel, as well as HM-PA 
nanofibers. However, on control D-PA nanofibers endothelial cells showed only a 
few tubes and cell migration. All images are bright-field and taken at 100x 
magnification (n = 3 for all conditions; representative images are shown).  
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SO3-PA nanofiber matrix induced lower number of tubes and migration than D-PA 
(Figure 2.17a and 2.16f), even though SO3-PA nanofibers have both sulfonate and 
carboxylic acid groups, but D-PA has only carboxylic acid groups (Figure 2.2).  This 
suggests that factors (other than variety of functional groups) such as number of 
functional groups (two carboxylic acids are included on D-PA), position of these 
functional groups on PA molecule or proximity of functional groups on PA molecule 
might affect bioactivity of nanofiber matrix. H-PA, which included no functional 
groups from heparin, induced no angiogenic phenotype in endothelial cells, similar to 
bare tissue culture plate (Figure 2.17c, d).   
 
 
Figure 2.17. In vitro angiogenesis assay - SO3-PA, K-PA/heparin, H-PA and TCP. 
HUVECs were cultured on SO3-PA (a), K-PA/heparin (b), H-PA (c) nanofiber 
matrices and bare tissue culture plate (d); then followed for 48 h to evaluate 
migration and tube formation. Cells show a few tubes and a little migratory 
phenotype on SO3-PA matrices. On other surfaces, no sign of angiogenesis can be 
observed.  All images are bright-field and taken at 100x magnification (n = 3 for all 
conditions; representative images are shown).   
42 
 
Overall, these data strongly suggest that proper composition of functional groups 
from heparin on PA nanofiber matrix induce angiogenic phenotype in endothelial 
cells. Also, lack of this necessary composition of functional groups severely impairs 
potency of nanofiber matrix.  
Surprisingly, heparin carrying nanofibers (K-PA/heparin) also seemed to be 
incapable to induce angiogenesis, in that they were not different from tissue culture 
plate (Figure 2.17 b and d). Although K-PA and heparin formed a self-supporting gel 
with similar mechanical properties with HM-PA/K-PA gel, heparin chains probably 
are not stabilized by K-PA molecules and optimal presentation of heparin is not 
achieved by nanofibers. Previously, Rajangam et al. reported a difference between a 
heparin-binding PA and its scrambled sequence regarding interaction with heparin.
52
 
Scrambled PA sequence with basic residues at the end, similar to K-PA, bound to 
heparin with strong affinity and formed nanofiber gel.
4
 However, binding mechanism 
there allowed higher dissociation rate of heparin from nanofiber system and probably 
its suboptimal presentation to growth factors and cells, resulting in lower tubule 
formation at in vitro by endothelial cells than heparin-binding PA.
4
 To understand 
whether K-PA – heparin  interaction is also driven by similar mechanism, that is 
through electrostatic interactions, we measured thermodynamic parameters such as 
change in enthalpy and entropy by using Isothermal Titration Calorimetry (ITC). We 
observed that although K-PA bound strongly to heparin (Ka ~ 2 x 10
8
), interaction 
was driven through electrostatic interactions, as indicated by high enthalpic change 
(ΔH = -7.2 x 105 +/- 5.1 x 104) (Figure 2.18). High enthalpy change was also 
observed by Rajangam et al. when heparin and scrambled form of heparin-binding 
PA interacts.
52
 These data collectively suggest that proper presentation of heparin to 
extracellular environment by PA nanofibers is critical, which cannot be achieved by 
K-PA/Heparin nanofibers here.  
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Figure 2.18. Measurement of binding constant and thermodynamic parameters in K-
PA and heparin interaction by using ITC. The top graph shows heat change per unit 
time during heparin titration into K-PA solution and the bottom graph displays the 
integrated data (filled squares) and the best fit to a nonlinear function assuming one 
set of binding sites. K-PA and heparin showed high affinity to each other 
(Ka=2.14+/- 1.03 x 10
8
).    
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Quantification of total length of the capillary-like formations per cell culture plate 
well revealed that HM-PA matrix is the most effective matrix when compared to 
basement membrane gel (Matrigel
TM
) and other controls. Among the two most potent 
PA matrices - HM-PA and D-PA - HM-PA enhanced tube formation capability of 
HUVECs nearly four times more than D-PA (Figure 2.19a). The other PA nanofibers 
also demonstrated poor angiogenesis activity, likely because of the deficiency of 
right composition of functional groups.  
Also interestingly, addition of further growth factors didn`t contribute to further tube 
formation on HM-PA or D-PA matrices, in terms of tube length (Figure 2.19b). In 
HM-PA matrices, we can claim that maximal tube formation is achieved with ‘no 
growth factor’ group, which can be deduced from existence of tubes and minimal 
cell aggregates on every part of the surface of the HM-PA nanofiber matrix. 
Probably signals inducing tube formation had already been at saturation and addition 
of further growth factors didn`t have any contributions to tube formation. However, 
surprisingly, growth factor addition was not effective to change tube formation 
potential of D-PA nanofiber matrix also. This might be due to several reasons. One is 
D-PA nanofibers can not bind optimally to growth factors and cannot present them to 
cells, which is important for heparin-binding growth factors such as VEGF and FGF-
2 used in this study. Presence of heparan sulfate in environment is required for 
proper presentation of growth factors to their receptors on cell surfaces and effective 
signaling to occur.
47, 57
 Rajangam et al. reported that PA nanofiber matrix that is not 
optimal for presentation of heparin showed similarly deficient in vitro angiogenesis 
in the presence or absence of growth factors, emphasizing the importance of proper 
presentation of heparin by nanofiber system and its interaction with growth factors.
4
 
Another is mentioned growth factor cocktail (VEGF/FGF-2) might be insufficient to 
induce angiogenic pathway themselves, therefore we didn`t observe their 
contributory effect to angiogenesis on control PA matrix. 
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Figure 2.19. Quantification of lengths of tubes formed by endothelial cells 
(HUVECs). a. Quantification of tube lengths by HUVECs cultured on Matrigel, HM-
PA gel, D-PA gel, or tissue culture plate (TCP) (a.u. is arbitrary unit). Statistical 
differences between groups were analyzed by one-way ANOVA test. Bonferroni’s 
multiple comparison test was used as posthoc analysis. p < 0.001 between Heparin-
mimetic PA (HM-PA) gel and D-PA gel or TCP. p < 0.05 between HM-PA gel and 
Matrigel. b. Graph illustrates quantification of tube lengths for different growth 
factor treatment conditions (most potent two scaffolds are shown). Low dose: 10 
ng/mL VEGF/FGF-2, high dose: 50 ng/mL VEGF/FGF-2. p < 0.001 between HM-
PA and D-PA scaffolds (analyzed by two-way ANOVA) (n = 3 for all conditions) 
Error bars indicate standard error mean. 
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One might address viability issue of cells on matrices and claim that cells respond to 
toxicity of matrices in this way – through aggregating (which we percept as tube 
formation). In order to understand whether endothelial cells are viable on PA 
nanofiber matrices, we treated cells them with Calcein AM, a chemical which is 
degraded in metabolically active cells and producing fluorescence. Thus, in viable 
cells, we should observe green fluorescence. This assay revealed that the cells 
cultured on HM-PA nanofiber matrices, as well as on basement membrane, control 
PA gels, and tissue culture plate were metabolically active (Figure 2.20). Individual 
cells, cellular aggregates and tubes all showed fluorescence, precluding toxicity issue 
of nanofiber matrices to endothelial cells.  
 
 
Figure 2.20. Viability of cells cultured on PA nanofiber matrices. Calcein staining 
revealed that HUVECs grown on these matrices are metabolically active: a. 
Matrigel
TM
 b. Heparin-mimetic PA nanofiber matrix c. D-PA nanofiber matrix d. All 
images were taken at 100x magnification. (n = 3 for all conditions; representative 
images are shown). 
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In vitro tube formation potential of HM-PA nanofiber matrix was further investigated 
by using H5V cell line (mouse endothelial cell line).
72
 Similar to HUVECs, H5V 
cells also migrated and aggregated extensively and formed capillary-like tubes as 
well as polygonal structures on HM-PA matrices (Figure 2.21a). Although these cells  
were aggregated and migrated on D-PA matrix also, tube formation was ineffective 
and polygonal structures didn`t form (Figure 2.21b). On SO3- PA matrices, both 
migration and aggregation was lower than HM-PA and D-PA matrices, as well as 
formation of tubes and polygonal lattice was impaired (Figure 2.21c). Cells didn`t 
show any angiogenic phenotype when seeded on bare tissue culture plate (Figure 
2.21d). These results further confirm that functional group architecture of Heparin-
mimetic PA has inductive effect on endothelial cells towards angiogenesis.  
 
 
Figure 2.21. In vitro angiogenic performances of H5V (mouse endothelial cell line) 
cells on different PA nanofiber matrices. a. Heparin-mimetic PA, b. SO3-PA, c. D-
PA , d. Tissue culture plate. Extensive formation of tubes and polygonal network of 
tubes was observed only on HM-PA nanofiber matrix. 
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Proliferation of endothelial cells is one of the hallmarks of angiogenesis besides 
endothelial cell activation, migration, sprouting and tubule formation.
73
 In order to 
analyze whether Heparin-mimetic PA had any effect on proliferation of endothelial 
cells, BrdU-based proliferation assay was used. This assay relies on incorporation of 
BrdU into replicating DNA, thus gives information about proliferation status of 
given cell population. The results exhibited that all of the PA nanofibers utilized in 
this study exerted similar effects on the proliferation rates of endothelial cells, which 
was also similar to that of bare tissue culture plate (Figure 2.22). Therefore, it can be 
concluded that proliferation is not among the angiogenic processes induced by 
Heparin-mimetic PA nanofibers in endothelial cells. 
 
        
Figure 2.22. Proliferation of endothelial cells on different PA nanofiber matrices and 
tissue culture plate (TCP). Absorbance values indicate relative BrdU staining 
between different treatments given at X-axis. Differences between means are not 
significant according to one-way ANOVA analysis (n=3; p=0.2822;). This indicates 
that HM-PA or other nanofibers has no further proliferative or anti-proliferative 
effect on endothelial cells than TCP. Error bars indicate standard error mean. 
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In order to observe effects of HM-PA nanofiber matrix on endothelial cells and 
interaction of cells with nanofiber matrix with higher resolution, we obtained images 
of the cells (Figure 2.23) and their sprouts (Figure 2.24) on PA scaffold coated onto 
coverslip over TCP or on bare coverslip over TCP by SEM. The Heparin-mimetic 
PA matrix was observed to facilitate cell spreading and extensive sprouting (Figure 
2.23a-d) when compared with cells grown on tissue culture plate (Figure 2.23e, f).
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On tissue culture plate cells showed almost no sprouting with suboptimal spreading 
character and limited attachment sites (Figure 2.23 e, f). Multiple attachment sites of 
spreaded endothelial cell on HM-PA nanofiber matrix can be observed (Figure 2.23 
a). Cells interact with each other and matrix via their sproutings and extensions 
(Figure 2.23b). Multiple sproutings per cell, their length and branching phenotype 
indicate angiogenic phenotype and suitability of HM-PA nanofiber matrix for this 
purpose (Figure 2.23 c, d). 
Moreover, tubules with more than 4 µm diameter can be observed on Heparin-
mimetic PA matrix (Figure 2.24a).
75
 Sprouts are lengthy and varying in their 
diameter (Figure 2.24b, c). Vessel-like hollowness of sprouting is discernible from 
broken sprout in Figure 2.24c. Sprouts interact with 3d matrix and probably can grow 
in inside the nanofiber matrix (Figure 2.24 d-f). Overall, SEM images of endothelial 
cells on HM-PA nanofiber matrix and coverslips, demonstrate angiogenic phenotype 
gained by endothelial cells selectively on HM-PA nanofiber matrix. 
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Figure 2.23. Electron micrographs of endothelial cells on HM-PA nanofiber 
scaffolds (a-d) and coverslip (e, f). Endothelial cells exhibit heavily sprouting 
phenotype – multiple sprouts per cell and branching sprouts – on HM-PA matrices a-
d, while almost no sprout on tissue culture plate (e, f) (Images a and b are artificially 
colored).  
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Figure 2.24. Electron micrographs of sprouts formed by endothelial cells on HM-PA 
nanofiber scaffolds. a. Tubule formed by endothelial cells with more than 4 µm 
diameter. b. Sprouts on nanofiber matrix (a and b are artificially colored). c. Long 
sprouts and hollow tube-like interior can be discerned from broken sprout. d-f.  
Cellular sprouts interact with fibrous matrix and can elongate inside the matrix. 
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2.3.3. Interaction of VEGF with PA nanofibers 
As previously mentioned, glycosaminoglycans regulate growth factor-receptor 
interactions in the natural cellular environment. For example, VEGF cannot induce 
endothelial cells when there is no glycosaminoglycan in the microenvironment.
49, 52
 
Therefore, induction of angiogenesis by Heparin-mimetic PA nanofibers is possibly 
caused by their ability to bind to and present the growth factors that are secreted by 
the endothelial cells, which is critical for long-lasting angiogenic signaling to 
occur.
52
 Specific growth factor binding to HM-PA nanofibers was investigated by 
isothermal titration calorimetry (ITC), which measure heat change after titrating 
VEGF molecules into the PA solutions (Figure 2.25 and 2.26). The binding constants 
between VEGF and both solution and nanofiber forms of HM-PA and D-PA were 
calculated by ITC (Figure 2.25, 2.26 and Table 2.3). As a result of this experiment, 
binding constant between HM-PA and D-PA molecules in nanofiber (mixed with K-
PA) or in solution form and VEGF was found to be similar to the binding constant 
between heparin and VEGF, which confirms high affinity of both molecules to 
VEGF at given concentration.
76
   
Interestingly, binding constants of solution forms of PAs with VEGF were higher 
than nanofiber forms with VEGF (5 fold for HM-PA and more than 2 fold for D-PA) 
(Table 2.3). These data suggest that bindings may be driven by charge-charge 
interactions, since the nanofiber forms are prepared by mixing K-PA into the solution 
form which neutralizes some of the negative charges on HM-PA and D-PA. Also, 
HM-PA molecules are mixed with 2 moles of K-PA, while D-PA molecules are 
mixed with 1 mole of K-PA to make final theoretical charge of the system similar. 
This might explain why we observed bigger difference between solution and 
nanofiber forms of HM-PA than D-PA (Table 2.3).  
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Figure 2.25. Isothermal Titration Calorimetry (ITC) graphs for titration of Heparin-mimetic 
PA molecules in solution form with VEGF. The top graph shows heat change per unit 
time during VEGF titration into Heparin-mimetic PA solution, and the bottom graph 
displays the integrated data (filled squares) and the best fit to a nonlinear function 
assuming one set of binding sites. Data indicates strong affinity between HM-PA 
molecules and VEGF (Ka calculated = 2.93x10
6 ± 5.12x105 M-1).  
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Figure 2.26. Isothermal Titration Calorimetry (ITC) graphs for titration of Heparin-
mimetic PA (HM-PA) molecules in nanofiber form – mixed with K-PA – with 
VEGF. The top graph shows heat change per unit time during VEGF titration into 
Heparin-mimetic PA nanofiber solution, and the bottom graph displays the integrated 
data (filled squares) and the best fit to a nonlinear function assuming one set of 
binding sites. Data indicates strong affinity between HM-PA nanofibers and VEGF 
(Ka calculated =7.37x10
5± 5.1x104 M-1). 
55 
 
Since at higher concentrations aggregation of PA molecules and gel formation are 
observed, in this experiment we used low concentration of both PA molecules to 
make an experimental measurement possible. Both HM-PA and D-PA molecules 
revealed similar binding affinity to VEGF. This suggests that VEGF-PA interaction 
at this concentration was supported mainly by opposite charges between VEGF and 
PA molecules but not specific functional group architecture on nanofiber. Moreover, 
VEGF binding was driven by large enthalpic changes, which further support that 
electrostatic interactions have taken a role in the VEGF-PA binding (Table 2.3).
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The decrease in entropy indicates the loss of conformational freedom for interacting 
molecules and the formation of more ordered complex structures (Figure 2.13 and 
Table 2.3).
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Table 2.3. Binding constants of VEGF – PA interaction at 30 °C measured by ITC. 
Peptide Amphiphile 
Binding constant 
(Ka) (M
-1
) 
Enthalpy change  
(∆H) 
(cal/mol) 
Entropy  
change (∆S) 
(cal/mol/deg) 
Heparin-mimetic PA*    2.93x10
6 ± 5.12x105 -6.163x105 ± 1.130x105 -2x103 
Heparin-mimetic PA** 7.37x10
5 ± 5.1x104 -4.122x107 ± 1.79x106 -1.82x104 
D-PA* 3.02x10
6 ± 1.43x106 -9.312x105 ± 6.723x105 -3.04x103 
D-PA** 1.40x10
6 ± 8.4x104 -3.870x107 ± 1.24x106 -1.48x104 
* PA used in solution form  
**PA used in nanofiber form (PA was mixed with K-PA before titration) 
 
 
We further investigated the interaction of VEGF with PA nanofibers, but this time 
with nanofiber network formed by PA molecules. For this, we designed a growth 
factor release assay by encapsulating VEGF into gels formed by the PA nanofibers. 
VEGF release from HM-PA, D-PA, and K-PA/Heparin gels were monitored for 7 
days to analyze the release rate. We observed burst release of growth factors from D-
PA and heparin gels at 2 h, whereas the release rate was significantly lower for HM-
PA gels (Figure 2.27). At the end of 7 days, only ∼5% of the encapsulated VEGF 
was released from HM-PA gel, whereas this ratio was nearly 40% for heparin gel and 
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33% for D-PA gel. Because gelation and structural properties of the PA molecules 
revealed no significant differences, as analyzed by SEM, AFM, rheology, and CD; 
the possibility of physical release causing difference in release rate between Heparin-
mimetic PA gel and other gels was eliminated. We concluded that VEGF binds to 
Heparin-mimetic PA nanofibers more strongly than D-PA and K-PA/heparin 
nanofibers. Although ITC results revealed similar binding affinities for both HM-PA 
and D-PA molecules to VEGF (Table 2.3), when these molecules are used in very 
dilute amounts (∼10-4 M), the release rates of the VEGF from the corresponding 
gels, which are composed of densely packed nanofibers, was significantly different 
(Figure 2.27).  According to the results of the release assay, it can be suggested that 
HM-PA nanofibers provide more specific binding sites for VEGF compared with D-
PA nanofibers. The release profile of VEGF from K-PA/Heparin gel further 
demonstrates inappropriate presentation of heparin in this gel, impairing its growth 
factor binding capacity, which we have previously suggested according to the results 
of the in vitro angiogenesis assay and ITC measurement of interaction of K-PA and 
heparin (Figure 2.17b and 2.18). Importantly, slow release rate of VEGF from 
Heparin-mimetic PA gel is a significant finding because the formation of robust 
vessels requires long-term release of growth factors at low concentrations.
11, 21
 
Growth factor concentrations above the microenvironmental threshold (therapeutic 
range) cause vessel malformation with leaky and aberrant character.
11, 21, 79
 HM-PA 
gel was observed to release VEGF within the narrow therapeutic range, which is 
important for clinical applications. 
 
57 
 
 
Figure 2.27. Release profile of vascular endothelial growth factor (VEGF) from 
various PA gels. Release of VEGF from 3 different PA gels was followed for 7 days. 
VEGF concentration in release buffer was measured by ELISA method. HM-PA gels 
released VEGF considerably slower than D-PA and K-PA/Heparin gels (n = 5 for 
Heparin-mimetic PA; n = 3 for D-PA and K-PA/heparin) Error bars indicate standard 
error mean. 
 
Charges of these peptide nanofiber systems are important since they can give 
information about how growth factor binding to PA nanofiber systems depends on 
charge.  Zeta potentials of PA solutions and nanofibers (with K-PA) were measured 
to understand the charge of the peptide systems (Figure 2.28). All carboxylate and 
sulfonate functionalized PAs and heparin revealed high negative potentials. When K-
PA with a positive potential was added to the aforementioned solutions, negative 
charge in all solutions decreased. While HM-PA and SO3-PA had zeta potentials of 
~-90 and -70 mV, HM-PA/K-PA and SO3-PA/K-PA combinations had potentials of 
nearly -30 mV (Figure 2.28). We observed a similar trend in heparin and K-PA 
mixture, when potential of heparin solution increased decreased from -60 to -45 mV. 
Whereas, D-PA potential increased to -5 mV from -60 mV after addition of K-PA 
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(Figure 2.28). Since bioactivity of heparan sulfates (i.e. growth factor binding) is 
related to their high negative charges caused by functional groups, we adjusted molar 
ratios of these mixtures for all experiments so that the net theoretical charge of the 
system will be negative (-1). However, zeta potential data indicated that charge 
density on PA complexes was not the same. This observation can be related to the 
presence of sulfonate (-SO3) group in Heparin-mimetic PA and SO3-PA, as well as 
heparin. Sulfonate group’s pKa (∼1) is lower than carboxylate group’s pKa (∼5), 
making charge neutralization of D-PA easier than that of sulfonate-bearing PAs. 
Therefore, the presence of sulfonate group increases the negative charge density on 
PA nanofibers, which might have an activatory role in growth factor binding. 
However, SO3-PA nanofibers and heparin/K-PA did not as much reveal bioactivity 
compared with Heparin-mimetic PA nanofibers, as discussed above (Figure 2.16 and 
2.17). Therefore, bioactivity of PA nanofibers is not only related to the charge of the 
system. Moreover, growth factor release rates from K-PA/Heparin gel shown in 
Figure 2.27 were significantly faster than those from HM-PA gel and D-PA gel, 
although charge of K-PA/Heparin system was more negative than HM-PA and D-
PA. Picture drawn by all of these data suggests that growth factor interaction with 
PA nanofiber system is not an entirely function of charge of the system. Rather 
proper presentation of functional groups (or heparin in case of K-PA/Heparin) by 
nanofibers determines interaction of vascular endothelial growth factor with 
nanofiber scaffold and induction of angiogenic processes in endothelial cells. 
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Figure 2.28. Zeta-potential measurements of PA combinations. K-PA is a positively 
charged peptide at physiological pH and showed positive zeta potential, while 
negatively charged PAs and their mixtures with K-PA had negative zeta potentials. 
Negative charge of D-PA neutralized very sharply upon mixing with K-PA, while 
heparin, HM-PA and SO3-PA retained their negative charge considerably better.   
 
2.3.4. Gene expression analysis of angiogenic switch in endothelial cells  
Angiogenesis is initiated and maintained through distinct regulatory mechanisms that 
take place inside the endothelial cells. Toward this purpose, phases of endothelial 
cell activation and proliferation, followed by cellular migration and finally 
stabilization of tubular structures are required. Expressions of several genes are 
strictly regulated during these phases. To investigate further the mechanism of 
angiogenic switch in endothelial cells caused by Heparin-mimetic PA nanofibers, we 
analyzed the expression of genes involved in angiogenesis at mRNA level. Six 
different genes were selected from three different stages of angiogenesis. VEGF and 
FGF-2 are mainly involved in endothelial cell activation and proliferation; integrin 
α5 (IA5), integrin αv (IAV), and integrin β3 (IB3) take roles in cellular migration, 
and angiopoietin-1 (Ang-1) induces stabilization of vascular tubes.
80
 Endothelial 
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cells were cultured on PA matrices for three different durations (6 h, 24 h, and 48 h) 
to simulate sequential activation of angiogenic stages in natural environment. We 
expected that, during the natural course of angiogenesis, VEGF and FGF-2 are 
upregulated at 6 h, integrins at 24 h, and Ang-1 at 48 h. Table 2.4 shows time-
dependent expression of each gene, where each PA treatment was compared with the 
tissue culture plate. We observed that Heparin-mimetic PA scaffold enhanced the 
expression of genes for the aforementioned three stages of angiogenesis at expected 
time points (VEGF at 6 h, IA5 and IB3 at 24 h, whereas Ang-1 at 48 h; Table 2.4, 
Figure 2.29). FGF-2 levels were lower than VEGF, indicating that angiogenic switch 
was mainly driven by VEGF. The D-PA scaffold upregulated genes involved in 
endothelial cell activation and migration (VEGF, IA5, IB3, and IA5), whereas it 
downregulated Ang-1 (Figure 2.29). This observation is consistent with in vitro tube 
formation results (Figure 2.16, 2.21), where D-PA scaffold failed to form a stable 
tubular network, which is mainly maintained by Ang-1. Moreover, Heparin-mimetic 
PA nanofibers were more potent than D-PA regarding the expression of VEGF, IA5, 
IB3, and Ang-1, which indicates that Heparin-mimetic PA scaffold actively triggers 
endothelial cells to enter into angiogenic route. 
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Table 2.4. Gene expression profiles in endothelial cells cultured on PA nanofibers. 
        Gene    Time point   PA nanofiber  % change in expression 
 
Integrin α5 
 
 
6 h 
D-PA 4% upregulated 
HM-PA 27% upregulated 
 
24 h 
D-PA 29% upregulated 
HM-PA 75% upregulated 
 
48 h 
D-PA 20% upregulated 
HM-PA 19% upregulated 
Integrin αV 
 
6 h 
D-PA 10% downregulated 
HM-PA 16% upregulated 
 
24 h 
D-PA 7% upregulated 
HM-PA 15% downregulated 
 
48 h 
D-PA 31% downregulated 
HM-PA 39% downregulated 
Integrin β3 
 
6 h 
D-PA 15% upregulated 
HM-PA 19% upregulated 
 
24 h 
D-PA 42% upregulated 
HM-PA 39% upregulated 
 
48 h 
D-PA 5% downregulated 
HM-PA 4% downregulated 
VEGF 
 
6 h 
D-PA 47% upregulated 
HM-PA 123% upregulated 
 
24 h 
D-PA 29% upregulated 
HM-PA 66% upregulated 
 
48 h 
D-PA 21% upregulated 
HM-PA 21% upregulated 
FGF2 
 
6 h 
D-PA 5% upregulated 
HM-PA 9% upregulated 
 
24 h 
D-PA 17% upregulated 
HM-PA 55% downregulated 
Ang1 
 
24 h 
D-PA 19% upregulated 
HM-PA 52% downregulated 
 
48 h 
D-PA 27% downregulated 
HM-PA 42% upregulated 
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Figure 2.29. Investigation of expression profiles of angiogenic genes in endothelial 
cells (HUVEC) cultured on PA nanofiber matrices or tissue culture plate. Expression 
profiles of genes involved in different angiogenic stages were investigated at 
different time points by qRT-PCR. Activities of PA matrices tested here were 
compared with tissue culture plate, and results are illustrated as change in gene 
expression (%). Peak time point was selected for each gene and shown in this figure 
(n = 3 for all experiments). Error bars indicate standard error mean. 
 
Since gene expression analysis in HUVECs revealed elevated expression of VEGF 
mRNA in endothelial cells cultured on HM-PA nanofibers and because capillary-like 
formations by endothelial cells can be triggered without any addition of exogenous 
VEGF by using these nanofibers, we asked whether VEGF secretion from HUVECs 
was also altered when cultured on HM-PA nanofibers. We checked VEGF secretion 
from HUVECs, cultured on HM-PA or D-PA nanofiber matrices or tissue culture 
plate, by using ELISA. ELISA results revealed that time-dependent VEGF secretion 
from HUVECs on HM-PA matrices increased exponentially as a function of time 
(Figure 2.30). At the end of 48 h, HM-PA induced four times more VEGF secretion 
than bare tissue culture plate and nearly two times more than D-PA. These results 
suggest that besides elevated expression of VEGF, the induction of VEGF secretion 
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is in effect. This might be due to autocrine signaling, where released VEGF 
molecules from cells are possibly entrapped and presented to the cells better with the 
HM-PA matrix, inducing the VEGF signaling pathways more robustly than the D-PA 
matrix and bare tissue culture plate. 
 
 
Figure 2.30. Determination of VEGF secretion from endothelial cells (HUVECs) 
cultured on PA nanofiber matrices or tissue culture plate. Time-dependent VEGF 
secretion from HUVECs cultured on different PA matrices or tissue culture plate 
were measured by using ELISA. p < 0.001 between Heparin-mimetic PA and Asp-
PA or tissue culture plate at 48 h (analyzed by two-way ANOVA) (n = 3 for all 
conditions). Error bars indicate standard deviation. 
 
2.3.5. In vivo neovascularization assay  
The construction of robust vessels integrated into the circulatory system is crucial for 
functional tissue formation. To investigate in vivo efficacy of Heparin-mimetic PA 
(HM-PA) nanofibers, a rat corneal micropocket neovascularization assay was used. 
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Because the cornea is devoid of blood vessels, neo-vascularization in response to 
treatment condition can be easily detected.
81
 Our treatment groups included HM-PA 
gel with growth factors (VEGF/FGF-2 combination) and growth factor solution only. 
Although the growth factor amount used was several times lower than the ones that 
were used in the literature,
82
 it was sufficient to induce neo-vascularization when 
used in combination with HM-PA gel (Figure 2.31a). Moreover, vascularization after 
growth factor treatment without PA gel was limited and significantly lower than that 
induced by growth factors in combination with HM-PA gel (Figure 2.31 and 2.32). 
 
 
Figure 2.31. Evaluation of in vivo bioactivity of HM-PA nanofibers by corneal 
angiogenesis assay. a. Injection of 1 wt% HM-PA gel with 10 ng of VEGF and bFGF 
induced robust vascularization in cornea. b. Application of growth factor solution (10 
ng of VEGF and bFGF) in physiological saline (without PA gel) did not induce 
vascularization. Photos were taken after perfusing animals with Indian ink. 
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Figure 2.32. Quantification of vascularized area in corneal angiogenesis assay. Ratio 
of vascularized area to total area was calculated for both groups (n = 3 for each 
group). Heparin-mimetic PA gel with growth factor (Gel + GF) was significantly 
higher than growth factor alone (GF) solution treatment as compared with Student’s t 
test (***p < 0.001) (n = 3 for both treatments). Error bars are standard deviations. 
 
In the corneal angiogenesis assay, the samples were introduced to the center of 
cornea, which is located far from the endothelial cells, therefore there are no 
detectable angiogenic growth factors in this area in healthy animals. Likely due to 
mentioned reasons, no significant vessel formation was observed in animals injected 
with Heparin-mimetic PA gel without growth factor (Figure 2.33b). This observation 
also shows that angiogenic activity observed in Figure 2.31a and 2.33a is not caused 
by inflammatory response against PA nanofibers but is because of slow release of 
growth factors from Heparin-mimetic PA gels. Moreover, Indian ink, which was 
used for perfusing the animals, entered and stayed in the newly formed capillaries, 
confirming that new vessels are robust and integrated to the circulatory system 
(2.31a). 
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Figure 2.33. Effect of HM-PA gel alone or with growth factors on corneal 
angiogenesis. Treatments: a. HM-PA gel with growth factors (10 ng VEGF/FGF2) b. 
HM-PA gel alone (n=3 for each treatment). While robust vascularization is observed 
with HM-PA gel with growth factors, no detectable vascularization is observed with 
HM-PA gel alone.  
 
2.4. Experimental Details 
2.4.1. Materials.  
9-Fluorenylmethoxycarbonyl (Fmoc) and tert-butoxycarbonyl (Boc) protected amino 
acids, [4-[α(20, 40 dimethoxyphenyl) Fmocaminomethyl] phenoxy] 
acetamidonorleucyl-MBHA resin (Rink amide MBHA resin), Fmoc-Asp(OtBu)-
Wang resin, and 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) were purchased from NovaBiochem and ABCR. 
Heparin was purchased from Sigma-Aldrich. The other chemicals were purchased 
from Fisher, Merck, Alfa Aesar, or Aldrich. All chemicals were used as provided. 
VEGF (vascular endothelial growth factor) used in angiogenesis assays were 
purchased from Sigma-Aldrich (mouse) and Invitrogen (human). Both mouse and 
human bFGFs (fibroblast growth factor) (FGF-2) were purchased from e-
Biosciences.  
67 
 
2.4.2. Synthesis of Peptide Amphiphiles  
PAs were constructed on Rink Amide MBHA resin or Fmoc-Asp(OtBu)-Wang resin. 
Amino acid couplings were performed with 2 equiv of Fmoc-protected amino acid, 
1.95 equiv of HBTU, and 3 equiv of N,N-diisopropylethylamine (DIEA) for 2 h. 
Fmoc removal was performed with 20% piperidine/dimethylformamide solution 
(DMF) for 20 min. We used 10% acetic anhydride solution in DMF to block 
remaining free amine groups after amino acid coupling. After each step, resin was 
washed by using three times DMF, three times DCM, and three times DMF, 
respectively. Sulfobenzoic acid was added to the side chain of lysine to synthesize 
sulfonated PAs. A lysine residue with 4-methytrityl (Mtt) side-chain protection was 
used for selective deprotection of amine groups. Mtt removal was performed by 
shaking resins for 5 min with TFA/TIS/H2O/DCM in the ratio of 5:2.5:2.5:90. 
Cleavage of the PAs from the resin was carried out with a mixture of TFA/TIS/H2O 
in the ratio of 95:2.5:2.5 for 2 h. Excess TFA was removed by rotary evaporation. 
The remaining viscous PA solution was triturated with ice-cold ether, and the 
resulting white precipitate was dried under vacuum. PAs were characterized by 
liquid chromatography-mass spectrometry (LC-MS). Mass spectrum was obtained 
with Agilent 1200 LC-MS equipped with Agilent 6530 Q-TOF with an ESI source 
and Zorbax Extend-C18 2.1 x 50 mm column for basic conditions and Zorbax SB-C8 
4.6 mm x 100 mm column for acidic conditions. A gradient of (a) water (0.1% 
formic acid or 0.1% NH4OH) and (b) acetonitrile (0.1% formic acid or 0.1% 
NH4OH) was used. Agilent 1200 preparative reverse-phase HPLC system equipped 
with a Zorbax Extend-C18 21.2 x 150 mm column for basic conditions and a Zorbax 
SB-C8 21.2 x 150 mm column for acidic conditions was used to purify the peptides. 
A gradient of (a) water (0.1% TFA or 0.1% NH4OH) and (b) acetonitrile (0.1% TFA 
or 0.1% NH4OH) was used.  
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2.4.3. Peptide Amphiphile Nanofiber Formation.  
To investigate angiogenic potentials of PA nanofibers presenting heparin-mimicking 
functional groups, we designed and synthesized several PA molecules. Functional 
group content varied for each molecule: Heparin-mimetic PA (HM-PA) was 
synthesized with sulfonate, hydroxyl, and carboxylic acid groups, SO3-PA with 
sulfonate and carboxylic acid groups, and D-PA with only carboxylic acid groups 
(Figure 2.2). To induce gel and nanofiber formation, we prepared PA formulations 
by mixing HM-PA PA, D-PA, and SO3-PA molecules with K-PA at 1:2, 1:1, and 1:1 
molar ratios, respectively. H-PA solution was adjusted to pH 7.4, and heparin was 
mixed with K-PA at ~1:8 molar ratios. 
 
2.4.4. AFM Imaging of PA Nanofibers 
AFM sample solutions were dropped on the silicon wafer surface and mixed by 
pipetting up and down. We mixed 25 μL of 0.02 wt% Heparin-mimetic PA or 
equimolar concentrations of SO3-PA and D-PA with 25 μL of 0.02 wt% positively 
charged K-PA. Heparin was mixed with K-PA, and H-PA solution was adjusted to 
pH=7 for nanofiber formation. After 30 s, solvent on the wafer was removed by 
using dust-free tissue paper, and the rest was air dried. Contact mode atomic force 
microscopy (AFM) was performed by using model MFP-30 from Asylum Research. 
All images were taken with 0.5 Hz scan rate. Tips with resonance frequency of 13 
kHz and spring constant of 0.2 N/m were used in all experiments. 
 
2.4.5. SEM Imaging of PA Gels 
PA gels (1 wt% Heparin-mimetic PA gel and equimolar amount for the rest) were 
transferred onto a metal mesh, and network dehydration was performed by 
incubating gels for 30 s in 20, 40, 60, 80, and 100% ethanol sequentially. Then, gels 
were critical-point dried by using Autosamdri-815B (Tousimis). Dried gels were 
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coated with 6 nm of Pt. SEM (FEI Quanta 200 FEG) images were taken by using 
ETD detector at high vacuum mode with 30 keV beam energy. 
 
2.4.6. TEM Imaging of PA Nanofibers and Nanofiber Size Measurements 
PA nanofiber size measurements were made according to TEM images for each 
nanofiber type.
83
 TEM sample was prepared by mixing HM-PA, SO3-PA, and D-PA 
(1 wt%) with K-PA (1 wt%). Gel was diluted 10 times, and 30 μL from this solution 
was drop casted onto a hydrophobic surface. TEM grid was placed onto droplet and 
incubated for 3 min. Staining was performed with 2% uranyl acetate. Nanofiber 
diameters were measured by Image J software (NIH). 
 
2.4.7. SEM Imaging of Cells on the PA Gels 
In vitro tube formation experiment was performed (as described above) on round 
glass coverslips located in 24-well plates. After 48 h, media on cells were aspirated, 
and cells were washed with 1x PBS twice. Cells were fixed with 2% glutaraldehyde 
1 h prior to fixation with 1% osmium tetroxide (OsO4). After network dehydration, 
critical-point drying was performed as described above for SEM imaging of PA gels. 
Samples were coated with 6 nm Au-Pd coating, and SEM imaging was performed as 
described above. 
 
2.4.8. Isothermal Titration Calorimetry 
To investigate the interaction between VEGF and PAs, we used the iTC200 system 
(MicroCal, GE Healthcare). VEGF titration (6.25 μM) into four different PA 
solutions (0.08 mM) was performed on HM-PA (solution form), HM-PA/K-PA 
(nanofiber form), D-PA (solution form), and D-PA/K-PA (nanofiber form). VEGF 
into H2O and H2O into HM-PA with K-PA titrations were performed as control to 
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eliminate dilution heats. Reaction was performed at 30 °C with 400 rpm stirring 
speed. Twenty-five injections were performed, where the injection period was 4 s 
and space between injections was 200 s. The data were integrated and fit to a curve 
with MicroCal Origin software to calculate the binding constant. For VEGF to PA 
solution titrations, best-fitting was obtained with one set of sites model, whereas for 
VEGF to PA nanofiber titrations, best-fitting was obtained with sequential binding 
sites model, and binding constants were calculated accordingly. To determine 
supramolecular heparin-mimetic system concentration, we performed calculations 
based on approximations made by Silva et al.
6
 (average diameter of fiber disk = 6 
nm; circumference of nanofiber (Πd) = 18.8 nm, number of PA molecules/radial disk 
= 50). Width of radial disk ≈ size of 1 molecule = 18.8 nm/50 = 0.376 nm. A 100 nm 
length PA nanofiber can contain ~13,300 PA molecules with 50 PA molecules per 
radial disk and 0.376 nm width. HM-PA and K-PA were mixed at 1:2 molar ratio. 
Therefore, the number of HM-PA molecules per 100 nm nanofiber was calculated to 
be 13,300/3 = 4433 molecules. By assuming that the average nanofiber length was 
100 nm, nanofiber concentration = 0.08 mM/4433 = 1.8 x 10
-5
 mM. D-PA and K-PA 
were mixed with 1:1 molar ratio. The number of D-PA per 100 nm nanofiber was 
calculated to be 13,300/2 = 6650 molecules. By assuming that average nanofiber 
length was 100 nm, nanofiber concentration = 0.08 mM/6650 = 1.2x10
-5
 mM. The 
nanofiber dimensions were also measured by using TEM imaging, as described 
above. All solutions that were used in ITC experiments were at pH=7. To investigate 
the interaction between heparin and K-PA, heparin (100 μg/mL) was titrated into K-
PA solution (40 μg/mL). Reaction was performed at 30 oC with 400 rpm stirring 
speed. Twenty-five injections were performed, where injection period was 4 s and 
space between injections was 150 s. The data were integrated and fit to a curve with 
MicroCal Origin software to calculate the binding constant. Best fitting was obtained 
with one set of sites model. 
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2.4.9. Oscillatory Rheology 
Oscillatory rheology measurements were performed with an Anton Paar Physica 
RM301 rheometer operating with a 25 mm parallel plate configuration at 25 
o
C. Each 
sample of 180 μL total volume with a final PA concentration of 1 wt% HM-PA or 
equimolar concentrations for other PA molecules was carefully loaded on the center 
of the lower plate and incubated for 15 min before measurement. After equilibration, 
the upper plate was lowered to a gap distance of 0.5 mm. Storage moduli (G`) and 
loss moduli (G``) values were scanned from 100 to 0.1 rad/s of angular frequency, 
with a 0.5% shear strain. 
 
2.4.10. Circular Dichroism 
JASCO J815 CD spectrometer was used at room temperature. We measured 2 x 10
-4
 
M peptide solutions from 300 to 190 nm, data interval and data pitch were 0.1 nm, 
scanning speed was 100 nm/min, and all measurements were performed with three 
accumulations. DIT was selected as 1 s, bandwidth as 1 nm, and the sensitivity was 
standard. Molar ellipticity was calculated using the equation: [θ] = 100 x θ/(C x l), 
where C is the concentration in molar, and l is the cell path length in centimeters. [θ] 
= θ/(Cx l) = deg/(mol/1000 cm3) x 0.1 cm = 10 cm 10-3 deg 1000 cm3 mol-1 = 100 
deg cm
2
 dmol
-1
. 
 
2.4.11. Zeta Potential Measurement 
The zeta potential of equimolar PA solutions (0.16 mM) and heparin (0.5 mg/mL) 
was measured by Nano-ZS Zetasizer (Malvern). Zeta potential converts measured 
mobility to zeta potential by using Smoluchowski equation. After measuring zeta 
potential of each PA solution, K-PA was mixed with HM-PA (2:1 molar ratio), SO3-
PA (1:1 molar ratio), D-PA (1:1 ratio), or heparin and the zeta potential of the 
solution was measured again. Molar ratios were the same as those used for cell 
culture and other experiments (net theoretical -1 charge for each combination). 
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2.4.12. Cell Lines and Cell Culture Reagents 
H5V mouse endothelial cells
72
 were a kind gift from Dr. Annunciata Vecchi, 
Instituto Clinico Humanitas, IRCCS, Rozzano, Milano, Italy. Human umbilical vein 
endothelial cells (HUVECs) were donated by Yeditepe University, Istanbul, Turkey. 
HUVECs were purified as described
84
 and were characterized by staining with 
CD34, CD31, and CD90 surface markers. These cells were found to be positive for 
CD31 and CD34 but negative for CD90. All media, sera, and other cell culture 
reagents were purchased from Invitrogen. Matrigel was purchased from BD 
Biosciences. 
 
2.4.13. In Vitro Angiogenesis Assay 
Equimolar concentrations of PAs (0.2 wt % for Heparin-mimetic PA and equimolar 
amount for the rest) were used to form gels in 96-well plates. Coated plates were 
incubated at 37 
o
C for 30 min, prior to overnight incubation in laminar flow hood at 
room temperature for solvent evaporation. The next day, PA matrix formed on 96-
well plates was UV-sterilized, and endothelial cells were cultured on these matrices 
or Matrigel, which was used as a positive control. HUVECs cultured in DMEM with 
10% FBS (growth medium) were collected at 80-90% confluency and resuspended in 
DMEM with 5% FBS for angiogenesis assay. Cell number was adjusted to 2 x 10
5
 
cells/mL, and 200 μL of this suspension was added to each well either alone or 
mixed with low (10 ng/mL) or high (50 ng/mL) dose of VEGF/bFGF combination. 
After 48 h, cells were imaged by using bright-field microscopy at 100x 
magnification. For fluorescence imaging, media over cells were aspirated, and cells 
were washed with PBS. Calcein solution (2 μM, 100 μL) was added to cells and 
incubated for 30 min at 37 °C. Cells were imaged with fluorescence microscopy. 
Mouse endothelial cells (H5V) were also grown in DMEM with 10% FBS until 80-
90% confluency. Cells were collected and resuspended in minimal essential media 
(MEM) with 2% FBS during angiogenesis assay. Cell numbers were adjusted to 3 x 
10
5
 cells/mL. We added 100 μL from this suspension (3 x 104 cells) to each PA 
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matrix. Cells were incubated for 48 h, and imaging was performed by using bright 
field microscopy. All of the in vitro experiments and other measurements were 
performed at least three times.  
 
2.4.14. Cell Proliferation Assay 
 96-well plates were coated with PA matrices, as described above for in vitro 
angiogenesis assay, or left uncoated (TCP). HUVEC (1 x10
4
) were added to each 
well in DMEM with 10% FBS. BrdU-based kit (Roche) was used to evaluate cell 
proliferation at the end of 54 h. In brief, 16 h before ending an experiment, BrdU was 
added to each well. After 16 h, cells were fixed and stained by using labeled antibody 
against BrdU. Cells were washed three times with PBS, and substrate solution was 
added. After 5, 10, and 20 min, color development was measured at 370 nm by using 
microplate reader (Molecular Devices) and subtracted from reference wavelength 
(492 nm) values. 
 
2.4.15. Quantification of in vitro tube formation 
In total, 12 images (100x magnification) were taken for each treatment group (four 
different images per well). Quantification of endothelial tube lengths on each image 
was performed by using NIH Image J software according to previously published 
criteria.
85
 Tube length values obtained for each well (three wells per treatment group) 
were summed, and mean value of data obtained from three wells was calculated. 
Two-way ANOVA was used for statistical analysis. 
 
2.4.16. Growth Factor Release from PA Gels 
Heparin-mimetic PA, D-PA, and heparin solutions (25 µl) were combined with K-
PA (25 µl; premixed with 100 ng of VEGF) to induce gel formation (1 wt% for 
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Heparin-mimetic PA gel and equimolar amount for the rest). After 1 h of incubation 
at 37 °C, 250 μL of 1x PBS was added to each gel. Buffer over gels was collected 
and replaced with fresh buffer at four different time points (2, 24, 72, and 168 h). 
VEGF released in the buffer solutions was quantified by ELISA method. VEGF 
incubated in same buffer solution (without gel) was accepted as 100% release. 
 
2.4.17. Real-Time Gene Expression Study 
HUVECs (3 x 10
5
 cells/ well) were cultured on bare tissue culture plate (NC), HM-
PA, or D-PA nanofiber matrices (as described in the In Vitro Angiogenesis Assay 
section) for three different durations (6, 24, and 48 h). Total RNAs were extracted 
from cells by using TRIzol (Invitrogen) according to the manufacturer’s instructions. 
Concentration and purity of isolated RNAs were measured by Nanodrop. Samples 
were diluted to a concentration of 50 ng/μL prior to their use. RNAs were converted 
to cDNA and amplified by using SuperScript III Platinum SYBR green one step 
qRT-PCR Kit (Invitrogen). Primer sequences for each gene are given at Table 2.5. 
Specificity of amplifications was determined by the presence of single peaks/gene in 
melting curve analysis and detection of the product size by running PCR products in 
1.5% agarose gel. Gene expression levels were normalized with GAPDH expressions 
for each sample, and relative expressions were calculated by 2
-ΔΔCt
 method according 
to the below formula: ΔCt (NC) =(Ctgene-Ctreference); ΔCt (PA-coated) = (Ctgene- 
Ctreference); ΔΔCt = ΔCt (PA nanofiber-coated) - ΔCt (NC); fold expression =2
-ΔΔCt
; % 
change in expression: 100 x 2
-ΔΔCt
. 
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Table 2.5. Investigated genes taking role in angiogenesis process. 
Genes Angiogenic stage  Primer sequences 
 
VEGF 
Endothelial cell 
activation 
5′-ATCTTCAAGCCATCCTGTGTGC-3′       
5′-CAAGGCCCACAGGGATTTTC-3′           
86 
FGF-2 
Endothelial cell 
activation
 
5′-ACGGCGTCCGGGAGAA-3′       
5′-ACACTCCCTTGATGGACACAACT-3′   
87 
Integrin α5 
(IA5) 
Cell migration 
5'-TGCAGTGTGAGGCTGTGTACA-3' 
5'-GTGGCCACCTGACGCTCT-3'                 
88
 
Integrin αv 
(IAV) 
Cell migration 
5'-AATCTTCCAATTGAGGATATCAC-3' 
5'-AAAACAGCCAGTAGCAACAAT-3'       
88
 
Integrin β3 
(IB3) 
Cell migration 
5'-CCGTGACGAGATTGAGTCA-3' 
5'-AGGATGGACTTTCCACTAGAA-3'        
88
 
Angiopoietin
-1 (Ang1) 
Vascular maturation, 
stabilization 
5'-ACCCGAGCCTATTCACAGTA-3'  
5'-CATTCAGTTTTCCATGGTTT-3'             
89
 
 
 
2.4.18. Detection of VEGF Secretion by Endothelial Cells 
HUVECs were cultured at a density of 4 x 10
4
 cells/well on different PA matrices 
and bare tissue culture plates, as described above (In Vitro Angiogenesis Assay 
section). Supernatants were collected at three different time points (12, 24, and 48 h). 
Concentration of VEGF in these supernatants was quantified by ELISA (Invitrogen). 
Two-way ANOVA was used to determine the significance of difference between 
VEGF secretion amount from cells cultured on PA matrices or tissue culture plate. 
 
2.4.19. In Vivo Corneal Micropocket Angiogenesis Assay 
Animal model and experimental setup were approved by the Animal Ethics 
Committee of Fatih University Medical School. The in vivo assay was carried out 
with 200-220 g female Sprague-Dawley rats. A surgical micropocket was opened in 
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the cornea ~1.5 mm from the limbus under anesthesia, as described.
5
 Three 
conditions were tested with this model: 1 wt% HM-PA gel with 10 ng bFGF and 
VEGF; growth factor solution including 10 ng bFGF and VEGF; and 1 wt% HM-PA 
gel without growth factors. Gels were made in situ by mixing HM-PA and K-PA. 
Eleven days after injection, rats were anesthetized with xylazine/ketamine solution 
and perfused through injection of India ink to the left ventricular region of their 
hearts to observe integration of newly formed vessels into the circulatory system. 
Quantification of vascularization as a response to each treatment (n = 3 per group) 
was done with NIH Image J software according to previous work.
5
 Student’s t test 
was used for statistical analysis of difference between treatment groups. DC-1 digital 
camera (Topcon Europe, Ijssel, The Netherlands) was used for imaging the cornea. 
 
2.5. Conclusion 
In this chapter, requirement for heparin for growth factor activity was eliminated by 
using peptide nanofibers decorated with bioactive chemical groups from heparin 
(sulfonate, carboxylic acid, and hydroxyl). The in vitro angiogenesis assays revealed 
that sulfonate group itself is not sufficient for an optimal angiogenic outcome. By 
using other biologically active chemical groups along with the sulfonate group, we 
were able to induce in vitro formation of capillary-like structures by mouse and 
human endothelial cells on bioactive peptide scaffold without further addition of 
growth factors and other angiogenic supplements (e.g. heparin). Endogenous 
angiogenic growth factors that bind to the bioactive PA nanofibers were sufficient 
for vessel formation. In addition, heparins induce more robust signaling when they 
are presented to the cells in a special conformation,
52, 90
 and Heparin-mimetic PA 
nanofibers mimic this structure by presenting critical functional groups of heparin 
appropriately and induce more sustained growth factor signaling (Figure 2.34). 
Proper distribution of heparin-mimetic functional groups on the peptide nanofibers 
allows specific binding to endogenous growth factors released from cells and 
maintain their interaction with receptors on same cells. Potentially, Heparin-mimetic 
PA nanofibers bind to heparin-binding growth factors with a specific affinity, present 
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them effectively to target receptors for the formation of active growth factor-receptor 
complex, and achieve sustained angiogenic signaling (Figure 2.34). Materials 
presented here provide new opportunities for angiogenesis and tissue regeneration by 
avoiding the use of heparin and exogenous growth factors. The synthetic scaffolds 
enriched with proper chemical functional groups shown here can induce the desired 
physiological response for tissue regeneration. 
                 
 
Figure 2.34. Suggested mechanism for the induction of angiogenesis by bioactive 
HM-PA nanofibers. HM-PA nanofibers bind to growth factors (red balls) and present 
them to endothelial cells appropriately, which activate the angiogenic process. 
However, growth factors alone do not induce angiogenic signaling as shown 
previously. 
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CHAPTER 3 
 
3. SELECTIVE GROWTH FACTOR BINDING BY HEPARIN-
MIMETIC PEPTIDE NANOFIBERS. 
 
  This work is partially described in the following publication: 
Mammadov R., Mammadov B., Guler M. O., Tekinay A.B. Biomacromolecules, 
2012, 13 (10), pp 3311–3319.91 
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3.1. Objective 
Growth factors bind to receptors on cells and induce signaling pathways, which are 
critical for healing of damaged tissues. Heparan sulfates are extracellular elements, 
which bind to growth factors and through maintaining their local accumulation, 
protecting them from degradation and assisting in their interaction with cellular 
receptors, enhance their functioning. Materials mimicking chemical structure of 
heparan sulfates would be beneficial for tissue engineering and regenerative 
medicine purposes. In this work, our aim was to understand interaction affinity of 
peptide nanofibers carrying chemical functional groups from heparan sulfates to 
various growth factors used in tissue engineering. We also asked whether this 
interaction happens through same domains of growth factors that binds to heparan 
sulfates and whether interaction between peptide nanofibers and growth factors is 
translated into cellular activity.  
 
3.2. Introduction 
Functional biomaterials can improve efforts to control cell behavior and promote 
tissue regeneration. New-generation biomaterials differ from conventional ones in 
terms of controlling dose and bioactivity of delivered molecules (e.g. growth factors) 
more precisely besides acting as mere scaffolds.
92
 Immobilization of growth factors 
either covalently or noncovalently to a scaffold provides spatial distribution of 
growth factors inside the scaffold. Although covalent immobilization enables 
prolonged release of growth factors, specificity of coupling site on the growth factors 
is difficult to achieve and proteins may lose their bioactivity during coupling 
process.
93
 Materials can also be programmed to interact with growth factors through 
decoration of specific binding sites that interact with growth factors noncovalently. 
This type of interaction is predominant in nature. For example, heparan sulfate 
proteoglycans in extracellular matrix bind to heparin binding growth factors mainly 
through electrostatic interactions.
8
 Binding to heparan sulfates is critical for growth 
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factor signaling, protection from degradation and local accumulation of growth 
factors in the vicinity of cells.  
Maximal dose of growth factors that can be loaded onto materials correlates with the 
amount of growth factor binding epitopes on the scaffolds. Designing bioactive 
scaffolds that can present maximum number of epitopes while enabling control over 
epitope number would be beneficial for regenerative medicine applications. Several 
strategies for designing growth factor binding scaffolds were proposed previously. 
Sulfated alginate hydrogels, inspired from sulfated characteristics of 
glycosaminoglycans (e.g. heparan sulfate), showed superior affinity to heparin 
binding growth factors, than bare alginate hydrogels.
24
 Fibrin matrices functionalized 
with 12-14 type three repeats of fibronectin, which non-selectively interact with 
various growth factors, performed as an efficient growth factor delivery system, 
intensifying growth factor bioactivity in vitro.
94
 However, the relatively larger 
meshwork size of these polymeric scaffolds limits the density of epitope presentation. 
Moreover, epitope concentration on a polymer chain should be determined before 
synthesis. On the other hand, peptide amphiphiles (PA), which are small building 
blocks, can be triggered to form supramolecular assemblies such as high-aspect-ratio 
nanofibers in a controlled manner.
1
 Nanoscale properties maximize epitope density, 
while epitope concentration can be controlled via epitope dilution before inducing 
nanofiber formation.
7
 Previously, heparin-binding PAs were reported to form 
nanofiber scaffolds when mixed with heparin, where heparin was used to bind to 
growth factors inside the scaffold.
5
 This system induced in vivo angiogenesis more 
efficiently than standard scaffolds. However, since heparin long chain was used as 
growth factor binding ligand, epitope dilution was limited. Moreover, contaminants 
in heparin batches have been reported to induce side effects in humans.
56
  
Considering these issues, we designed a heparin mimetic PA (HM-PA) molecule, 
which bears key functional groups present in heparin and can be readily induced to 
form nanofiber scaffolds for regenerative medicine applications.
43
 In chapter 2, we 
have shown that these nanofibers bind VEGF and induce in vitro and in vivo 
angiogenesis, efficiently. The arrangement of functional groups on HM-PA/K-PA 
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nanofibers might be sufficient to bind other heparin binding growth factors and in a 
manner that would elevate the bioactivity of these growth factors. In this work, we 
studied the interactions of heparin mimetic peptide nanofibers with various growth 
factors and the bioactivity of nanofiber - growth factor complexes. This part of thesis 
presents the high potential of heparin mimetic peptide nanofibers in binding various 
heparin binding growth factors, which are widely used in regenerative medicine and 
in directing cellular activity.  
 
3.3. Results and Discussion 
In this chapter, binding of various heparin-binding growth factors, that are widely 
used in regenerative medicine studies, to peptide nanofibers was studied. (Table 3.1). 
Peptide molecules forming the nanofibers are depicted in Figure 3.1, and nanofiber 
formation mechanisms are explained in the Materials and Methods section. E-PA 
nanofibers are used as control of peptide nanofibers carrying negative charge. While 
forming nanofibers, the ratio of negatively charged PAs (HM-PA and E-PA) to 
positively charged K-PA in nanofibers is critical as it determines the net charge on 
nanofibers. Molar ratios of 1:2 and 1:1 for HM-PA/K-PA and E-PA/K-PA were 
chosen, respectively, in order to make both nanofibers to have (theoretically) net one 
negative charge. Also, heparin carrying nanofibers are used as positive control and to 
understand that to what extent functional groups on HM-PA mimic functionality of 
heparin in terms of growth factor binding.  Heparin carrying nanofibers are prepared 
by mixing K-PA with heparin (2:1 weight ratio) to render them to have  
(theoretically) net one negative charge.  
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Table 3.1. Growth factors used in this study.  
 
Growth 
Factor 
 
Physiological Function* 
Heparin 
affinity 
Dissociation 
constant 
(Kd)** 
 
VEGF 
 
Angiogenesis, vasculogenesis, 
endothelial cell growth and migration 
 
High 
(VEGF165) 
None 
(VEGF121) 
 
 
165 nM 
95
 
 
HGF 
 
Cell motility, mitogenesis and matrix 
invasion 
 
High 
 
12 nM 
95
 
 
FGF-2 
 
Migration, proliferation and survival 
of endothelial cells, inhibition of 
differentiation of embryonic stem cells 
 
High 
 
23 nM 
95
 
39 nM 
96
 
 
BMP-2 
 
Differentiation and migration of 
osteoblasts 
 
High 
 
20 nM 
97
 
 
NGF 
 
Survival and differentiation of neural 
cells 
 
Moderate 
 
Not 
determined 
    * Functions were reproduced from Lee et al.
93
 and NCBI. 
** Dissociation constant of heparin – growth factor interaction. 
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Figure 3.1. Chemical structure of PA molecules and heparin; illustration of 
nanofibers investigated for growth factor binding. Negatively charged HM-PA, E-PA 
or Heparin were mixed with positively charged K-PA to form respective 
nanofibers. Tiny spheres on nanofibers depict functional groups (Red - sulfonate, 
Green - hydroxyl, Blue - carboxylate). Dashed line in red indicates heparin. After 
nanofiber formation, heparin and functional groups of PAs are assumed to be 
presented by nanofibers into surrounding aqueous media. Density of heparin and 
functional groups of HM-PA on PA nanofibers does not reflect actual density. 
 
3.3.1. Analysis of interaction of PA nanofibers with heparin-binding growth 
factors. 
Growth factor-peptide nanofiber interaction was investigated in-depth by several 
methods to understand the effect of heparin mimicking functional groups 
(carboxylate, hydroxyl, and sulfonate) on nanofibers in growth factor binding. 
Firstly, we used ELISA-based growth factor binding assay to study the binding 
mechanism. All three types of peptide nanofibers were coated onto an ELISA plate 
as revealed by AFM imaging, which were clearly distinguishable in terms of 
roughness when compared to bare ELISA plate (Figure 3.2). 
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Figure 3.2. AFM images (5 µm x 5 µm) of PA nanofibers coated onto ELISA plates. 
After extensive washing of ELISA plate, coverage of surface with nanofibers can be 
observed for HM-PA/K-PA (a) E-PA/K-PA (b) and K-PA/Heparin (c) nanofibers.  
Bare plate surface (d) can be clearly distinguished from nanofiber-coated surfaces. 
 
After confirming the nanofiber coating on ELISA plates, growth factors bound to the 
peptide nanofibers were detected with ELISA assay. Bare plate surface, which 
excluded only nanofibers used in other groups and was used as the negative control, 
showed almost no binding signal (Figure 3.3). This indicates reliability of binding 
signal observed with nanofiber including samples and implies that this signal is 
caused by growth factor – nanofiber interaction.  
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Although heparin-carrying (heparin with K-PA) nanofiber gels showed weak affinity 
to VEGF165 in release assay in previous chapter (Figure 2.26), here surfaces coated 
with K-PA/Heparin nanofibers showed the strongest binding signal (Figure 3.3). 
Difference between these two systems was molar ratio between K-PA and heparin. In 
this study, we used 2:1 weight ratio for K-PA/Heparin to make nanofibers to have 
theoretically net one negative charge (similar to E-PA and HM-PA nanofibers), 
which corresponds to approximately 60:1 molar ratio (8:1 molar ratio was used to 
make K-PA/Heparin nanostructures). Probably, using higher PA concentration 
compensate for suboptimal binding of K-PA to heparin and stabilize heparin chains 
on nanofibers that allows large surface area presentation of heparin chains.
4
  This 
would allow proper interaction of heparin with growth factors which is observed in 
Figure 3.3. 
HM-PA nanofibers showed a comparable level of binding to VEGF165 with heparin-
carrying nanofibers (Figure 3.3). At higher growth factor concentration (50 ng/mL), 
binding levels were similar, however this might be due to saturation of binding signal 
- maximal level of absorbance value is reached. At lower concentration (10 ng/mL), 
both HM-PA and heparin showed binding signals at measurable range and heparin 
showed 2.5 fold higher binding than HM-PA. Nanofiber control (E-PA/K-PA) 
showed significantly less binding level to VEGF165 (more than 3-fold) than HM-
PA/K-PA nanofibers (Figure 3.3). An E-PA/K-PA 2x sample containing two-folds 
higher control nanofiber concentration was used to eliminate the possible effect of 
incomplete coverage of the surface on binding. There was no significant difference 
between E-PA/K-PA and E-PA/K-PA 2x samples, indicating complete coverage and 
saturation of the surface with one-fold control nanofibers (Figure 3.3). 
By using same methodology, we investigated binding affinities of PA nanofibers to 
other growth factors. Binding signals of PA-free surface was subtracted from PA 
nanofiber binding signal for all growth factors and shown at Figure 3.4. HM-PA 
nanofibers showed a higher binding level to three growth factors - HGF, VEGF, and 
FGF-2 -than control E-PA nanofibers. This difference confirms that growth factor 
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and nanofiber interaction is further strengthened by additional functional groups on 
HM-PA nanofibers (Figure 3.4).  
 
Figure 3.3. Measurement of VEGF165 binding to nanofiber coated surfaces by using 
ELISA-based assay. Binding levels of 10 or 50 ng/mL of VEGF165 with different 
nanofibers or PA-free surface are shown. Difference between HM-PA/K-PA and 
other treatments was significant for both growth factor concentrations (***p<0.001). 
Statistical analysis was performed with two-way ANOVA with Bonferroni post-hoc 
analysis. Experiment was performed with 3 replicates (n=3). Error bars indicate 
standard deviations. 
 
Growth factor − peptide nanofiber interactions were analyzed at two different growth 
factor concentrations to investigate the effect of growth factor concentration on 
binding signal. VEGF165 and HGF showed higher level of binding to HM-PA 
nanofibers than control nanofibers for both 10 ng/mL and 50 ng/mL growth factor 
concentrations (Figure 3.4a, 3.4b). In addition, FGF-2 bound to HM-PA nanofibers 
significantly more than control nanofibers at higher growth factor concentration 
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(Figure 3.4b). In spite of its heparin-binding property, BMP-2 exhibited a strong 
binding pattern to both HM-PA and control nanofibers at both low and high growth 
factor concentrations (Figures 3.4a, 3.4b). Negative charge provided by carboxylate 
groups on control peptide nanofibers might be sufficient to bind to BMP-2 strongly, 
leading to a similar binding pattern of BMP-2 to E-PA and HM-PA nanofibers. 
However, the binding site of BMP-2 might differ between HM-PA and E-PA 
nanofibers, which could change its bioactivity. One of the weakest binding patterns 
was observed with NGF, where HM-PA nanofibers showed slightly better binding at 
higher growth factor concentration. However, it was clear that even this degree of 
binding makes a remarkable difference in inducing cellular activity, which will be 
described in more detail in the following sections. VEGF121, which lacks heparin-
binding domain, did not reveal any binding signal to HM-PA nanofibers, while it 
exhibited very weak binding to E-PA/K-PA nanofibers. Thus, heparin-binding 
domain of VEGF is critical for its binding to HM-PA nanofibers. These results 
indicate that HM-PA nanofibers with heparin mimicking functional groups stand to 
be an excellent analogue for heparin regarding growth factor binding capability. 
To validate and visualize growth factor – peptide nanofiber interactions, we 
performed immunogold staining of growth factors bound to the nanofibers. For this 
experiment, we chose HGF as the model growth factor. We treated HGF bound 
nanofibers with specific primary antibody, which was treated with gold nanoparticle-
conjugated secondary antibody. TEM was used to image the complex of heparin-
mimetic peptide nanofibers and gold nanoparticle-conjugated antibody against HGF. 
Both individual nanofibers (Figure 3.5a, c) and nanofiber aggregates (Figure 3.5a, 
3.5b) were observed to bind to growth factors (white dots in a,c; black dots in b). 
When primary antibody for growth factor was not used, no growth factor binding 
was observed, excluding the possibility of nonspecific binding of gold attached 
secondary antibodies to nanofibers (Figure 3.5d). Nanofiber aggregates bound to 
growth factors in TEM imaging were studied by energy-dispersive X-ray (EDX) 
analysis, and a strong sulfur signal caused by sulfonate group of HM-PA (Figure 3.6) 
was observed demonstrating the presence of peptide nanofibers interacting with the 
growth factor.  
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Figure 3.4. Binding levels of different growth factors to HM-PA/K-PA or E-PA/K-
PA nanofibers are measured by ELISA-based assay. a. 10 ng/mL b. 50 ng/mL 
***p<0.001, *p<0.01, *p<0.05, ns=not significant. Statistical analysis was 
performed with Student’s t-test. Experiment was performed with 3 replicates (n=3). 
Error bars indicate standard deviations. 
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Figure 3.5. TEM images of immunogold stained HGF on HM-PA/K-PA nanofibers. 
a. HGFs were observed on both individual nanofibers and PA aggregates. White dots 
indicate gold nanoparticles. b. Inverted image, gold nanoparticles were visualized as 
black dots. c. Magnified version of an individual nanofiber shown in image a, 
presenting gold nanoparticles. d. Negative control (without primary antibody) shows 
no staining. 
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Figure 3.6. EDX analysis of nanofiber aggregates shown in TEM images at Figure 
3.5. Sulfur (S) atoms indicate HM-PA, while Au indicates gold nanoparticles.   
 
3.3.2. Role of Heparin-Binding Domains of Growth Factors in Their Interaction 
with HM-PA/K-PA Nanofibers. 
While growth factor − nanofiber binding has been emphasized in the literature, the 
binding site of growth factor to material should also be taken into consideration when 
designing biomaterials for regenerative medicine applications. Growth factors 
interact with heparan sulfates through their “heparin-binding domain”.47-48, 97-101 
Growth factor − heparan sulfate binding induces dimerization/oligomerization of 
growth factor receptors (generally tyrosine kinase receptors), which is required for 
autophosphorylation of receptors and subsequent activation of signaling pathways.
50, 
102-103
 For signaling to be effective, a threshold number of receptor-growth factor 
complexes should be active on the surface of cells for an appropriate period of 
time.
104
 This requires stability of growth factor − receptor interactions, which are 
maintained by heparan sulfates acting as coreceptors.
104-105
 Thus, a material designed 
to mimic heparan sulfates should bind to growth factors through their heparin-
binding domains, which would prevent blocking of other sites on growth factors such 
as “receptor binding site” that is critical for signaling. VEGF165 and VEGF121 
exhibited significantly different binding levels to HM-PA/K-PA nanofibers in 
ELISA-based binding assay. To clarify the necessity of heparin-binding domain in 
HM-PA nanofiber - growth factor interaction, differential affinity of VEGF165 and 
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VEGF121 to HM-PA/K-PA nanofibers was further tested by using ITC. In chapter 2, 
binding constant between VEGF165 and HM-PA/K-PA nanofibers measured by using 
ITC technique was given (Figure 3.7, also Figure 2.25).
43
 Here, interaction between 
VEGF121 and HM-PA/K-PA nanofibers was investigated through a similar protocol 
(Figure 3.8). While the binding constant of HM-PA/K-PA−VEGF165 was similar to 
the binding constant of heparin−VEGF165, VEGF121 revealed no binding signal with 
HM-PA/K-PA; further supporting the critical contribution of the heparin-binding 
domain in VEGF−HM-PA/K-PA nanofiber interaction.  
To understand the role of heparin-binding domains of other growth factors in HM-
PA/K-PA nanofiber binding, a competition assay was performed, where heparin and 
HMPA/K-PA nanofibers competed for binding to growth factors. In this assay, 
growth factors bound to heparin were expected to be washed away, while those that 
bound to HM-PA nanofibers were expected to stay as bound to the plate and be 
detected with ELISA. Thus, diminishing signal in ELISA would indicate that both 
heparin and HM-PA nanofibers compete for the same binding site. In total agreement 
with previous assays, the VEGF165 binding signal showed a very sharp decline as 
heparin concentration was increased, further supporting that HM-PA/K-PA 
nanofibers compete for nonredundant heparin-binding domain (Figure 3.9a). 
Interestingly, only FGF-2 showed a similar pattern to VEGF165 among other growth 
factors (Figure 3.9). The inhibitory effect was specific to heparin, since chondroitin 
sulfate (another sulfated glycosaminoglycan) was not able to inhibit FGF-2 binding 
to HM-PA/K-PA nanofibers (exhibited only limited inhibitory effect at maximal 
dose, Figure 3.10). Heparin was more inhibitory at its minimal dose than chondroitin 
sulfate at its maximal dose. Since heparan sulfate (or heparin) binding is critical for 
bioactivity of VEGF165 and FGF-2,
51, 57
 binding to the same site with heparin renders 
HM-PA/K-PA nanofibers a very efficient scaffold for delivery of these growth 
factors. Heparin-binding domains of HGF and BMP-2 were more redundant than 
those of VEGF and FGF-2 in HM-PA nanofiber binding (Figure 3.9a).  
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Figure 3.7. Measurement of affinity between VEGF165 and HM-PA/K-PA nanofibers 
by using Isothermal Titration Calorimetry (ITC). VEGF165, which has heparin 
binding domain, showed high affinity to HM-PA/K-PA nanofibers with binding 
constant of 7.37x10
5 ± 5.1x104.  
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Figure 3.8. Measurement of affinity between VEGF121 and HM-PA/K-PA nanofibers 
by using Isothermal Titration Calorimetry (ITC). VEGF121, which lacks heparin-
binding domain, showed no affinity to HM-PA/K-PA nanofibers.  
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IC50 for HGF and BMP-2 calculated from competitive binding curves in Figure 3.9a 
were nearly 10 times higher than IC50 of VEGF and FGF-2 (Figure 3.9b). 
Dissociation constants of heparin and these growth factors were shown to be similar 
to each other in the literature (Table 3.1). Thus, the difference between IC50 values of 
heparin between these two groups of growth factors cannot be attributed to any 
difference in their affinity to heparin. This difference could be caused by the 
existence of extra binding sites, other than the heparin-binding site, on BMP-2 and 
HGF for HM-PA/K-PA nanofiber binding. NGF binding to heparin is known to be 
moderate,
106
 compared to strong binding affinities of other growth factors, which 
may be the reason for poor competition between heparin and HM-PA/K-PA 
nanofibers for binding to NGF. Nonetheless, NGF seems to have different binding 
sites for HM-PA/K-PA nanofibers and heparin (Figure 3.9). IC50 of heparin for NGF 
was nearly 80 times higher than IC50 of heparin for VEGF/FGF-2 and 7−8 times 
higher than IC50 of heparin for HGF/BMP-2 (Figure 3.9b). 
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Figure 3.9. Competition assay between heparin and HM-PA/K-PA nanofibers for 
growth factor binding. a. Dose dependent interference of heparin with growth factor 
binding to HM-PA/K-PA nanofibers. For each growth factor, binding signal to HM-
PA/K-PA nanofibers when there was no heparin in milieu was taken as 100%. b. IC50 
value of heparin inhibit HM-PA/K-PA nanofiber binding of each growth factor was 
calculated and represented. Experiment was performed with 3 replicates (n=3). Error 
bars indicate standard deviations.  
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Figure 3.10. Competition assay between heparin or chondroitin sulfate (cs) and HM-
PA/K-PA nanofibers for FGF-2 binding. 100% indicates (no heparin/cs) binding 
signal of FGF-2 to HM-PA/K-PA nanofiber when there is no heparin or cs in milieu. 
X-axis denotes logarithmic concentration of heparin or cs. Error bars indicate 
standard deviations. 
 
3.3.3. HM-PA/K-PA nanofiber - growth factor interaction is translated to 
cellular activity. 
As mentioned above, improper interaction of materials with growth factors (e.g., 
through improper binding site) can block growth factor activity unexpectedly. Hence, 
growth factor’s biological functionality should be validated after it is tethered on the 
material. NGF, which had the weakest interaction with HM-PA among the growth 
factors that were tested in this study and whose heparin-binding domain was the least 
required for HM-PA/K-PA nanofiber binding, was selected for studying biological 
activity. In order to investigate the effect of HM-PA/K-PA nanofiber binding on 
NGF functionality, neurite outgrowth by PC-12 cells cultured on NGF-coated PA 
nanofiber surfaces was analyzed. NGF retained its ability to induce neurite 
outgrowth fully when it was bound to HM-PA/K-PA nanofibers. Neurite outgrowth 
performances of PC-12 cells did not deteriorate when NGF was presented to cells as 
coated on nanofibers compared to its soluble form (Figure 3.11). To exclude any 
possibility of bioactivity reduction due to differential amount of growth factors 
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between “soluble” and “coated” treatments, unbound growth factors in “coated” 
treatment were not removed and stayed in solution. Considering that the total growth 
factor amount was same in both “soluble” and “coated” treatments, HM-PA/K-PA 
nanofibers enhanced NGF signaling, since neurite outgrowth activity in “coated” 
samples was significantly higher than “soluble” samples (Figure 3.11a) in the 
presence of low growth factor concentration. No significant increase in bioactivity 
was observed at higher growth factor concentration (Figure 3.11b). This difference 
could be due to the fact that higher concentration of growth factors in the vicinity of 
cells did not necessitate their accumulation and preservation with HM-PA/K-PA 
nanofibers for cellular activity. Interestingly, we did not observe such a difference 
with E-PA/K-PA nanofibers, indicating contribution of functional groups on HM-
PA/K-PA nanofibers for NGF signaling.  
Moreover, higher binding of HM-PA/K-PA nanofibers to NGF, although it was 
statistically not significant, was translated to elevated cellular activity when 
compared to control nanofiber systems (Figure 3.12).  Here, unbound NGFs on HM-
PA/K-PA nanofiber and control surfaces were washed away, and bioactivity 
comparison was performed only between bound NGFs. NGF-coated and washed 
HM-PA/K-PA nanofibers (50 ng/mL) led to significantly longer neurites compared 
to E-PA/K-PA nanofiber and PDL controls (Figure 3.12). There was no such 
difference when 10 ng/mL NGF was used, which is in good correlation with the 
results of growth factor binding analysis by ELISA (Figure 3.4a).  
In summary, HM-PA/K-PA nanofibers interact with NGF moderately and this 
interaction is translated into cellular response without any loss in bioactivity of 
growth factor. Promotion of the neurite length on HM-PA/K-PA nanofibers is clearly 
dependent on HM-PA−NGF interaction that could be translated to differentiation 
response.  
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Figure 3.11. Neurite outgrowth performance of PC-12 cells on NGF treated and 
NGF-free substrates. NGF coated indicates that substrates were treated with NGF 
without removal of unbound NGF on which cells were seeded. Soluble NGF 
indicates that cells cultured on NGF-free substrates were induced with soluble NGF 
in culture media. NGF amounts used were 10 ng/mL (a) or 50 ng/mL (b). There was 
no significant difference for any substrate when coated NGF is compared with 
soluble NGF, except for HM-PA/K-PA and PDL at 10 ng/mL (*p<0.05. Statistical 
test was performed with  two-way ANOVA with Bonferroni post-hoc analysis, n=3). 
Error bars indicate standard deviations. 
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Figure 3.12. Neurite outgrowth response of PC-12 cells to washing away of unbound 
NGF from NGF treated substrates. PDL and PA substrates were treated with 10 
ng/mL or 50 ng/mL NGF after which they were washed to remove any unbound 
NGF. HM-PA/K-PA interaction with NGF leaded to longer neurites on this surface 
when 50 ng/mL NGF was used, probably due to higher amount of NGF remained on 
HM-PA/K-PA nanofiber coated surface than E-PA/K-PA and PDL after washing 
(***p<0.001 between HM-PA/K-PA and other surfaces at 50 ng/mL, *p<0.05 
between HM-PA/K-PA and E-PA/K-PA 2x or PDL, p=ns between HM-PA/K-PA 
and E-PA/K-PA at 10 ng/mL. Statistical test was performed with  two-way ANOVA 
with Bonferroni post-hoc analysis, n=3). Error bars indicate standard deviations. 
 
Immunostaining against β-III-tubulin, a neuron-abundant microtubule protein, and 
synaptic protein Synaptophysin 1 (Syn1) revealed higher expression of these proteins 
when cells were cultured on HM-PA - NGF substrates (Figure 3.13). Neural 
morphology was also more prominent on this surface correlating with the longer 
neurites (Figure 3.12). β-III-tubulin is a neuron-specific tubulin subunit that is 
abundantly expressed along neurites as well as cell soma.
107
 Syn1 is a synaptic 
protein abundant in presynaptic nerve terminal, and its presence along the axonal 
protrusions indicates presynaptic nerve terminal development.
108-109
 Expression 
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profiles of PC-12 cells cultured on HM-PA-NGF substrate is consistent with the 
expected localization of these neural marker proteins. β-III-tubulin was found to be 
localized in cell soma along with neurites (Figure 3.13a). Cells also expressed β-III-
tubulin on E-PA/K-PA and PDL in cell soma and expression in a few short neurites 
was observed on E-PA/K-PA (Figure 3.13d, g). A dramatic difference in the 
expression profile of Syn1 was found when cells were cultured on different 
substrates, which can be attributed to differential interaction of these surfaces with 
NGF leading to differential cell responses (Figure 3.13b, e, h). Syn1 expression was 
heavily concentrated along neurites and nerve terminals on HM-PA/K-PA, while 
weak expression in cell soma was observed on other substrates. Thus, it can be 
concluded that higher level of binding of HM-PA to NGF induces neural 
differentiation of PC-12 cells more efficiently, leading to the formation of 
presynaptic nerve terminals, an indicator of neural maturation, on this substrate. 
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Figure 3.13. Immunostaining of PC-12 cells against β-III-Tubulin (a, d, g) and 
Synaptophysin I (b, e, h) on NGF treated surfaces. a-c. HM-PA/K-PA, d-f. E-PA/K-
PA, h-i. PDL. c, f and i shows merged images of Syn1 staining and β-III-Tubulin on 
same cells. Higher expression of both neural markers along with specific localization 
of Synaptophysin I in nerve terminals was clear in cells cultured on HM-PA/K-PA.  
 
3.4. Experimental details. 
3.4.1. Materials 
 9-Fluorenylmethoxycarbonyl (Fmoc) and tert-butoxycarbonyl (Boc) protected 
amino acids, [4-[α-(20,40-dimethoxyphenyl) Fmoc-aminomethyl] phenoxy] 
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acetamidonorleucyl-MBHA resin (Rink amide MBHA resin), Fmoc-Asp(OtBu)-
Wang resin, and 2-(1Hbenzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HBTU) were purchased from NovaBiochem and ABCR. The 
other chemicals for PA synthesis were purchased from Fisher, Merck, Alfa Aesar, or 
Aldrich. All chemicals were used as provided. Heparin and chondroitin sulfate were 
purchased from Sigma-Aldrich. ELISA reagents were obtained from Invitrogen. 
Paired antibodies for different growth factors were purchased from R&D, except for 
VEGF (Invitrogen). Gold-attached secondary antibody (Aurion Immunogold 
reagent) was obtained from Electron Microscopy Sciences. Growth factors were 
obtained from e-bioscience (VEGF121, HGF, FGF-2, BMP-2), Invitrogen (VEGF165), 
and Sigma-Aldrich (NGF). 
 
3.4.2. Peptide Synthesis  
HM-PA and Lauryl-VVAGK-Am (K-PA) were constructed on Rink Amide MBHA 
resin, while Lauryl-VVAGE-Am (E-PA) was constructed on Fmoc-Asp(OtBu)-
Wang resin (Figure S1, Supporting Information). Amino acid couplings were 
performed with 2 equiv of Fmoc-protected amino acid, 1.95 equiv of HBTU, and 3 
equiv of N,N-diisopropylethylamine (DIEA) for 2 h. To remove the Fmoc group, 
20% (v/v) piperidine/dimethylformamide solution (DMF) was added for 20 min. To 
block the remaining free amine groups after amino acid coupling, 10% (v/v) acetic 
anhydride solution in DMF was used (30 min). After each step, the resin was washed 
by using DMF, dichloromethane (DCM), and DMF (three times each). To synthesize 
HM-PA, sulfobenzoic acid was added to the side chain of lysine. A lysine residue 
with 4-methytrityl (Mtt) side-chain protection was used for selective deprotection of 
amine groups. Resins were treated with a TFA/TIS/H2O/DCM mixture (5:2.5:2.5:90 
ratio; TFA = trifluoroacetic acid; TIS = triisopropyl silane) for 5 min to remove Mtt. 
To cleave PAs from the resin, TFA/TIS/H2O mixture (95:2.5:2.5 ratio) was treated 
with resin for 2 h. Excess TFA was removed by rotary evaporation. The remaining 
viscous PA solution was triturated with ice-cold ether, and the resulting white 
precipitate was dissolved in aqueous solution and freeze-dried. PAs were 
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characterized by liquid chromatography and mass spectrometry (LC-MS). Mass 
spectrum was obtained with Agilent 1200 LC-MS equipped with Agilent 6530 Q-
TOF with an ESI source and Zorbax Extend-C18 2.1 × 50 mm column for basic 
conditions and Zorbax SB-C8 4.6 mm × 100 mm column for acidic conditions. A 
gradient of (a) water (0.1% (v/v) formic acid or 0.1% (v/v) NH4OH) and (b) 
acetonitrile (0.1% (v/v) formic acid or 0.1% (v/v) NH4OH) was used. An Agilent 
1200 preparative reverse-phase HPLC system equipped with a Zorbax Extend-C18 
21.2 × 150 mm column for basic conditions and a Zorbax SB-C8 21.2 × 150 mm 
column for acidic conditions was used to purify the peptides. A gradient of (a) water 
(0.1% (v/v) TFA or 0.1% (v/v) NH4OH) and (b) acetonitrile (0.1% (v/v) TFA or 
0.1% (v/v) NH4OH) was used.  
 
3.4.3. Nanofiber Formation Mechanism  
Nanofiber formation mechanisms were based on mixing oppositely charged PAs, 
which neutralized net charge on each other and induced self-assembly to higher-
order nanofibers. Three different types of nanofibers were used in this study (Figure 
3.1). Bioactive HM-PA nanofiber was prepared similar to one in previous chapter. 
HM-PA (−3 charge) and K-PA (+1 charge) were mixed in a 1:2 molar ratio for HM-
PA/K-PA nanofibers, while E-PA (−2 charge) and K-PA (+1 charge) were mixed in 
a 1:1 molar ratio for control E-PA/K-PA nanofibers, to make both nanofibers to have 
theoretically net one negative charge. Since the K-PA amount is lower for E-PA/K-
PA nanofibers than HM-PA/K-PA nanofibers in this case, we used E-PA/K-PA 2x 
nanofibers as a control for this issue. For E-PA/KPA 2x nanofibers, we used both E-
PA and K-PA in doubled concentrations but same molar ratio (1:1). Heparin carrying 
nanofibers were also prepared by mixing heparin and K-PA as showed in chapter 2, 
however here their ratio was adjusted to make system to have net one negative 
charge.  For this, weight ratio of heparin to K-PA was adjusted to 1:2.  Heparin/K-
PA nanofibers were used as a positive control. All PAs used for nanofiber formation 
were at pH 7.  
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3.4.4. ELISA-Based Binding Assay 
ELISA technique was exploited to compare binding levels of growth factors to HM-
PA/K-PA nanofibers and control nanofibers. MaxiSorp plates (Thermo Scientific, 
NUNC) were coated with PA nanofibers or blank solution overnight at 4 °C. The PA 
nanofiber formation was performed on plates by mixing negatively and positively 
charged PAs. Briefly, 0.05% HM-PA / 0.05% K-PA, 0.025% E-PA / 0.025% K-PA, 
0.05% E-PA / 0.05% K-PA, or 0.05% heparin / 0.1% K-PA (all are w/v) equal 
volume mixtures were prepared. The next day, the solutions were removed and the 
wells were washed with washing buffer (Tween 20 in 0.9% (w/v) NaCl solution, pH 
= 7.4). These plates are high-affinity binding plates for a broad range of molecules 
with hydrophobic/hydrophilic character, thus, even after extensive washing, plates 
were observed to be coated completely with PA nanofibers (Figure 3.2). After 
tapping for drying, blocking buffer (Assay buffer, Invitrogen) was added. This was 
followed by the addition of growth factor solution, biotinylated antibody against 
growth factor, streptavidin-linked horseradish peroxidase (HRP) and HRP substrate 
(3,3′,5,5′ tetramethylbenzidine (TMB). After 15−20 min of incubation, the reaction 
was stopped with sulfuric acid. Absorbance change due to color formation was 
measured by a Spectramax M5 microplate reader (Molecular Devices) at 450 nm 
wavelength. This value was subtracted from the reference value (650 nm). All 
treatments were performed with three replicates and are shown as mean ± standard 
deviation. Experiments were repeated at least two times independently. For statistical 
analysis, two-way ANOVA with Bonferroni posthoc analysis and Student’s t-test 
were used.  
 
3.4.5. Atomic Force Microscopy (AFM) Imaging  
AFM imaging was performed to determine the coating efficiency of PA nanofibers 
on ELISA plates. Coating was performed similarly to “ELISA-binding assay” 
procedures. After overnight incubation of plates with PA nanofiber solution, the 
solution was aspirated and the plate was washed 2−3 times with ELISA washing 
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buffer (Tween 20 in 0.9% (w/v) NaCl solution, pH = 7.4). The plates were dried by 
tapping, and the coated bottom part was removed for AFM imaging. Bare ELISA 
plates were also imaged with AFM to understand their surface roughness. Non-
contact-mode AFM was performed by using model MFP-30 from Asylum Research. 
All images were taken with a 0.5 Hz scan rate. Tips with resonance frequency of 300 
kHz and spring constant of 40 N/m were used in all experiments (BudgetSensors). 
 
3.4.6. Isothermal Titration Calorimetry (ITC) 
To investigate the interaction between HM-PA/K-PA nanofibers and VEGF121, we 
used the iTC200 system (MicroCal, GE Healthcare). VEGF121 (0.27 mg/mL in 1x 
PBS solution) was titrated into HM-PA/K-PA nanofiber solution. For HM-PA/K-PA 
nanofiber solution, 0.04% HM-PA and 0.04% K-PA (both in H2O and w/v) were 
mixed to form nanofibers in solution, which was diluted 2-fold with 2x PBS to obtain 
HM-PA/KPA nanofiber solution in 1x PBS. Reaction was performed at 25 °C with 
500 rpm stirring speed. Twenty injections were performed, where the injection 
period was 4 s and the space between injections was 150 s. All solutions that were 
used in ITC experiments were at pH 7. 
 
3.4.7. Immunogold Staining and Transmission Electron Microscopy (TEM) 
Imaging.  
Hepatocyte growth factor (HGF) binding on HM-PA/K-PA nanofibers was 
visualized by using immunogold staining and TEM imaging. First, HM-PA/K-PA gel 
was formed by mixing 20 μL of 1% HM-PA with 1% K-PA (w/v). Gel was diluted 
10 times, and 30 μL of the diluted solutions was dropped onto parafin film. Cu grids 
were reversed onto these drops and incubated for 5 min. The tiny amount of liquid 
left on the grids was absorbed with dust-free paper, and the grids were dipped into 1x 
PBS solution two times to wash weakly bound nanofibers. Grids were reversed onto 
30 μL of blocking solution (Assay buffer, Invitrogen) and incubated for 1 h at room 
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temperature. Drops on grids were absorbed, and HGF (500 ng/ mL in assay buffer) 
was added onto the grids. After 2 h of incubation, grids were washed with PBS five 
times. Primary antibody (25 μg/mL, R&D) against human HGF was added onto grids 
and incubated overnight at 4 °C. Grids were washed with PBS 5 times. Gold-
attached antibody (25 nm gold particles conjugated to antimouse IgG), 1/20 diluted 
from stock with assay buffer, was put onto paraffin film, and grids were reversed 
onto this solution, to prevent precipitation of gold particles onto the grid surface due 
to gravitation. After 1 h, grids were washed five times with PBS and three times with 
double-distilled water (ddH2O). After drying at room temperature for at least 3 h, 
TEM (FEI, Tecnai G2 F30) imaging was performed. All images were taken in STEM 
mode with an HAADF (high angle annular dark field) detector. 
 
3.4.8. HM-PA/K-PA Nanofiber versus Heparin Competition Assay 
HM-PA/K-PA nanofiber and heparin competition for the same site of growth factor 
was studied by increasing doses of heparin (0.0003% to 0.3%, w/v) in the presence 
of various growth factors just before latter ones were incubated with HM-PA/K-PA 
nanofibers. HM-PA/K-PA nanofiber coating and the rest of the assay was performed 
similarly to ELISA-based binding assay. IC50 (half-maximal inhibitory 
concentration) of heparin to inhibit growth factor and HM-PA/K-PA nanofiber 
binding was calculated for each growth factor by using GraphPad Prism software. 
Nonlinear regression analysis with robust fitting was carried out for this purpose. We 
performed the same experiment with chondroitin sulfate instead of heparin (only for 
fibroblast growth factor-2 (FGF-2) to control the effect of heparin. All treatments 
were performed with three replicates and are shown as mean ± standard deviation. 
Experiments were repeated twice, independently. 
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3.4.9. NGF Induced Neurite Extension Assay 
To determine biological activity caused by  interaction of PA nanofibers with nerve 
growth factor (NGF), PC-12 cells were cultured on NGF-coated PA nanofiber 
surfaces. PA nanofiber gel scaffolds with −1 charge were prepared as described 
below. For HM-PA/K-PA nanofiber gel, 1.5 mM HM-PA was mixed with 3 mM K-
PA at equal volumes (40 μL for 96 well-plate). E-PA/K-PA nanofiber gel was 
formed in the same way by mixing 1.5 mM E-PA with 1.5 mM K-PA, while E-
PA/K-PA 2x gel was prepared by mixing 3 mM EPA with 3 mM K-PA. 0.1% (w/v) 
Poly-D-lysine (PDL) was coated as a control since it is not expected to bind NGF 
due to its dense positive charge. After gel formation, plates were dried under a 
laminar flow hood and UV sterilized. For NGF coating on PA coated surfaces, NGF 
was added at concentrations of 10 ng/mL or 50 ng/mL. After 2 h of incubation at 
room temperature, wells were washed three times with PBS to remove any unbound 
NGF. PC-12 cells (5 × 103 cells/well) were then seeded and cultured on these 
surfaces for 4 days. In another experimental group, incubated NGF was not removed 
to test the effect of surface bound and soluble NGF at the same time (total 
concentration was the same with other groups). In this case, cells were added directly 
on NGF solution over PA or PDL coated surfaces. For soluble NGF groups, the same 
concentration of NGF was added on cells after seeding (n = 3 for all samples). At the 
end of 4 days, images (5 images/well) were taken at 200x magnification, and neurite 
lengths were quantified with Image J. For statistical analysis, two-way ANOVA with 
Bonferroni posthoc analysis was performed (Figures 6 and S4). For immunostaining, 
PA nanofiber coating was carried out by using the same protocol except that PAs 
were coated on glass coverslips placed in 24 well-plates (total volume: 300 μL/well). 
NGF coating (50 ng/mL) was performed as described above and 3 × 104 cells/well 
were seeded. After 4 days of culture, cells were fixed with 4% paraformaldehyde, 
permeabilized with 0.3% TritonX-100, and blocked with 10% goat serum. 
Antibodies against β-III-Tubulin (Millipore, 1:250 dilution) and synaptophysin 1 
(Sigma-Aldrich, 1:400 dilution) were incubated overnight at 4 °C. After washing, 
cells were incubated with goat-antirabbit IgG-Cy3 (Chemicon, 1:200 dilution) and 
goatantimouse IgG-Cy2 (Chemicon, 1:400 dilution) for 1 h at room temperature and 
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washed to remove any unbound antibodies. Coverslips were then removed from 
wells, mounted by using Prolong gold antifade reagent (Invitrogen), and imaged with 
a confocal microscope (Carl Zeiss, LSM510). 
 
3.5. Conclusion 
In summary, the functionality of heparan sulfates in extracellular matrix can be 
achieved synthetically through presenting key functional groups of heparan sulfates 
on peptide nanofibers. While forming hydrogel scaffolds, these nanofibers bind to 
heparin-binding growth factors that are utilized commonly in regenerative medicine 
studies and present them to cells effectively. Interestingly, for VEGF and FGF-2, this 
binding specifically requires the presence of heparin-binding domain of growth 
factors, which may be critical for proper presentation of growth factors to cells. 
Growth factor binding property of HM-PA nanofibers could be advantageous for 
different tissue engineering applications, such as angiogenesis shown in previous 
chapter and  neural differentiation shown here. 
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CHAPTER 4 
    
 
4. VIRUS-LIKE NANOSTRUCTURES FOR TUNING IMMUNE   
RESPONSE: SHAPE DOES MATTER 
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4.1. Objective 
Rational design of vaccines is required to drive immune response to desired context 
safely. Various pathogenic biochemical patterns, such as CpG DNA, has been 
proposed as vaccine adjuvant, to alarm immune system against co-delivered antigen. 
In nature, immune system sense pathogens as a whole with biochemical and 
biophysical signals together. In this study, we aimed to understand how immune 
system reacts to pathogenic biochemical signals, specifically CpG DNA, in the 
context of specific physical signals – shape of its carrier. Our purpose was to 
engineer immune response through synergistic action of biochemical and biophysical 
pathogenic patterns, and also delineate some basic principles about the effect of 
shape of vaccine complex on generated immune response. 
 
4.2. Introduction 
Developing novel vaccines is crucial as prospect of pandemic threat by infectious 
diseases such as flu (influenza virus) and SARS (coronavirus) looms large. Current 
vaccinology relies on inactivated or live attenuated viruses to introduce the 
characteristics of evolved virus to immune system as much as possible.
110
 Widely 
used egg-based vaccine production depends on viral growth characteristics in eggs. 
Sluggish growth of virus or scarcity of egg resources might slow vaccine production 
during pandemic, when time is the limiting factor. Moreover, live attenuated viruses, 
which are known to be superior to inactivated viruses in eliciting immune 
response,
110-111
 carry risk of becoming virulent as in the case of oral poliovirus 
vaccine
112
 or causing side effects on immunocompromised individuals.
113
 Due to 
above-mentioned reasons, rational design of simpler vaccines with easier production 
process along with robust effectiveness are vitally needed. In order to achieve this 
purpose, we should understand principles required to drive immune response to 
desired context (such as what type of cytokines and co-stimulatory molecules are 
expressed or what type of innate and adaptive immune cells will be activated).
33
 
These principles lie in how immune cells recognize and respond to different features 
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of pathogens, in the broader classification - biochemical and biophysical features. In 
this regard, pathogen-associated molecular patterns (PAMPs) stand out to be 
biochemical pathogenic signatures, which can be used as adjuvants to enhance 
immunogenicity of antigen.
113-114
 PAMPs trigger innate immune cells to elevate 
antigen presentation and cytokine secretion, which eventually induce adaptive 
immune response.
115-116
 In this context, DNA with unmethylated CpG motives, 
signature of bacterial/viral DNA, have extensively been studied and proved to boost 
humoral and cellular responses to vaccines (Figure 4.1).
40, 117-119
  
In nature, biochemical signals act in the context of biophysical ones, such as size and 
shape of pathogen. This synergy play critical role in shaping immune response and 
should be projected onto the vaccine for robust effectiveness. For example, physical 
proximity of antigen and adjuvant (e.g. CpG DNA), which allows both to be 
internalized by the same immune cells, has been shown to be critical for inducing a 
strong immune response.
117, 120
 Therefore, covalent conjugation of antigen with 
adjuvant elevates antigen-specific Th1 immune response - cytotoxic T cell activity, 
significantly.
120-122
 However, covalent conjugation entails chemical modification to 
antigen and adjuvant, which depends on chemistry of antigen and might be 
inefficient for some antigens.
122
 To overcome this problem, wide range of materials 
including cationic microparticles, liposomes, nanoparticles, and nanorods have been 
proposed for delivery of antigen and adjuvant in close proximity.
123
 These 
micro/nanocarriers boost immune reaction to antigen/adjuvant also through enhanced 
cellular uptake and protection from enzymatic degradation.
123
 Moreover, 
nanoparticle carriers can alter the nature of immune response (e.g. inducing different 
cytokine profile) to CpG oligodeoxynucleotides (CpG ODNs). Nanoparticles 
carrying CpG ODN or CpG ODNs which fold and aggregate to form nanoparticles 
(known as A type ODN) induce production of high amounts of interferon-alpha 
(IFNα) cytokine, which mediates anti-viral response from plasmacytoid dendritic 
cells.
124-127
 Interestingly, high interferon-alpha response is similarly observed in 
immune reaction to viruses. On the other hand, linear (i.e. not folding and 
aggregating to form higher order structures) CpG ODN itself is known to be a poor 
interferon inducer, while being a strong inducer of IL-6 and TNFα production and 
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expression of maturation markers on cell surface.
118, 128
 This dichotomy was linked to 
differing subcellular localization of nanoparticulate and linear CpG ODN in 
plasmacytoid dendritic cells and induction of distinct signaling pathways.
129
 
 
 
Figure 4.1. Potential therapeutic applications of CpG oligodeoxynucleotides 
(ODNs). CpG-induced innate immune response can protect the host from infectious 
pathogens. Therefore, CpG ODNs might be used as stand-alone agents to reduce 
susceptibility to infection. When combined with allergen, these ODNs stimulate an 
antigen-specific T helper 1 (Th1)-cell response that inhibits the development of Th2-
cell-mediated allergic asthma. CpG ODNs also improve the function of professional 
antigen-presenting cells (APCs), and create a cytokine/chemokine milieu that is 
conducive to the development of an adaptive immune response to co-administered 
vaccines. Finally, the immune cascade that is elicited by CpG ODNs results in the 
activation of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) that 
facilitates (alone or in combination with other therapies) the treatment of cancer 
(Reproduced wıth permission from ref. 130 copyright © 2004 Macmillan Publishers 
Ltd.)
130
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All these studies suggest profound effects of physical features of the vehicles (virus 
or synthetic vaccine particle) carrying biochemical signals (such as viral DNA or 
antigen) in shaping immune response. However, a systematic investigation of how 
mammalian immune system responds to viral biochemical signals in the context of 
main viral shapes - spheres and rods - is not available. To answer this question, we 
compared immune response against CpG DNA, delivered by zero- and one- 
dimensional nanostructures formed by self-assembling peptide molecules and CpG 
ODNs (Figure 4.2). These nanostructures resemble viruses in several ways: i) their 
size and shape are comparable to viruses, where nanofibers resemble rod-like viruses 
and nanospheres are similar to spherical viruses; ii) they carry ODNs with motives 
from viral DNA (CpG), which is known to activate TLR9 during viral infection
35
; 
and iii) they can be engineered to carry viral antigens through peptide domain. In this 
chapter, virus-like nanostructures capable of potently eliciting anti-viral immune 
response are presented and modification of immune response against CpG DNA, 
through changing physical properties of the carrier vehicle it, is demonstrated (Figure 
4.2).  
 
Figure 4.2. Schematic plot of designed virus-like nanostructures and tunability of  
immune response with these nanostructures. CpG ODNs mimick immunostimulatory 
CpG motives (red) of viral DNA. Mixing CpG ODNs with proline-rich peptides give 
rise to nanospheres with 15-20 nm diameter. While, mixing with β-sheet forming 
peptide leads to formation of one-dimensional nanofibers with 10-15 nm of diameter 
and  >1 µm length. CpG ODNs are known in the literature to induce Th1-biased 
immune response. Delivering them on nanospheres and nanofibers elevates this 
effect, while nanofibers are being more potent. 
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4.3. Results and Discussion 
Functional self-assembled architectures with varying morphologies can be developed 
depending on the molecular nature of building blocks.
131
 The properties of amino 
acids guide self-assembly of peptide molecules and determine their structural 
properties. Valine and alanine residues in the peptide molecules, known as “β-sheet 
formers”, favor formation of one-dimensional nanostructures, while proline residues, 
“β-sheet breakers”, support self-assembly of zero-dimensional spherical 
nanostructures.
132-134
 In addition, self-assembly of peptides into one or zero 
dimensional nanostructures can be promoted by mixing oppositely charged 
biomacromolecules. Non-covalent interactions such as hydrogen bonding, and 
electrostatic and hydrophobic interactions between the peptides and 
biomacromolecules enable formation of supramolecular assemblies.
2, 135-136
 
In this study, we combined self-assembling peptide molecules with oppositely 
charged immunostimulatory oligodeoxynucleotides (CpG ODNs) to obtain one-
dimensional (nanofibers) and zero-dimensional (nanospheres) virus-like 
nanostructures. For this purpose, we synthesized two positively charged peptide 
amphiphile (PA) molecules by changing backbone motifs (K-PA and P-PA; Figure 
4.3) to direct self-assembled nanostructures into different morphologies. Both PA 
molecules include a lauryl group to drive self-assembly in aqueous solution, a 
glycine residue as spacer and a lysine residue to provide positive charge at the 
physiological pH. K-PA included valine-valine-alanine residues as a backbone to 
drive hydrogen bonding and β-sheet formation (Figure 4.3). While P-PA included 
proline-proline-proline to prevent hydrogen bonding and β-sheet formation which 
impairs formation of one-dimensional nanostructures (Figure 4.3). 
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Figure 4.3. Chemical representations of  K-PA (C12-VVAGK)  and P-PA (C12-
PPPGK) molecules used in this study. K-PA and P-PA are mixed with CpG ODNs to 
induce nanofiber and nanosphere formation, respectively.   
 
Both K-PA and P-PA molecules were purified with High-Performance Liquid 
Chromatography (HPLC) and analyzed with liquid chromatography-mass 
spectrometry (LC-MS). As explained in Chapter 2, in LC analysis, PA molecules 
were eluded according to hydrophilicity and detected with UV detector (at 220 nm 
wavelength. Elution time points given in LC chromatograms (Figures 4.4.a – 4.5.a) 
were consistent with hydrophilicity of molecules. More hydrophilic P-PA (due to 
three proline residues) was eluded at earlier time point than K-PA (two valines and 
one alanine). Mass spectra of peaks obtained in LC chromatograms indicated that 
both synthesized PA molecules have similar masses to the expected ones (Figures 
4.4.b – 4.5.b). These purified molecules were used in further studies. 
 
116 
 
 
Figure 4.4. LC-MS analysis of synthesized K-PA molecule.a. LC chromatogram of 
purified K-PA molecules at 220 nm indicates high purity of molecule. b. Mass 
spectrometric analysis of peak in K-PA LC chromatogram. 
[M+H]+(calculated)=654.48,  [M+H]+(observed)=654.50. 
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Figure 4.5. LC-MS analysis of synthesized P-PA molecule. a. LC chromatogram of 
purified P-PA molecules at 220 nm indicates high purity of molecule. b. Mass 
spectrometric analysis of peak in P-PA LC chromatogram. 
[M+H]+(calculated)=676.47, [M+H]+(observed)=677.51. 
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4.3.1. Structural characterizations of PA/ODN complexes 
Since secondary structures of peptide amphiphiles play critical role in nanostructure 
shape, we investigated secondary structure characters of PA combinations. For this 
reason, we obtained circular dichroic (CD) spectra of K-PA, P-PA and their ODN 
complexes. The K-PA molecule has a Val-Val-Ala peptide sequence, and revealed β-
sheet characteristic peaks (negative at 217 nm, positive at 197 nm) in circular 
dichroism (CD) spectra (Figure 4.6). While, P-PA molecule including Pro-Pro-Pro 
peptide sequence showed PPII helix secondary structure (a strong negative band at 
203 nm and a weak positive band at 227 nm), similar to polyproline structures 
(Figure 4.6).
133-134, 137
 PA/ODN complexes also demonstrated similar secondary 
structures of K-PA and P-PA and showed β-sheet and PPII helix characteristics in 
CD spectra, respectively.   
      
Figure 4.6. Circular dichroic (CD) spectra of K-PA and P-PA molecules alone or 
mixed with immunostimulatory ODN. CD spectra shows that secondary structures 
formed by ODN complexes of P-PA and K-PA are completely different. K-PA alone 
and K-PA/ODN complex shows characteristic signals for β-sheet secondary 
structure. However, P-PA alone and P-PA/ODN comples shows characteristic signals 
for PPII helix secondary structure. 
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Structural analyses of PA/ODN complexes were examined by using Small-angle X-
ray Scattering (SAXS), which provides information on the size and shape of 
nanostructures, and have an advantage of studying nanostructures in aqueous 
environment (Figure 4.7). The low q regions of the small-angle X-ray scattering data 
of K-PA/ODN and P-PA/ODN complexes were best fitted to an elliptical cylinder 
model
138
 with a major radius of 8.6±0.4 nm and oblate core shell sphere model139-140 
with a major radius of 7.2±0.3 nm, respectively. The results obtained from fitting of 
SAXS curve showed that K-PA/ODN complexes self-assembled into one- 
dimensional high-aspect-ratio cylindrical nanofibers, while P-PA/ODN complexes 
formed zero-dimensional oblate spherical nanostructures (Figure 4.7a, b; Table 4.1 
and 4.2). The elliptical cylindrical structural properties of K-PA/ODN complexes 
showed similar characteristics with Tobacco Mosaic Viruses (TMVs), which can 
form hollow cylinders with an ellipsoidal cross-section according to SAXS 
measurements.
141
  
For control experiments, K-PA and P-PA solutions at the same concentrations with 
PA/ODN complexes were prepared and SAXS analysis was performed. SAXS 
profiles of K-PA and P-PA nanostructures were also best fitted to an elliptical 
cylinder model with a major radius of 8.0±0.3 nm and oblate core shell sphere model 
with a major radius of 5.1±0.3 nm, respectively (Figure 4.8; Table 4.3 and 4.4). 
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Figure 4.7. SAXS analysis and model fitting for self-assembled PA/ODN 
nanostructures. According to Guinier plots, radius of gyration (Rg) of (a) K-PA/ODN 
self-assembled nanostructures was calculated to the best fit, elliptical cylinder model 
and (b) P-PA/ODN self-assembled nanostructures was calculated to the best fit, 
oblate core shell sphere model. PDDF histograms of (c) K-PA/ODN and (d) P-
PA/ODN self-assembled nanostructures also showed characteristics of elliptical 
cylinder and oblate core shell sphere model, respectively.  
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Table 4.1. Structural results obtained from fits to the SAXS data of K-PA/ODN 
complexes with elliptical cylinder model.   
 
Fitting Results (Elliptical Cylinder Model) K-PA+ODN 
Scale 4.6 
Minor radius (nm) 7.6±0.3 
Major radius (nm) 8.6±0.4 
Length (nm) 235.2±1.2 
SLD Cylinder (Å-2) 6.8×10
-5
 
SLD Solvent (Å-2) 3.7×10
-6
 
 
 
Table 4.2. Structural results obtained from fits to the SAXS data of P-PA/ODN 
complexes with oblate core shell sphere model.    
 
Fitting Results (Oblate Core Shell Model) P-PA+ODN 
Scale 2.6 
Minor core (nm) 1.8±0.1 
Minor shell (nm) 4.9±0.2 
Major core (nm) 2.0±0.1 
Major shell (nm) 5.2±0.2 
SLD core (Å-2) 1.3×10
-6
 
SLD shell (Å-2) 3.1×10
-5
 
SLD Solvent (Å-2) 1.4×10
-7
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Table 4.3. Structural results obtained from fits to the SAXS data of K-PA with 
elliptical cylinder model.   
 
Fitting Results (Elliptical Cylinder Model) K-PA 
Scale 4.6 
Minor radius (nm) 7.0±0.3 
Major radius (nm) 8.0±0.3 
Length (nm) 235.2±1.2 
SLD Cylinder (Å-2) 4.8×10
-5
  
SLD Solvent (Å-2) 3.7×10
-6
 
 
 
 
Table 4.4. Structural results obtained from fits to the SAXS data of P-PA with oblate 
core shell sphere model.   
  
Fitting Results (Oblate Core Shell Model) P-PA 
Scale 2.6 
Minor core (nm) 1.2±0.1 
Minor shell (nm) 3.2±0.2 
Major core (nm) 1.5±0.1 
Major shell (nm) 3.6±0.2 
SLD core (Å-2) 1.3×10
-6
 
SLD shell (Å-2) 2.0×10
-5
 
SLD Solvent (Å-2) 1.4×10
-7
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Figure 4.8. SAXS analysis and model fitting for self-assembled PA nanostructures. 
According to Guinier plots, radius gyration (Rg)  of (a) K-PA self-assembled 
nanostructures was calculated to the best fit, elliptical cylinder model and (b) P-PA 
self-assembled nanostructures was calculated to the best fit, oblate core shell sphere 
model. PDDF histograms of (c) K-PA and (d) P-PA self-assembled nanostructures 
also showed characteristics of elliptical cylinder and oblate core shell sphere model, 
respectively.  
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In order to visualize structures formed by K-PA/ODN and P-PA/ODN complexes we 
performed imaging by using Scanning Transmission Electron Microscope (STEM), 
TEM and AFM. STEM images of the K-PA/ODN and P-PA/ODN complexes 
revealed cylindrical and spherical morphology, respectively, in complementary to 
SAXS measurements (Figure 4.9a, b, 4.10, 4.11). In addition, phosphorus signal 
obtained by EDX (Energy-dispersive X-ray) spectroscopic analysis on spherical 
nanostructures and cylindrical fibers indicated interaction of ODNs with peptide 
molecules, and formation of peptide/ODN complexes (Figure 4.10 and 4.11).  
 
 
Figure 4.9. Imaging of PA/ODN nanostructures with TEM and AFM. TEM images 
of K-PA/ODN (a) and P-PA/ODN (b) self-assembled nanostructures and AFM 
images of K-PA/ODN (c) and P-PA/ODN (d) self-assembled nanostructures in 
aqueous environment. 
125 
 
AFM imaging of the peptide ODN complexes were performed to analyze these 
systems in aqueous environment to eliminate drying or staining effect in imaging. 
The peptide ODN complexes were imaged with AFM tip oscillating at the 
water/surface interfaces. The K-PA/ODN and P-PA/ODN complexes showed 
cylindrical and spherical morphologies, respectively, in complementary to SAXS 
measurements and TEM imaging (Figure 4.9c, d). On the other hand, K-PA/ODN 
self-assembled into cylindrical bundles, and larger aggregates of P-PA/ODN 
spherical complexes were observed in the aqueous environment. The aggregation and 
bundle formation on the AFM images in aqueous environment is related to the 
dynamic nature of peptide ODN complexes and self-assembly of the peptides. 
 
Figure 4.10. STEM images of self-assembled K-PA/ODN peptide fibers. The initial 
fiber formation and peptide bundles can be seen in images (scale bars: left image 2 
µm, right image 50 nm). EDX analysis (from the region shown with red rectangle in 
left STEM image revealed P atoms on the peptide bundles and self-assembly of DNA 
molecules with K-PA.  
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Figure 4.11. STEM images of self-assembled P-PA/ODN peptide spherical 
nanostructures. The spherical morphology of the nanostructures can be seen in 
images (scale bars: left image 50 nm, right image 100 nm). EDX analysis (from the 
region shown with the red rectangle in left STEM image revealed P atoms on the 
spherical nanostructures and self-assembly of DNA molecules with P-PA.  
 
In addition, AFM imaging of dried peptide ODN complexes on the surfaces showed 
similar cylindrical and spherical morphologies of K-PA/ODN and P-PA/ODN 
complexes compared to aqueous environment at the same conditions (Figure 4.12). 
For control experiments, TEM images of K-PA and P-PA nanostructures at the same 
concentrations with PA/ODN complexes were taken and similar cylindrical and 
spherical morphologies were observed (Figure 4.13). 
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Figure 4.12. AFM images of self-assembled K-PA/ODN and P-PA/ODN 
nanostructures dried on mica and glass surfaces, respectively. (a) K-PA/ODN 
solution was dropped onto the cleaned mica surface and dried overnight; the imaging 
was performed on dry mica surface. (b) P-PA/ODN solution was dropped onto the 
glass surface and dried overnight; the imaging was performed on dry glass surface.   
 
 
 
Figure 4.13. TEM and STEM images of self-assembled K-PA and P-PA 
nanostructures. (a) The K-PA fiber formation and peptide bundles can be seen in 
images. (b) The spherical morphology of the P-PA self-assembled nanostructures can 
be seen in images (scale bars: 100 nm). 
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To discern the effect of nanostructure from basal immune response to CpG motives, 
we prepared all groups with equal amounts of CpG ODNs (nanofiber, nanosphere 
and CpG ODN alone). The PA concentration was adjusted to make all ODNs in 
solution to bind to nanostructures. Since negatively charged ODN interacts with 
positively charged lysine residue on peptide molecules, the number of CpG ODNs 
bound to nanostructures is directly related with ODN to peptide ratio. To find critical 
ODN/peptide ratio, where all ODNs in solution are bound to nanostructures, we 
prepared formulations with varying ODN/PA ratios. All of the formulations were run 
on polyacrylamide gel electrophoresis (PAGE) in order to analyze the amount of 
ODNs, which were not bound to peptides. Molecules should have a net negative 
charge to be able to run in the PAGE experiment. Since the ODNs interacting with 
peptides would lose negative charge, they would not be able to run in polyacrylamide 
gel. Accordingly, any formulation not displaying an ODN band in gel suggested that 
all ODNs in that formulation would be bound to nanostructures. As a result of PAGE 
analysis, we found that 1:70 and 1:2500 ratios were critical for ODN/K-PA and 
ODN/P-PA complexes, respectively (Figure 4.14a, b).  
Zeta potential measurements were also consistent with PAGE results and indicated 
that similar ratios of ODN/peptide are critical for binding of all ODNs to 
nanostructures (Fig. 4.15). ODN solution with no PA molecules revealed -33 mV 
zeta potential due to high negative charge of ODN molecule (Figure 4.15). As PA 
amount increased in ODN solution, zeta potential values increased, expectedly. For 
ODN/K-PA solution, we observed a positive potential (+6 mV) at 1:100 ratio, 
indicating total neutralization of ODN with PA. For ODN/P-PA, 1:2500 ratio was 
critical (+21 mV), similar to PAGE experiment (Figure 4.15). In summary, these two 
sets of data revealed the critical ODN/PA ratios to incorporate all ODNs in solution 
onto nanostructures. Interestingly, full neutralization of ODNs requires more of P-PA 
than K-PA. This might be due to concealment of positive charges on P-PA molecules 
during further aggregation of individual micelles mentioned above, which makes 
accessible charges of P-PA lower than K-PA.
142-143
 Indeed, zeta potential of the P-PA 
was several folds lower than equimolar K-PA (Figure 4.16). Zeta potential for K-PA 
showed linear dependency from concentration, indicating that all of lysine molecules 
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are presented to aqueous media and accessible for zeta potential measurement. 
Although both carries single lysine amino acid to make them positively charged at 
pH 7, K-PA showed similar zeta potential to P-PA with 25 fold higher concentration 
(Figure 4.16). This suggests that at least some of the positive charges provided by 
lysine molecules in P-PA are buried in aggregates or nanospheres (Figure 4.13b) and 
concealed from zeta potential measurement and probably negatively charged 
molecules in aqueous media (Figure 4.15). Positive zeta potential observed for P-PA 
probably comes from lysine molecules on the surface of nanospheres.  
Based on these findings, we prepared ODN/K-PA complexes with 1:100 ratio and 
ODN/P-PA complexes with 1:2500 ratio. 
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Figure 4.14. Determination of critical ODN/Peptide ratio by using polyacrylamide 
gel electrophoresis (PAGE). ODN/Peptide (a.K-PA, b.P-PA) formulations with 
varying ratios were prepared and subjected to PAGE. ODN band (verified by 20 bp 
marker band) dwindles away as PA amount in the mixture increases. ODN is not 
detectable after 1:70 ratio for K-PA, while 1:2500 ratio for P-PA, indicating binding 
of all ODNs in medium to PA nanostructures (ODN is ODN alone; M denotes 
marker, which is mixture of known ODN molecules from 10bp to 100bp).  
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Figure 4.15. Zeta Potential measurements of PA/ODN complexes for  determination 
of critical ODN/Peptide ratio. ODN/Peptide formulations with varying ratios were 
prepared and subjected to zeta potential measurement. Highly negatively charged 
ODN molecule shows negative zeta potential, which increases as concentration of 
PA molecule in the complex increases. Zeta potential of above zero was accepted as 
an indicator of total neutralization of ODN molecule, that also suggests binding of all 
ODNs in solution to PA nanostructures. For K-PA, zeta potential appeared above 
zero at 1:100 ODN/PA ratio, while for P-PA, this ratio was observed to be 1:2500. 
Sharp increase of zeta potential in K-PA samples at 1:300 also implies that K-PA 
molecules added to 1:100 sample didn`t bind to ODN molecules since all of them 
had already bound to PA nanostructures.   
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Figure 4.16. Zeta potential values of PA molecules at various concentrations. K-PA 
shows higher zeta potential values than P-PA at similar concentrations. Moreover, 
zeta potential of K-PA shows linear increase with its concentration, indicating total 
presentation of lysine of K-PA into aqueous media. While P-PA requires to be 
concentrated nearly 25 fold to show comparable zeta potential value to K-PA. This 
suggests that at least some of the lysine molecules in P-PA are concealed in 
aggreagates/nanospheres formed by P-PA.        
 
4.3.2. Characterization of immune response to ODN nanostructure complexes 
Cytokine production profiles of mouse spleen cells indicated that direction of 
immune response to CpG ODN was shifted by nanostructures. Spleen carries 
panoply of immune cells and can give insights into how interplay between immune 
cells would react to virus-like nanostructures. To delineate the reaction of spleen 
cells to virus-like shapes of the ODN delivery agents, we treated cultured splenocytes 
with various doses of ODN prepared as K-PA/ODN, P-PA/ODN and ODN alone 
(with same amount of CpG ODN between groups). To exclude any CpG-free effect, 
we also treated cells with similar experimental groups with control ODN instead of 
CpG ODN (with reverted CpG motif, see Methods section). Supernatants were 
collected after 48 h of culture and analyzed for cytokine (IFN-γ, IL-12 and IL-6) 
profiles with ELISA. These cytokines were chosen to reflect the immediate 
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proinflammatory response (IL-6) and Th1 response (IL-12 and IFN-γ), which fights 
against intracellular pathogens. IFNγ is also a critical mediator of anti-viral response 
and is extensively involved in anti-tumor response. Cytokine measurements showed 
that dose-dependent CpG-specific response saturates at higher concentrations and 
even become sub-optimal, as reported in literature (Figure 4.17, 4.18 and 4.19).
144
  
 
 
Figure 4.17. Effect of nanostructures on (CpG ODN) dose-dependent IFNγ cytokine 
production by splenocytes. After treating splenocytes with various doses of ODN 
alone or ODN bound to nanostructures, IFNγ secreted to culture media were detected 
with ELISA.  ODN-dependent secretion of IFNγ saturates at 0.1 µg/ml of ODN and 
then becomes suboptimal. At optimal concentrations, ODN bound to nanostructures 
seem to be more potent than ODN alone, while nanofibers are more potent than 
nanospheres. IFNγ secretion is still CpG-specific when nanostructures are used as 
nanofibers and nanospheres with control ODN induced non-detectable and low 
amount of  IFNγ, respectively (N.D is not detectable).     
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Figure 4.18. Effect of nanostructures on (CpG ODN) dose-dependent  IL-6 cytokine 
production by splenocytes. After treating splenocytes with various doses of ODN 
alone or ODN bound to nanostructures, IL-6 cytokine secreted to  culture media were 
detected with ELISA. Nanostructures impaired CpG ODN-induced IL-6 secretion at 
doses of 0.03 and 0.1 µg/ml, at which IL-6 is detectable in culture media. IL-6 
secretion is still CpG-specific when nanostructures are used as nanofibers and 
nanospheres with control ODN induced non detectable (N.D.) amount of  IL-6 
secretion (N.D is not detectable). 
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Figure 4.19. Effect of nanostructures on (CpG ODN) dose-dependent IL-12 cytokine 
production by splenocytes. After treating splenocytes with various doses of ODN 
alone or ODN bound to nanostructures, IL-12 secreted to culture media were 
detected with ELISA.  ODN-dependent secretion of IL-12 saturates at 0.1 µg/ml of 
ODN and then becomes suboptimal for ODN and P-PA/ODN. At 0.1 µg/ml, IL-12 
secretion was similar between ODN bound to nanostructures and ODN alone, while 
nanostructures seem slightly less potent. IL-12 secretion is still CpG-specific when 
nanostructures are used as nanofibers and nanospheres with control ODN induced 
non-detectable or low amount of  IL-12, respectively (N.D is not detectable).     
 
0.1 µg/ml of CpG ODN was optimal concentration for each formulation regarding 
induction of cytokine production. Cytokine production by different formulations at 
this concentration are shown at Fig. 5. Interestingly, nanostructures shifted cytokine 
response to CpG from a high IL-6 and low IFN-γ profile to a low IL-6 and high IFN-
γ (Figure 4.17, 4.18 and 4.20). This shift in immune response was even more 
pronounced for nanofibers when compared to nanospheres. NF-ODN induced IFN-γ 
response 3-4 times higher than CpG ODN alone and nearly two times higher than 
NS-ODN (Figure 4.17, 4.20a). However, IL-6 production was diminished nearly 
two-folds in response to both K-PA/ODN and P-PA/ODN when compared to CpG 
ODN alone (Figure 4.20b). IL-12 induction with K-PA/ODN or P-PA/ODN was not 
significantly different from ODN alone, indicating that higher IFN-γ induction with 
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K-PA/ODN and P-PA/ODN was not IL-12 dependent (Figure 4.19). High IFN-γ 
production from PBMCs (peripheral blood mononuclear cells) by CpG ODNs with 
nanoparticulate structure (A-type ODN) were shown to be IFN-α dependent.145 
ODNs lacking CpG motives were not effective generally, even when supplied on 
nanostructures, which indicates that altered immune response with nanostructures 
was still CpG-dependent (Figure 4.17-4.20). At lower concentrations than 0.1 µg/ml, 
P-PA/ODN preserved its potency of IFN-γ production better than K-PA/ODN and 
ODN alone (Figure 4.17). Possibly at very low concentrations, K-PA/ODN 
complexes do not form full-fledged nanofibers, causing a sharp drop in activity.  
Linear ODNs (such as ODN1826 used in this study), which do not form any higher 
order structures, are known for their ability to induce production of high amounts of 
IL-6, but low amounts of IFN-α from immune cells.144 On the other hand, 
nanoparticle-forming A-ODNs, with polyG sequences at both end, or linear ODNs 
bound to nanoparticles were shown to induce several folds higher IFN-α /IFN-γ and 
lower IL-6 production than linear B-ODNs, with no polyG sequence.
124-125, 144
 This 
change in immune profile was explained by retention of nanoparticulate ODNs in 
early endosomes of plasmacytoid dendritic cells  much longer than linear ODNs and 
inducing a different signaling pathway -  MyD88–IRF-7.129   
While B-ODNs rapidly localize to lysosomes and induce MyD88– NF-κB pathway. 
Our spherical particles with CpG ODN resemble morphologically to nanoparticles 
used in these studies (both can be called as zero-dimensional) and similarly induced 
higher IFNγ and lower IL-6 response than CpG ODN. Remarkably, our findings 
reveal that one-dimensional nanofibers synergize with CpG ODN better than 
nanospheres in terms of IFNγ production, which indicates that immune response is 
driven further to Th1 direction. To the best of our knowledge, this is the first report 
showing thetunable nature of immune response to pathogenic DNA motives by 
changing shape of carrier nanostructures. Difference between immune profiles of 
ODN alone, K-PA/ODN and P-PA/ODN might also be caused by different retention 
time in early endosomes and differential induction of sıgnallng pathways like 
MyD88–IRF7. 
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Figure 4.20. Nanostructures shift CpG-induced cytokine secretion profile of 
splenocytes. Mouse splenocytes were treated with indicated formulations and 
cytokine concentrations in culture media were detected with ELISA (a.IFNγ, b.IL-6).  
ODN concentration in all groups is 0.1 µg/mL. Statistical significance between 
groups was measured by Student’s t-test. N.D. means “not detected”.   
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Upregulation of co-stimulatory molecules on the surfaces of immune cells is another 
mechanism of immune activation induced by infection signals such as CpG DNA. To 
understand effect of nanostructures to this process, we cultured splenocytes with 
ODN, K-PA/ODN and P-PA/ODN similar to cytokine assay and checked expression 
of cell surface markers CD86 (also known as B7.2) and CD40 by flow cytometry. 
These molecules are expressed by antigen presenting cells (APC) upon sensing 
infection and important in development of adaptive immune response to foreign 
antigen. Interaction of CD86 molecule with CD28 on T-cell surfaces is required for 
recognition of antigen as foreign and activation of T-cells during antigen presentation 
to T-cell receptors. CD40 binding to target cells induces B-cells and number of 
CD86 expressing cells in splenocytes is further upregulated by NF-ODN from 17% 
with ODN alone to 22%, while effect is strictly CpG signal specific that nanofibers 
with control ODNs were similar to non-treated sample (~1%, Figure 4.21a). The P-
PA/ODN treatment induced CD86 expression in 19% of cells, which did not have a 
statistically significant difference from ODN alone (Figure 4.21a). On the other 
hand, CD40 expression profiles were different. While, all CpG-containing 
formulations induced CD40 expression (30-40%) in splenocyte population better 
than the control ODN (~10%), P-PA/ODN showed the highest signal in this context 
(48%) (Figure 4.21b). In addition, ODN induced more cells (44%) to express CD40 
than K-PA/ODN (37%). Overall, nanostructures seem to synergize with ODN in the 
induction of expression of co-stimulatory molecules. The shapes of the 
nanostructures made a difference: the nanofibers induce more CD86 expression than 
nanospheres, which induce CD40 expression better than nanofibers.   
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Figure 4.21. Effect of nanostructures on CpG-induced surface expression of co-
stimulatory molecules. Mouse splenocytes were treated with indicated formulations 
for 24 h and percentage of cells expressing CD86 (a) or CD40 (b) in total population 
were detected by flow cytometry. Statistical significance between groups was 
analyzed by Student’s t-test.  
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Besides inducing alterations in the cytokine profile of splenocytes, nanostructures 
also stimulated morphological changes in cellular behavior. Depending on the 
magnitude of CpG signal, cells formed granular structures through aggregation 
among a number of individual cells (Figure 4.22). Increase in the CpG ODN 
concentration caused increase in number and size of granules (Figure 4.16a-c, e-g, i-
k). Remarkably, we couldn’t find any report regarding this observation in the 
literature. Even more interesting observation was the correlation between formation 
of granules and induction of IFNγ from splenocytes. Splenocytes treated with K-
PA/ODN complex induced a higher number and size of granules than P-PA/ODN 
and ODN alone (Figure 4.22a-c). Granulation was strictly dependent on CpG signal, 
since non-treated groups (Figure 4.22l) and nanostructures obtained with control 
ODN didn’t induce this type of structures (Figure 4.22d, h). This indicates that 
formation of granules is not due to the toxic effect of nanostructures or ODNs, but 
due to the existence of infection signal in the environment. These cellular 
aggregations resemble granuloma – a clinical pathological pattern observed during 
diseases such as tuberculosis. In these cases, immune system walls off foreign signal, 
which cannot be destroyed by normal activities of immune cells. Macrophages fuse 
and aggregate together in the center of these granulomas surrounded by lymphocytes. 
In vivo IFNγ depletion by monoclonal antibodies was found to suppress both number 
and size of granulomas in mice.
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 Thus, high IFNγ production by K-PA/ODN 
nanostructures might be acting as a perpetuating infection signal on splenocytes, 
which coalesce to form granules with a higher number and size.  
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Figure 4.22. Morphological changes in splenocytes upon stimulation with K-
PA/ODN (a-0.3 µg/mL, b-0.1 µg/mL, c-0.03 µg/mL), K-PA/cont.ODN (d-0.3 
µg/mL), P-PA/ODN (e-0.3 µg/mL, f-0.1 µg/mL, g-0.03 µg/mL), P-PA/cont.ODN (h-
0.3 µg/mL), ODN alone (i-0.3 µg/mL, j-0.1 µg/mL, k-0.03 µg/mL), media alone (l).  
 
4.3.3. Uptake of nanostructure ODN complexes into immune cells 
Recent studies have shown that the shape of the particle significantly modifies its 
cellular uptake. High-aspect-ratio PEG particles were internalized into HeLa cells 4 
times faster than low-aspect-ratio particles and were rapidly translocated into nuclear 
membrane.
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 In another work, shape of the surface of particle at the point of initial 
contact with macrophages was shown to determine whether it will be phagocytosed 
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or not.
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 Polystyrene particles with oblate ellipsoid shape displayed higher 
internalization and phagocytosis into macrophages than prolate ellipsoid and 
spherical particles,
149
 while prolate ellipsoid particles were better in cellular binding. 
Barua et al. showed that polystyrene nanorods coated with antibodies specific to 
cellular receptors exhibit higher cellular (HER2-expressing breast cancer cell line) 
binding, uptake and bioactivity than polystyrene nanospheres.
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 However, regarding 
non-specific uptake (no specific antibody on nanostucture to bind to cellular 
receptors), rods were inferior than spheres. This might be due to the fact that rods 
have larger contact area with cellular surface, which cause higher adhesion to surface 
through receptor-ligand interactions.
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 Considering these studies, we hypothesized 
that differential responsiveness of immune cells to K-PA/ODN, P-PA/ODN and 
naked ODN might be caused by differential uptake into immune cells.  
To analyze uptake of K-PA/ODN, P-PA/ODN and ODN into different immune cells, 
we prepared these complexes by using FITC-conjugated CpG ODNs. Mouse 
splenocytes were cultured with FITC-ODN alone or FITC-ODN bound to 
nanostructures for two different durations (2 and 12 h) prior to staining cells with 
labeled antibodies against B220 and CD11c or F4/80 - surface markers of various 
types of TLR9+ positive cells in mice. Internalization of ODN-FITC into cells was 
measured by flow cytometer. In all types of cells investigated, uptake of ODN alone 
or bound to nanostructures increased as a function of time, except K-PA/ODN uptake 
into dendritic (CD11c+) and plasmacytoid dendritic (CD11c+B220+) cells (Figure 
4.23). These results indicate that 2 h is not sufficient for maximal uptake of CpG 
ODNs into relevant immune cells. However, nanofiber-bound ODNs achieved 
maximal uptake into dendritic cells (DC) and plasmacytoid dendritic cells (pDC) at 2 
h (Figure 4.23a, b). At both 2 h and 12 h, K-PA/ODN positive cells in DC and pDC 
populations were about 65% and 85-90%, respectively. ODN alone or bound to 
nanospheres achieved this level of uptake at 12 h. At 2 h, ODNs were internalized by 
44% and 50% of DCs and pDCs, while P-PA/ODN was internalized by 34% and 
42% of DCs and pDCs, respectively. Previously, removal of CpG ODNs from 
cellular culture media before 8 h of culture was reported to reduce its immune 
activating potential
151
, which suggests that time is a determinant factor for entry of 
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CpG ODNs into TLR9-positive endosomes. Nanofibrous structure accelerated uptake 
of CpG ODNs into DCs. This result also correlates well with higher potential of K-
PA/ODN than ODN and P-PA/ODN to induce IFNγ secretion from splenocytes and 
upregulate maturation marker – CD86.  
 
Figure 4.23. Uptake profile of FITC-ODN alone or bound with nanostructures into 
TLR9-expressing cell subsets in splenocytes. Percentage of FITC (ODN)+ cells in 
CD11c+ (dendritic cells), CD11c+B220+ (plasmacytoid dendritic cells), B220+ (B 
cells) and F4/80+ (macrophages) populations. Red and blue bars indicate 2 h and 12 
h culture with ODN formulations, respectively. *p<0.05, **p<0.01 according to 
Student’s t-test.  
 
Increased uptake of K-PA/ODN to pDCs might be an explanation for their capability 
to induce IFNγ. As mentioned above, IFNγ production can be induced by IFNα 
released from pDCs upon stimulation with nanoparticulate CpG ODNs.
145
 Higher 
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uptake of nanospherical ODN complex at 12 h than ODN also might contribute to its 
potential of inducing IFNγ better than ODN. Previously, scavenger receptor 
CXCL16 on plasmacytoid dendritic cells was charged with binding to nanoparticle 
forming D-ODN (analogue of A-ODN, with polyG sequences at ends) and 
facilitating its cellular uptake and modifying resulting immune response, such as 
IFNα response.152 Similar receptors might be functioning for recognition of 
nanofiber structure and its preferential uptake into DCs and pDCs.  
All groups were internalized similarly to B-cells (B220+) and macrophages 
(F4/80+). Uptake of ODN and K-PA/ODN (57% and 63%, respectively) to B-cells 
were higher at 12 h than P-PA/ODN (42%), while only difference between ODN and 
P-PA/ODN was statistically significant (Figure 4.23c). This might contribute to 
higher IL-6 induction by ODN alone, since CpG ODN is known induce B-cells to 
secrete IL-6 (Figure 4.23d). Overall, these results strongly suggest that K-PA/ODN 
system was better internalized by DCs and their subset – pDCs than their 
counterparts. These cells are critical to contain viral/intracellular bacterial infections 
and present processed antigens to T cells. Thus, better uptake of nanofibrous ODNs 
to these cells might be related to its unexpectedly high Th1-biased immune activating 
potential. 
 
4.3.4. Characterization of protection provided by nanostructures to ODN 
against enzymatic degradation   
K-PA/ODN and P-PA/ODN induced Th-1-biased immune stimulation better than 
ODN-alone at in vitro experiments, which make them promising candidates for in 
vivo applications. However, enzymatic degradation and short half-life is an important 
problem with CpG ODNs` in vivo application. To understand whether nanostructures 
provide any protection from enzymatic degradation, we performed DNAse assay. 
ODN, NF-ODN and NS-ODN were treated with DNAse I for different time periods. 
SDS detergent was used to remove ODNs bound to nanostructures for further 
investigation. All samples were run on polyacrylamide gel for visualizing remaining 
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ODNs after DNAse treatment. As it is shown in Figure 4.24a, ODN-alone was 
rapidly chopped off resulting in no visible bands in gel after 30 min of DNAse 
treatment. Calculation of band intensities also revealed that ODN was almost 
completely degraded after 24 h of treatment – 6% remained according to average of 
three samples (Figure 4.25). However, ODNs detached from K-PA/ODN or P-
PA/ODN complexes were clearly observable even after 24 h of DNAse treatment 
(Figure 4.24b, c). The P-PA/ODN system protected ODN better than K-PA/ODN: 
56% of ODNs remained after 24 h with P-PA/ODN, while 39% of ODNs remained 
with K-PA/ODN (Figure 4.25). These results indicate that nanostructures protect 
ODN from degradation, while nanospheres were more potent than nanofibers. 
Nanostructure binding possibly makes ODNs less accessible to enzymes, which 
might be serving as a mechanism for protection.  
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Figure 4.24. Resistance of ODNs to DNAse were investigated with polyacrylamide 
gel electrophoresis (PAGE). ODN alone (a), K-PA/ODN (b) and P-PA/ODN (c), 
which had been treated with DNAse I for different time periods, were subjected to 
PAGE. Lane 1 is Marker, Lane 2 is non-treated ODN, Lane3-Lane7= 10 min, 30 
min, 1 h, 4 h, 24 h treatment with DNAse. d. Time-dependent degradation of ODN in 
different formulations, plotted according to calculated band intensities. 
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Figure 4.25. Time-dependent degradation of ODN in different formulations, plotted 
according to calculated band intensities. ODN alone is almost completely degraded 
by DNAse I at the end of 24h, while ODN bound to nanostructures retain 
considerable amount of ODN intact. 
 
4.4. Experimental details   
4.4.1. Materials 
9-Fluorenylmethoxycarbonyl (Fmoc) and tert-butoxycarbonyl (Boc) protected amino 
acids, [4-[α-(20,40-dimethoxyphenyl) Fmoc-aminomethyl] phenoxy] 
acetamidonorleucyl-MBHA resin (Rink amide MBHA resin),  and 2-
(1Hbenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphate (HBTU) 
were purchased from NovaBiochem and ABCR. The other chemicals for peptide 
synthesis were purchased from Fisher, Merck, AlfaAesar, or Aldrich. All chemicals 
were used as provided. CpG and control ODNs were purchased from Invivogen. 
Paired antibodies and recombinant proteins of IFNγ and IL-12 were obtained from 
R&D systems, that of IL-6 from eBioscience. All cell culture and ELISA reagents 
were purchased from Invitrogen, except non-essential amino acid solution (Sigma 
Aldrich). Reagents for polyacrylamide gel electrophoresis were obtained from Sigma 
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Aldrich. Labeled antibodies were obtained from BD Pharmingen (B220 and CD11c) 
and eBioscience (F4/80, CD40, CD86). 
 
4.4.2. Peptide synthesis 
Lauryl-VVAGK-Am (K-PA) and Lauryl-PPPGK-Am (P-PA) were constructed on 
Rink Amide MBHA resin. Amino acid couplings were performed with 2 equivalents 
(equiv) of Fmoc-protected amino acid, 1.95 equiv of HBTU, and 3 equivalents of 
N,N-diisopropylethylamine (DIEA) for 2 h. To remove the Fmoc group, 20% (v/v) 
piperidine/dimethylformamide solution (DMF) was added and incubated for 20 min. 
To block the remaining free amine groups after amino acid coupling, 10% (v/v) 
acetic anhydride solution in DMF was used (30 min). After each step, the resin was 
washed by using DMF, dichloromethane (DCM), and DMF. Trifluoroacetic acid 
(TFA)/triisopropyl silane (TIS)/H2O/DCM mixture (5:2.5:2.5:90 ratio) was used to 
cleave the peptide from the resins.  
 
4.4.3. Preparation of virus-like nanostructures 
Virus-like nanostructures were prepared by using self-assembly of peptide molecules 
upon mixing with oligonucleotides. To form one-dimensional nanofibrous and zero-
dimensional nanosphere structures, positively charged K-PA and P-PA (Figure 4.3) 
molecules were mixed with CpG (ODN1826) or control ODNs, respectively. Two 
CpG motives in ODN1826 were reverted in control sequence: ODN1826: 5’-
tccatgacgttcctgacgtt-3’; ODN1826 control: 5’- tccatgagcttcctgagctt -3’. Exact molar 
ratio for making all ODNs in solution to interact with nanostructures was determined 
to be 100:1 for K-PA/ODN and 2500:1 for P-PA/ODN (Figure 4.14, 4.15). 
Nanostructures were prepared with these ratios for all experiments and named as 
nanofibrous ODN (K-PA/ODN) and nanospherical ODN (P-PA/ODN). In all 
experiments at least 3 independent nanofiber and nanosphere ODN formulations 
were prepared and tested. 
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4.4.4. Small Angle X-Ray Scattering (SAXS) analysis of self-assembled 
nanostructures 
The PA/ODN complexes for SAXS analysis was prepared as; ODN1826 solution (15 
µg/mL) was mixed with same volume of 0.375% (w/v) P-PA solution (2500:1 ratio) 
or 0.015 % (w/v) K-PA solution (100:1 ratio). The final ODN concentration in each 
PA/ODN complexes was equal. For control experiments, 0.008% (w/v) K-PA and 
0.188% (w/v) P-PA solutions were prepared. Each PA/ODN, K-PA and P-PA 
solutions were loaded into a quartz capillary cell for SAXS measurement. The SAXS 
measurements were performed with a Kratky compact HECUS (Hecus X-ray 
systems, Graz, Austria) system equipped with a linear collimation system and  X-ray 
tube Cu target ( λ=1.54 Å). The generator was operated at a power of 2 kW (50 kV 
and 40 mA). Simultaneous measurements of SAXS and WAXS range are possible in 
the system with a linear-position sensitive detector used with 1024 channel 
resolution. Distance between channels and the sample-detector are 54 µm and 31.5 
cm respectively. Scattering curves were monitored in q ranges of 0.004-0.55 Å-1 for 
SAXS and 1.03-2.15 Å-1 for WAXS. All PA/ODN complexes, K-PA and P-PA 
solutions were measured for 900 s at room temperature (23 °C).   
 
4.4.5. Transmission Electron Microscopy (TEM) imaging 
Nanostructures were imaged by TEM. 30 µL of PA/ODN complexes was prepared 
on parafilm sample by mixing 15 µL of 15 µg/mL ODN1826 with either 15 µL of 
0.375% (w/v) P-PA (2500:1 ratio) or 15 µL 0.015% (w/v) K-PA (100:1 ratio). For 
PA only samples, same concentrations of PAs were mixed with ddH2O instead of 
ODN. TEM grids were reverted onto these solutions. Grids were removed after 5 min 
and remaining solution on grid was absorbed by a lint-free paper. Staining was 
performed with 2% (w/v) uranyl acetate solution (Ted Pella, Inc) for 1 min. Grids 
were then immersed into ddH2O once and dried overnight at room temperature. TEM 
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imaging was performed next day by a FEI, Tecnai G2 F30 instrument. All images 
were taken in STEM mode with a high angle annular dark field (HAADF) detector.  
 
4.4.6. Atomic Force Microscopy (AFM) imaging 
The PA/ODN complexes for AFM imaging were prepared in liquid or dried 
conditions. ODN1826 solution at 15 µg/mL concentrations was mixed with same 
volume of 0.375% (w/v) P-PA solution (2500:1 ratio) or 0.015% (w/v) K-PA 
solution (100:1 ratio). The final ODN concentration in each PA/ODN complexes was 
equal. For K-PA/ODN complexes, the prepared solution was diluted 50 times and 
dropped onto the cleaned mica surface and imaged directly in liquid environment or 
dried overnight, then imaged on the mica surface. SiN soft contact tip was used for 
contact mode imaging of K-PA/ODN complexes. For P-PA/ODN complexes, the 
solution was diluted 100 times and dropped onto the cleaned glass surface and 
imaged directly in liquid environment  or dried overnight, then imaged on the glass 
surface. Si tip (150 kHz, 5 N/m) was used for soft-tapping mode imaging of P-
PA/ODN complexes. The dilutions of PA/ODN complexes were necessary because 
initial concentrations were high for high quality AFM imaging in liquid environment. 
During the imaging, MFP3D Asylum microscope was used. 
 
4.4.7. Circular Dichroism Spectroscopy 
Circular dichroism (CD) spectroscopy was performed with a JASCO J815 CD 
spectrometer at room temperature. 0.2 mM solutions of both K-PA and P-PA and 
their mixtures with ODN1826 (100:1 and 2500:1, respectively) were measured from 
300 to 190 nm. Data pitch was 1 nm, scanning speed was 100 nm/min, and all 
measurements were performed with three accumulations. DIT was selected as 4 s, 
bandwidth as 1 nm, and the sensitivity was standard. Molar ellipticity was calculated 
using the equation: [θ] = 100 x θ/(C x l), where C is the molar concentration, and l is 
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the cell path length in centimeters. [θ] =θ/(C x l) = deg/(mol/1000 cm3) x 0.1 cm = 
100 deg cm
2
 dmol
-1
. 
 
4.4.8. Polyacrylamide Gel Electrophoresis (PAGE) 
To identify critical ODN/PA ratio required to conjugate all ODNs in solution to 
nanostructure, PAGE was performed. 20 µg/mL ODN1826 solution (15 µL) was 
mixed with varying concentrations of PA solutions (15 µL) to prepare different 
ODN/PA ratios (from 1:10 to 1:2500). These solutions were mixed with Orange 
DNA loading dye (Fermentas) and loaded into 20% polyacrylamide gels. 10 µL of 
10 bp DNA ladder (O`range ruler
TM
, Fermentas) was used as marker. Gels were run 
at 75 V for 1 h and subsequently at 50 V for 2.5 h (in 1x TAE). Stains-all dye 
working solution (0.005%, w/v) was prepared freshly from stock solution (0.1% w/v) 
as suggested by manufacturer (Sigma Aldrich). Gels were incubated in Stains-all 
overnight (dark conditions and room temperature). Next day, destaining of gels was 
performed under sunlight and images were taken by a Nikon camera.  
 
4.4.9. Zeta Potential 
Zeta potential measurements were performed to find critical ratio of ODN/PA, where 
all ODNs in solution were neutralized (and bound) with PAs. 400 µL of 5 µg/mL 
ODN1826 solution was mixed with varying concentrations of PA solutions (400 µL) 
to prepare different ODN/PA ratios (from 1:10 to 1:2500). Zeta potentials of these 
solutions were measured with Nano-ZS Zetasizer (Malvern). Measured mobility was 
converted to zeta potential by using Smoluchowski equation. The measurements 
were performed in triplicate – by using 3 independently generated formulations.  
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4.4.10. Animals  
All experimental procedures have been approved by the Animal Ethics Committee of 
Ankara Diskapi Yildirim Beyazit Training and Research Hospital (Protocol # 
2013/25). Primary spleen cells were obtained from adult BALB/c (8-12 weeks old) 
mice, which were maintained under controlled conditions and fed ad libitum.  
 
4.4.11. Splenocyte culture and stimulation experiment 
Spleens were removed aseptically and grinded between petri plate surface and 
plunger end of syringe in culture media (2% FBS in RPMI-1640) in order to 
dissociate single cells from bulk tissue. Single cell suspension was collected 
carefully to exclude tissue debris. Cell suspension was centrifuged at 800 g for 10 
min. Supernatant was discarded and cell pellet was resuspended in culture medium 
(this step was performed twice). Cells were adjusted to 2 x 10
6
 cells/mL cell density 
and cultured in 96-well plates as 200 µL/well (4 x 105 cells/well). Culture media was 
composed of RPMI-1640 with 5% FBS (Pen/Strep, L-Glu, non-essential amino acids 
and HEPES (20 mM) were also added). Cell stimulation was performed immediately 
after distributing cells to wells. K-PA/ODN (nanofiber-ODN) and P-PA/ODN 
(nanosphere-ODN) were prepared as described above by different doses of 
ODN1826 or control ODN. Nanostructure and ODN alone solutions were further 
diluted with media and final concentration of ODN in cell suspension was from 1 
µg/mL to 0.01 µg/mL. For cytokine analysis, cells were cultured at 37 °C and 5% 
CO2 for 48 h and supernatants were collected at the end of the experiment. For 
analysis of surface markers (co-stimulatory molecules), cells were treated with same 
formulations (ODN dose - 0.3 µg/ml) for 24 h. Cells were collected at the end of 
experiment for further staining and for analysis by flow cytometry. Also, 
morphological changes were followed by using a light microscope. Experiments 
were performed in triplicate. Also, representative result of 3 independent 
experiments is shown.  
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4.4.12. ELISA  
Cytokine concentration in supernatants collected from cultures at the end of 
splenocyte stimulation experiment was measured by ELISA. MaxiSorp
TM
 plates 
(Thermo Scientific, NUNC) were coated with IL-6, IL-12 or IFN-γ primary 
antibodies (overnight incubation at 4 °C). Next day, plates were blocked with 0.5% 
BSA (2 h), incubated with supernatants of cell culture experiment or standard 
recombinant proteins (2 h), biotin-labeled secondary antibody (2 h) and HRP (horse 
radish peroxidase)-conjugated  streptavidin (1 h) consecutively at room temperature. 
Plates were washed 5 times with (in first two steps, washing was performed once for 
each step) washing buffer and dried by tapping between each consecutive steps. 
TMB (3, 3’, 5, 5’-Tetramethylbenzidine) substrate was added at the last step and 
reaction was stopped after 15-20 min by 1.8 N H2SO4. Color formation was 
measured by microplate reader (Spectramax M5, Molecular Devices) as absorbance 
at 450 nm wavelength. This value was subtracted from reference value (650 nm). All 
treatments were performed with at least three replicates and shown as mean +/- 
standard deviation. 
 
4.4.13. Internalization of ODNs into immune cells 
Internalization of ODNs into various immune cells expressing TLR9 in total 
splenocytes was analyzed by flow cytometry. For this purpose, FITC-conjugated 
ODN was used for preparing NF-ODN and NS-ODN. Freshly prepared mouse 
splenocytes were cultured in 96-well plates (4 x 10
5
 cells/well). Cells were treated 
with NF-ODN, NS-ODN and ODN alone  for 2 h or 12 h before flow cytometry 
experiment. Cells were collected into 1.5 mL Eppendorf tubes by pipetting, and were 
precipitated by centrifugation. Supernatants were discarded, cells were washed with 
1x PBS and cell pellet was obtained again by centrifugation for further staining and 
analysis by flow cytometry.  
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4.4.14. Staining of surface markers and flow cytometry  
For uptake study, cells were stained with anti-B220-PE and anti-CD11c-APC or anti-
F480-PE. While, for analysis of expression of co-stimulatory molecules, cells were 
stained with CD40 and CD86. Cells were washed with 1X PBS and centrifuged 
twice and resuspended in 1x PBS. Flow cytometry was performed with BD 
FACSAria
TM
 III equipment with BD FACSDiva
TM
 software. Number of events was 
at least 10,000 for all samples. The experiment was performed in triplicate and 
representative results of 2 independent experiments are shown. 
 
4.4.15. DNAse assay  
In order to understand whether nanostructure binding protects ODN from enzymatic 
degradation, we performed DNAse assay. Briefly, NF-ODN, NS-ODN and ODN 
alone were treated with DNAse I for different time periods and ODN digestion was 
analyzed with polyacrylamide gel electrophoresis. Reaction mixtures for each 
experimental group are shown in Table S1. Each sample was treated with DNAse I 
for 10 min, 30 min, 1 h, 4 h and 24 h at 37 °C. At t=0, samples had 3 µL of ddH2O 
instead of 3 µL of DNAse I. After incubation period, samples were loaded onto 10% 
polyacrylamide gel. Before loading, all samples were incubated with 3 µL of 1% 
SDS to disrupt electrostatic interaction between ODNs and PAs for 5 min at room 
temperature. Samples were run for 60 min at 75 V and subsequently 80 min at 50 V 
(in 1x TAE). All other conditions were same with PAGE experiment mentioned 
above. Band intensities were measured by Image J software. Representative gel 
images of 3 independent experiments are shown.  
 
4.5. Conclusion 
We demonstrated that immune response against viral/bacterial DNA patterns 
depends on shape of the carrier nanostructure. Nanofibers were more effective than 
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nanospheres in promoting CpG-induced immune response to Th1 phenotype, 
alarming immune system against intracellular pathogens. Conferring resistance to 
enzymatic degradation of ODNs makes nanofibrous ODN and nanospherical ODN 
complexes promising formulations for in vivo applications. Diversity of the peptide 
nanosystems can enable designing complex nanostructures to carry viral, bacterial or 
tumoral antigenic peptides. Delivering antigenic peptide and CpG ODN adjuvant in 
close proximity is also necessary for robust antigen-specific immune response. 
Considering high IFNγ production and CD86 expression, we think that nanofiber 
system might be beneficial to induce antigen-specific T-cell response, which is 
generally formidable task for vaccines. Investigation of whether increased innate 
immune activation by nanostructures can be translated into increased antigen-specific 
T and B-cell activity is necessary towards realization of this system as a vaccine 
model.  
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5. EPILOGUE 
As nanotechnology research expands and diversifies, we can engineer materials at 
nanoscale better. Chemical functional groups, and small peptide fragments relevant 
for cellular processes can be conjugated to nanosized fibers or spheres. These 
achievements urge researchers to develop functional materials through mimicking 
biological structures with an aim of influencing cellular behaviour for therapeutic 
purposes. However, signals controlling biological processes are complex, so 
mimicking all of them is not feasible. We need simpler strategies to manipulate this 
network of signals to induce regenerative processes in cells. In this thesis, new 
materials, carrying critical biochemical and biophysical signals for cells, are 
proposed for tissue engineering and vaccinology applications.  
First is peptide nanofibers decorated with chemical functional groups from heparan 
sulfates – an extracellular matrix component that bind to growth factors and regulate 
their functionality. We showed that heparin-mimetic peptide nanofibers bind to 
growth factors such as VEGF, HGF, BMP-2 and FGF-2 with comparable affinity to 
heparin, and a significantly higher affinity than control peptide nanofibers. 
Moreover, they bind to heparin-binding domains of growth factors, especially for 
VEGF and FGF-2. Binding to heparan sulfates is critical for bioactivity of these 
growth factors. Heparin-mimetic peptide nanofibers can be used for delivery of these 
growth factors into damaged area or to bind endogenous growth factors in damaged 
area and induce regenerative pathway. VEGF and FGF-2 are extensively involved in 
induction of angiogenesis, so heparin-mimetic PA scaffolds are potent to induce 
angiogenesis. Indeed, this is what we observed at in vitro and in vivo experiments – 
HM-PA scaffolds induced angiogenesis. At in vitro experiments, we observed 
capillary formation by endothelial cells even in the absence of exogenous growth 
factors. HM-PA nanofibers probably bind to endogenous growth factors and 
synergize with them. Considering side effects of growth factors due to misdose in 
clinical applications, exploiting endogenous factors would be beneficial for tissue 
engineering applications. Functions of these growth factors hint us about applications 
where HM-PA nanofiber scaffolds might perform better. As mentioned above, 
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VEGF/FGF-2 binding might be exploited to induce angiogenesis in cases such as 
treatment of chronic wounds and bone, cardiac or neural regeneration. HGF is an 
inducer of cell motility, such as promoting migration of keratinocytes to cover 
damaged area with epithelial tissue. This makes HM-PA nanofiber gels suitable for 
wound healing applications. Also, BMP-2 has roles in osteoblast differentiation and 
migration indicating that this material might be used for bone regeneration. Recent 
work from our group indicated that HM-PA nanofibers (both with BMP-2 or alone) 
were better than control PA nanofibers in upregulating osteogenic activity and 
mineralization by osteoblast cells.
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 This shows that HM-PA nanofibers bind and 
present BMP-2 relevant bone regeneration. Also binding potential of these 
nanofibers to other growth factors important in regeneration of cartilage or wound 
like TGFβ, PDGF should be investigated. In another recent study of our group, HM-
PA including scaffold induced chondrogenic (cartilage) differentiation better than 
control PA scaffolds.
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 Dose of growth factors bound to nanofibers can be 
controlled with changing concentration/ratio of functional groups on nanofibers. To 
achieve this, dose of HM-PA can be diluted with control PA molecules. Gels 
obtained by this way would allow also controlling release rate of growth factors 
encapsulated in gel.  Weak NGF binding observed by HM-PA nanofibers is really 
matter for bioactivity. In chapter 3, we observed significant differences between HM-
PA nanofibers and control nanofibers. Also, our group reported recently that HM-PA 
synergize with laminin-derived PA to induce neurite outgrowth, as well as slow NGF 
release better than control PA in laminin-derived PA gels.
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Besides presenting functional groups for growth factor binding, nanoscale size of 
fibers have several advantages. Nanoscale size allows presentation of functional 
groups and concomitantly growth factors with high density. Also the size of these 
fibers is similar to collagen fibers of ECM, making them suitable for cell attachment 
and survival. Indeed, this was what we observed in proliferation assay where all 
fibers (even with no functional groups on them) induced similar levels of 
proliferation and viability. It seems that peptide nanofibers themselves are sufficient 
to maintain cell survival. This renders HM-PA gels beneficial as a filler for damaged 
area, where neighboring cells will migrate and survive. Nanoscale size of fibers 
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synergize with functional groups in the induction of bioactivity by HM-PA gels. To 
further induce cell adhesion to fibers, peptide amphiphiles with integrin-binding 
epitopes (e.g. RGD) can be used, and they can be mixed with HM-PA. 
Stiffness of scaffolds is critical for determination of cell behaviour. Stiffness of these 
gels is about 500 Pa, so they can be mechanically supported for applications such as 
bone regeneration or wound healing. Also for better handling of these gels at in vivo 
applications, they can be co-delivered with polymeric materials which have better 
mechanical tunability, but poor bioactivity. Peptide segments derived from proteins 
such as elastin can be incorporated into HM-PA peptides or into accompanying 
peptides to gel system to increase elasticity.   
Second material proposed in this thesis is peptide nanofibers decorated with 
pathogenic DNA motives, known as CpG motives. Antigen itself in vaccines doesn’t 
generate immune response, since antigen presenting cells require additional signal 
from pathogens like CpG DNA to activate adaptive immune cells. These additional 
cues determine the fate and character of adaptive immune response generated against 
antigen. For example, CpG ODNs trigger innate immune system to release a number 
of pro-inflammatory cytokines and express co-stimulatory molecules on antigen-
presenting cells which eventually activates adaptive immune system. Character of 
this immune response is similar to that against intracellular pathogens such as viruses 
and mycobacterium. This type of immune response is called as Th1 immune 
response, which is characterized by activation of phagocytic macrophages and 
cytotoxic T cells. When we delivered CpG ODNs on nanofibrous and nanospherical 
peptidic structures immune response became more Th1-sided, while nanofibers being 
more potent. Therefore, nanofiber bound CpG ODNs are more useful as adjuvants 
for vaccines to shape immune response against intracellular pathogens and cancer. 
Cytotoxic T cells recognize peptidic fragments presented by cancer cells and induce 
cell death pathway. These nanofibrous ODNs can be given directly to tumorigenic 
area, which will induce local antigen-presenting cells to educate cytotoxic T cells 
with antigens from tumorigenic area. Nanofibrous CpG ODNs can be given together 
with antigen to direct immune response against antigen. CpG ODN and antigen 
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presented on the same particle has been shown to be more effective than freely 
floating in solution regarding immune response against antigen. So, nanofibers can 
be engineered to carry antigenic proteins through edc/nhs, biotin-avidin or s-s 
linkages. Also, small antigenic peptide fragments can be conjugated into nanofibers 
very easily. Overall, nanofibers carrying CpG DNA is promising for generating 
antigen specific immune response against intracellular pathogens and tumors.  
To conclude, this thesis claimed how simple chemical and physical signals synergize 
to generate otherwise unachievable outcome. Heparin-mimetic peptide nanofibers 
showed that right composition of simple chemical functional groups on nanofibers is 
very potent in terms of growth factor binding and inducing angiogenesis. CpG DNA 
carrying nanofibers and nanospheres demonstrated that simple physical shapes shift 
immune response against pathogenic biochemical signal – CpG DNA. We should 
search for such synergies in nature for designing simple and effective materials.  
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